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Abstract 
The problems associated with adverse drug reactions are well known. 
This thesis describes an assessment of the detection and reporting of 
adverse drug reactions (ADRs) by hospital pharmacists and by hospital 
pharmacy departments. Methods of increasing ADR reporting rates and, 
methods of improving the documentation and communication of data 
relating to ADRs are also investigated. 
Relatively few hospitals in the UK have local ADR reporting schemes and 
where they exist, they are pharmacy-led. The number of reports received 
by schemes tends to be low and previous estimates of under-reporting 
appear to be over-optimistic. Systems for ensuring the appropriate 
documentation and communication of ADRs and for monitoring the effects 
of newly marketed drugs were rare. A large increase in one local ADR 
scheme's reporting rates was achieved using passive promotional 
methods. General practitioners consider that the communication of ADR 
data from secondary to primary care is of a poor quality. The introduction 
of an notification and reporting system, HAROLD, described in this thesis 
was viewed positively. ADR-related admissions were identified as a 
significant problem and many of the ADRs concerned are similar to those 
that have been reported for a number of years. 
Using qualitative and quantitative analysis, this research found that 
hospital pharmacists viewed ADR reporting positively. Pharmacists have 
a reasonable knowledge of the Yellow Card Scheme and consider it a 
professional obligation to participate in it. Time appears to be a deterrent 
to reporting and despite having a good knowledge of the operation and 
purpose of the Yellow Card Scheme, pharmacists appear to be selective 
about which reactions they are prepared to report. Education and training 
were identified as key initiatives which could increase reporting rates. 
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Chapter 1: Introduction 18 
Chapter 1: Introduction 
1.1 Adverse Drug Reactions (ADRs) -a definition. 
A response to a drug which is noxious and unintended and which occurs at 
doses normally used in man for the prophylaxis, diagnosis or therapy of disease 
or for the modification of a physiological function. 
World Health Organisation, 19701 
The World Health Organisation definition of an ADR is used in this thesis as it is 
specific to the purposes of this research. The definition excludes events such 
as errors in drug administration and instances of intentional or unintentional 
poisoning or overdose which other definitions may include. This definition is 
widely used in literature describing the study of ADRs and is adhered to 
throughout this thesis. 
1.2 ADRs: the size of the problem. 
Estimated incidences of ADRs vary for a number of reasons. The population in 
question will affect the incidence of reported ADRs; for example, young patients 
requiring minor surgery and taking few medicines are less likely to suffer an 
ADR than an elderly patient suffering several clinical conditions receiving 
polypharmacy. 2'3 Variation in the precise definition of an ADR, differences in 
sample sizes investigated, that many ADRs are unreported or unidentified and 
the influence of specific specialities (for example, an excess of surgical or renal 
patients) may greatly affect the estimated incidence of ADRs. 
a 
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A review of studies examining ADR-related admissions to hospitals found that 
reported rates varied from 0.2% to 21.7% with an average rate of 5.5%. 4 
Recent work has suggested that 6.7% of hospital patients suffer serious' ADRs 
while 0.32% of hospital patients suffer fatal ADRs. Indeed ADRs have been 
suggested to have been between the fourth and sixth leading cause of death in 
5 the USA in 1994. 
1.3 Why ADRs are a problem. 
ADRs are a problem because they may: 
" complicate existing disease 
" cause hospital admissions 
" affect quality of life 
" delay relief or cure of the disease which they were intended to treat 
9 mimic other disease states 
" result in inappropriate treatment of unrecognised, drug-induced problems 
9 cause a patient to lose confidence in their carers and their medicines 
resulting in poor compliance and consequently, treatment failure. 6 
1.4 Clinical Trials. 
Clinical trials have numerous purposes and aim to demonstrate a drug's 
effectiveness and safety; however, they have a number of limitations. The 
numbers of patients involved in clinical trials are often limited due to the 
complexity of the investigations, monitoring of patients, co-ordination of trials 
and ultimately, cost. Patients are selected for clinical trials using specific criteria 
and it is unlikely that many different concurrent pathologies and drug therapies 
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will be encountered. Thus, the detection of certain drug-disease and drug-drug 
interactions and identification of long term side effects of drug therapy may not 
become apparent for a number of years after marketing and exposure to a 
larger unbiased population. Trials may also fail to obtain substantial data about 
the use of the agent concerned in very young or very old patients. Once 
marketed, drugs are often used for purposes other than those for which they 
were licensed, the so called "off-label" use, which may disclose further problems 
with a drug's safety profile. Due to the limits placed on the numbers of patients 
involved, clinical trials are also ineffective at detecting very rare ADRs. As few 
as 1000 patients may have been exposed to a new therapeutic agent or device 
prior to its marketing and it is thought that ADRs with an incidence of less than 1 
in 250 are unlikely to be detected. 7 In order to verify that drugs are as safe as 
clinical trials have suggested, it is therefore vital that post marketing surveillance 
is carried out to monitor the safety of these agents. 
1.5 Alms of post marketing surveillance. 
The aims of post marketing surveillance are the detection of previously 
unrecognised ADRs, to identify risk factors for ADRs in individual patients, to 
collate data concerning recognised ADRs and ultimately to determine the safety 
of drugs. It may be used to encourage the safe and effective use of drugs that 
have been licensed. 'Signals', generated by reports of ADRs, spontaneous or 
otherwise, provide suggestions of associations between drugs and potential 
hazards. These may then be followed up by more formal methods of 
pharmacovigilance, particularly if the 'signal' is strong, if it is new, if it is deemed 
clinically important and if preventative measures are possible. 
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1.6 Origins of pharmacovigilance In the United Kingdom. 
Although descriptions of adverse drug reactions have been reported for two 
thousand years, the first ADRs applying to "modem" medicine were observed in 
1848 when a 15-year-old child died as a result of chloroform anaesthetic. 8 As a 
result of concerns about the safety of anaesthetics, a commission was 
established to collate reports of anaesthetic related deaths, the findings of which 
were published in 'The Lancet in 1893.9 Almost a half a century later, the 
deaths of 107 patients exposed to diethylene glycol used as a solvent for 
sulphanilamide resulted in legislative developments in the USA in 1938.10 
However, it was another 23 years until pharmacovigilance was to be seriously 
explored. 
Thalidomide was first marketed in 1956 in Germany as `Distival' and promoted 
as a treatment for insomnia and nausea in pregnancy. Reports of foetal 
abnormalities, phocomelia and micromelia, thought to have been caused by 
thalidomide were first published in the medical literature in 196111 and it is now 
estimated that over 8000 babies were born with thalidomide-related 
deformities. 12 Almost 40 years after this tragedy, thalidomide remains a 
household name, synonymous with adverse and undesirable effects of drugs. 
As a result of the thalidomide tragedy and other less publicised but not dissimilar 
incidents, many countries decided that drug safety should become a priority. 
Prior to this, drugs could be marketed with little regard to their safety and 
efficacy. In the United Kingdom, with the co-operation of the Association of 
British Pharmaceutical Industry (ABPI) and the Proprietary Association, the 
Committee on Safety of Drugs (CSD) was established in 1963, becoming 
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operational on January 1st, 1964. Under the Chairmanship of Sir Derek Dunlop, 
the Committee's function was to monitor drug safety throughout the UK, to 
monitor and approve the introduction of new drugs, and to collect and act upon 
reports of adverse drug reactions. 
In 1968, the Medicines Act brought into effect several new laws relating to the 
marketing of therapeutic and diagnostic agents. In September 1971, under 
Section 4 of the Medicines Act, the Committee on Safety of Medicines (CSM) 
replaced the Committee on Safety of Drugs. Although the membership of the 
committee did not greatly after, the new committee now had statutory backing 
and authority. 
1.7 The Medicines Control Agency. 
The Medicines Control Agency (MCA) is the licensing arm of the UK's Drug 
Licensing Authority and is responsible for all aspects of the regulation of 
medicines in the UK. This includes the regulation of clinical trials, licensing 
medicines and monitoring their safety once on the market, investigating possible 
hazards and taking appropriate action to minimise the risks to users, protecting 
public health, inspection of premises manufacturing medicines and taking 
enforcement action if activities fall outside legal guidelines. 13 
1.8 The Committee on Safety of Medicines and Regional Monitoring 
Centres. 
The CSM is a sub-division of the MCA and provides expert advice to the UK's 
Drug Licensing Authority on questions of safety, quality and efficacy of 
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medicines. It is also responsible for encouraging the collection and investigation 
of reports on suspected adverse reactions to medicines already on the market. 
The CSM and MCA jointly run the Yellow Card Scheme. Using the Yellow Cards 
provided, reports are sent directly to the CSM / MCA or to one of the Regional 
Monitoring Centres (RMCs). These RMCs are associated with regional drug 
information services and local university departments of clinical pharmacology 
and pharmacists played an important role in their inception. Their aim is to 
stimulate ADR reporting by improving communications and providing feedback 
and follow-up to local reporters. Some RMCs publish regular newsletters 
concerning locally reported ADRs in an attempt to generate interest in 
pharmacovigilance. 
1.9 The Yellow Card Scheme. 
In 1964, the Committee on Safety of Drugs provided doctors and dentists with 
pre-paid yellow postcards with which to report adverse reactions to drugs thus 
creating the Yellow Card Scheme. Remodelled Yellow Cards may now be found 
in NHS prescription pads, the British National Formulary (BNF), The 
Compendium of Data Sheets and Summaries of Product Characteristics 
(formerly the ABPI Data Sheet Compendium), Monthly Index of Medical 
Specialities (MIMS) or may be obtained from the CSM / MCA. Nurses are not 
allowed to participate in the Yellow Card Scheme at present although a pilot 
scheme evaluating their potential role has recently been conducted. " 
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Over 350 000 Yellow Card ADR reports have now been made to the CSM / MCA 
and stored in their database. This database, the Adverse Drug Reactions On- 
line Tracking (ADROIT) system, is used to monitor Yellow Card reports, detect 
trends in reporting and improve the speed at which problems may be detected. '5 
Yellow Card reports are made to the CSM / MCA in confidence and personal 
details of reporters and patients are neither published nor used for purposes of 
litigation. Data collected by the Yellow Card Scheme are not only used for 
national drug safety surveillance but also for international surveillance. Along 
with several other countries, the United Kingdom submits reports of ADRs to the 
World Health Organisation's Adverse Drug Reaction Collaborating Centre where 
data are collated for international use. 
1.10 Action taken by the CSM I MCA. 
Once a specific problem has been identified with regard to a certain product, the 
CSM / MCA may take action in a number of ways. The CSM / MCA may choose 
to advise individual doctors as to the adverse effects of certain drugs. They 
may also publish their findings and advice to prescribers in 'Current Problems in 
Pharmacovigilance', a communication used to disseminate information about 
ADRs to doctors and pharmacists. Analysis of ADR reports received by the 
CSM / MCA may also result in the withdrawal of drugs from the market or the 
amendment of product licences. For example, terfenadine has recently had its 
classification amended from a 'Pharmacy' medicine to a 'prescription only 
medicine' (POM). 16 The CSM / MCA may also publish warnings in the British 
National Formulary to highlight particular aspects of drug safety. " Examples of 
this include warnings about the use of beta-blockers in asthmatics, the risks of 
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developing agranulocyctosis with carbimazole and the need to monitor hepatic 
function with cyproterone acetate. 
1.11 Under reporting of ADRs. 
Under reporting of ADRs is considered to be a long standing problem with 
several reasons thought to contribute to its persistence. It has been suggested 
that the incidence of reporting of serious ADRs is, at best, in the order of 10% 
and for non-serious ADRs it is estimated at 2-4%. 18 The data obtained through 
the Yellow Card Scheme is therefore incomplete and indeed, it is likely that 
many serious and fatal reactions are never brought to the attention of the 
regulatory authorities. Factors considered to dissuade potential reporters 
(medical practitioners) from completing an ADR report, are shown in Box 
1.1.19202' The concept of a fee has been proposed as a method of stimulating 
reporting and research has shown that a fee-based incentive can increase 
reporting rates but that on withdrawal of the fee, reporting rates fell 
substantially. 22 
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Box 1.1: Factors affecting reporting of ADRs 
Reaction not severe enough 
Reaction well known 
Familiarity with the suspect drug concerned 
Concern over potential legal implications 
Reaction may be predictable or expected 
Ignorance of how to report an ADR 
Lack of time, lethargy or complacency 
Lack of feedback following previous reports 
Failure to identify the presence of an ADR 
Guilt because of patient suffering 
Lack of confidence in making a report 
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The data collected in the Yellow Card Scheme are also open to significant bias 
and caution should be exercised in their interpretation. Reports of reactions 
appearing in the medical or lay press may result in numerous similar reports 
being submitted to the CSM / MCA. In turn, this may result in a 'false positive' or 
'true positive' sign that a problem exists. An example of a 'false positive' is the 
association of suicidal ideation with fluoxetine (Prozac), a concept perpetuated 
by the media and refuted by the authorities in pharmacovigilance. 18 An 
example of a 'true positive' is the association of paroxetine (Seroxat) with acute 
withdrawal symptoms in patients stopping therapy, which was found on further 
analysis to be substantiated. 18 
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The lessons of the practolol-induced oculomucocutaneous syndrome are worth 
noting. Following publication of a report on this syndrome in the medical press, 
over 200 reports of a similar nature were subsequently submitted to the CSM / 
MCA. Prior to the publication of the first report, only one report had been made 
to the CSM / MCA in four years. '9 This suggests that either practitioners had 
failed to associate a serious syndrome with a patient's drug therapy or that they 
had, but were unwilling to report it either because it was unrecognised or for 
other reasons. 
1.12 Successes of the Yellow Card Scheme. 
The CSM / MCA has been responsible for the identification of a number of 
important ADRs. Examples of successes of the scheme are outlined in Table 
1.1.18 The Yellow Card Scheme has provided important information concerning 
factors which may predispose patients to ADRs such as age, concurrent disease 
and concurrent medication; for example, the CSM / MCA suggests a reduced 
dose of azapropazone for the over 60s. 23 The Yellow Card Scheme has also 
allowed comparison between drugs in the same class; for example, the 
comparison between different NSAIDs to identify those with the greater risk of 
different adverse effects. 24 However, as discussed earlier, under reporting and 
biased reporting can distort true comparisons between different drugs. 
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Table 1.1: Notable successes of the Yellow Card Scheme since 1993.18 
Drug (Trade name) ADR reported Action taken 
Clozapine (Clozani) Myocarditis Additional warnings in 
product data sheet 
Remoxipride (Roxiam) Aplastic anaemia World-wide withdrawal by 
manufacturers 
Rifabutin (Myobutin) Uveitis / drug Additional warnings and 
interactions dose reduction 
Tiaprofenic acid Severe cystitis Additional warnings 
(Surgam) augmented and contra- 
indications altered 
Cyproterone acetate Hepatotoxicity Indications restricted and 
(Cyprostat, Androcu) requirement for hepatic 
monitoring introduced 
Alendronate Severe oesophageal Additional warnings and 
(Fosamax) reactions altered dosing instructions 
Tacrolimus (Pmgmf) Hypertrophic Additional warnings, dose 
cardiomyopathy reduction and monitoring 
required. 
Tramadol (Zydol) Psychiatric reactions Additional warnings 
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1.13 intensive monitoring of newly marketed agents. 
Inverted black triangles' are assigned to drugs new to the UK market or when 
drugs become available within new combinations of drugs, by a new, 
significantly different route of administration, or, as a novel drug delivery system. 
Drugs are initially assigned the black triangle symbol for a minimum of two years 
and the CSM request all reactions be reported for these drugs, regardless of 
their estimated causality or seriousness. However, in instances where there are 
particular concerns over the safety of a drug, it may retain the black triangle 
symbol for a longer period, for example tramadol (association with psychiatric 
disorders) and lamotrigine (association with serious skin disorders). Black 
triangle drugs are identified in the British National Formulary, Monthly Index of 
Medical Specialities, Summary of Product Characteristics & Data Sheet 
Compendium and all promotional material. A current list of black triangle drugs 
is maintained and made available, on request, by the CSM / MCA. 
The limitations of clinical trials have been discussed earlier (section 1.4). Thus, 
the detection of rare ADRs, be it due to underlying pathology, drug-drug 
interactions, drug-disease interactions, delayed onset or to their bizarre or 
unexpected nature, may not occur until long after the drug has been marketed. 
Reporting of ADRs to newly marketed drugs, that is, those marked with a black 
triangle is particularly important. 
1.14 Monitoring of established drugs 
Once drugs are no longer under intensive surveillance, the black triangle is 
removed and the emphasis on ADR surveillance alters. Relatively minor or well 
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documented reactions become less significant and instead of reporting all 
reactions, the CSM / MCA requests that only serious or unusual reactions be 
reported. Any reaction which is fatal, is life threatening, disabling, 
incapacitating, or which results in, or prolongs, hospitalisation should be 
reported, even if well recognised. " These data are especially of value when 
comparing drugs in the same dass. Examples of `serious' reports that are of 
particular interest to the CSM / MCA are listed in Box 1.2. 
Box 1.2. Examples of serious reports specifically requested 
by the CSM I MCA 
Anaphylaxis 
Blood disorders 
Convulsions 
Endocrine disturbances 
Effects on fertility 
Haemorrhage from any site 
Jaundice 
Hepatic abnormalities 
Renal abnormalities 
Ophthalmic disorders 
Severe CNS effects 
Severe skin reactions 
1.15 Problems with CSM I MCA data. 
Although the data received by the CSM / MCA are of great value with regard to 
pharmacovigilance, there are limitations to their use (Table 1.2). 25 For example, 
reporting rates for drugs tend to be at their highest following their introduction 
onto the market, particularly as they are marked with black triangles. 
Furthermore, owing to underreporting and because the number of patients 
taking a drug is unknown, it is impossible to calculate the incidence of specific 
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ADRs and it is only possible to hypothesise about identified problems. It is not 
uncommon for unusual or unexpected reactions to be reported at the expense 
of well recognised, albeit more serious, reactions. 
Table 1.2: Strengths and weakness of the Yellow Card Scheme. (Taken 
from Drugs 1999; 57 (4): 527) 
Strengths of scheme Weaknesses of scheme 
eA nation-wide reporting 
scheme 
9 Monitors a drug for its entire 
marketed life 
" Potential for all reactions to be 
reported for all patients 
" Provides a means for detecting 
rare ADRs 
" Allows monitoring in all practice 
areas 
" Allows for comparison of drugs 
with similar indications or 
similar drug classes. 
" Many reactions are dearly not drug- 
related 
" Many reactions are never reported 
9 Biases exist in reporting for example, 
severity or seriousness of reaction, 
ease of recognition of reaction, novelty 
of drug, promotion and publicity given 
to drug or adverse reaction, extent of 
use of drug, and / or reporting of 
reaction 
" Cause and effect relationship with 
drug cannot be established 
" Does not allow for assessment of 
incidence because the number of 
reactions and number of patients who 
received and took the drug are not 
known. 
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1.16 Other methods of pharmacovigilance. 
More robust or systematic methods employed in pharmacovigilance include 
case control studies, cohort studies and case register studies. These methods, 
rather than relying on spontaneous reports, focus on individual drugs with the 
aim of identifying ADRs. For example, the Prescription Event Monitoring (PEM) 
Scheme was developed at the University of Southampton and is designed to 
target particular drugs. 26 Alternatively, these studies focus on selected clinical 
conditions to identify potential relationships with individual drugs. 
1.17 Classification of ADRs. 
Traditionally, ADRs have been classified into two distinct categories (Table 1.3). 
'Type A' reactions tend to be extensions of a drug's pharmacological effects 
while 'Type B' reactions tend to be more bizarre in nature as they are 
idiosyncratic, unpredictable and unrelated to the pharmacological action of a 
drug. Currently, this classification is under review, primarily because the two 
groups are somewhat restrictive. Further subtypes of ADR that could be created 
are those caused by long term use of a drug, those caused by drug-drug 
interactions, ADRs resulting in carcinogenicity or teratogenicity and ADRs 
occurring as a result of an overdose. 
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Table 1.3: Classification of adverse drug reactions 
Reaction Nature of reaction Example of reaction type 
type 
Type A These reactions may be Dry mouth with anti- 
predicted from the choliner+gics, hypoglycaemia 
pharmacological actions of the with anti-diabetics 
drug and are usually dose- 
dependant. They tend to be 
mild, have low mortality and 
may be alleviated by a 
reduction in dose. 
Type B These reactions are 
unpredictable from the 
pharmacology of the drug and 
are not dose-dependent. They 
have a higher mortality rate 
than Type A reactions. 
Anaphylactic reactions to 
penicillin, hepatotoxicity with 
sulphasalazine. 
1.18 Role of clinical pharmacists 
Pharmacists are establishing themselves in roles that go far beyond the days 
when the manufacturing, compounding and dispensing of medicines were the 
roles for pharmacists. As clinical pharmacy began to evolve, drug history taking, 
drug information, patient counselling and education and, ward-based clinical 
pharmacy emerged as examples of this developing role. Many definitions of 
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clinical pharmacy exist but inherent in all of them, is that pharmacists are 
concerned with the safe and effective use of drugs. Indeed the concept of 
pharmaceutical care, which had a huge impact on the concepts surrounding 
these developing roles, is defined as "a practice in which the practitioner takes 
responsibility for a patients drug related needs and holds him or herself 
accountable for meeting these needs". 27 Included in this concept were the 
problems associated with adverse drug reactions. It was not surprising 
therefore that pharmacists began to look towards pharmacovigilance as a role in 
which they, 'the experts on drug therapy', could make a substantial contribution. 
While pharmacists may not posses the diagnostic skills of doctors, the clinical 
component of undergraduate and, postgraduate courses means that 
pharmacists are now well equipped to cope with complex pharmacology and 
therapeutic problems. 28 These skills may be used in the prediction, identification 
or prevention of adverse drug reactions. Ward pharmacists are well placed to 
identify and report ADRs. This may be achieved through interaction with 
medical staff, ward staff and patients. Identification of certain dues such as the 
sudden discontinuation of maintenance therapy, or prescriptions for medicines 
that may be used to treat ADRs, for example corticosteroids or anti-histamines, 
may suggest the occurrence of an ADR. 29 The possibility that ward pharmacists 
could identify ADRs in this manner was demonstrated in the early 1980s. 30 
Outside the United Kingdom, pharmacists were involved in post marketing 
surveillance schemes, but within the UK, this was not the case. A proposal by 
the RPSGB to initiate pharmacists reporting via a 'Pink Card' scheme was 
rejected by a CSM / MCA and Committee on Dental and Surgical Materials 
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and vaccines, and any reaction to a new drug (marked with the black triangle 
symbol'). A report may be made where there is a reasonable suspicion of an 
ADR; definite proof is not required. An education pack, "Pharmacovigilance, 
The Yellow Card Scheme: Information Pack for Pharmacists", containing details 
of the reporting protocol and information concerning the Yellow Card Scheme 
was sent by the CSM / MCA to each hospital pharmacy premises in the 
demonstration areas. The CSM / MCA RMCs provided workshops about this 
new role on a national basis in summer / autumn 1997. 
The potential role of community pharmacists in pharmacovigilance has also 
been explored. 3" Although it has been demonstrated that community 
pharmacists are able to identify and report ADRs, the studies were not carried 
out as part of the Yellow Card Scheme. In April 1997, the CSM / MCA 
established a demonstration scheme for community pharmacists to report ADRs 
via the Yellow Card Scheme in the four CSM / MCA RMC areas. 37 
1.20 The role of pharmacists In pharmacovigilance abroad. 
Pharmacists have been recognised as reporters in official, post marketing 
surveillance schemes for a number of years in many other countries. 38 In 
America, pharmacists have been able to report ADRs as part of MedWatch 
since its inception. It has been reported that ADR reports submitted by 
pharmacists to this scheme are of a high quality and that countries disregarding 
the potential of hospital pharmacist reporting should consider changing their 
practice. 39 The American Society of Health-System Pharmacists suggests that 
pharmacists should exert leadership in the development, maintenance and 
Chapter 1: Introduction 37 
ongoing evaluation of ADR programs. 40 It also states that pharmacists have a 
'responsibility and professional obligation to report any suspected ADRs'. This 
advice and guidance appears to have been effective as, in 1992, hospital 
pharmacists were the most frequent direct reporters of ADRs to the Food and 
Drug Administration. 41 In Australia, pharmacists are recognised reporters in the 
Adverse Drug Reactions Advisory Committee (ADRAC). 42 In the early 1980's, it 
was reported that nearly half of the ADRs received by ADRAC were from 
hospital pharmacists. 42 In Canada, pharmacists have also been involved in the 
Canadian Drug Adverse Reaction Reporting Program (CDARRP). 43 Like 
MedWatch, the program is a voluntary spontaneous reporting scheme and 
pharmacists play a significant part in its operation. 
In Canada, Australia and the USA, the associations concerned with hospital or 
health system pharmacists have produced guidelines on the importance of 
pharmacovigilance, how pharmacists should become involved in 
pharmacovigilance and what their role should be. In the United Kingdom, this 
support has not been provided. 
38 
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Chapter 2: Local adverse drug reaction reporting schemes 
2.1 The pharmacist's role in local schemes. 
Pharmacists have been instrumental in setting up ADR reporting schemes and are 
integral to their operation. 44,45 Such activity provides pharmacists with an 
opportunity to interact with other health care professionals and patients, and to 
become directly involved in the monitoring, management and evaluation of ADRs. 
2.2 Hospital-based local adverse drug reaction-monitoring schemes. 
The problem of under-reporting of ADRs and its effect on pharmacovigilance has 
been partly addressed in the United States of America where hospitals are required 
by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) to 
have procedures for reporting ADRs. * This is also the case in Australia where the 
Australian Council on Healthcare Standards (ACHS) requires hospitals to operate 
such schemes. 47 In the United Kingdom, although such a requirement does not 
exist some hospitals have set up in-house or local ADR reporting schemes. 
Local ADR reporting schemes in current operation are not designed to replace the 
Yellow Card Scheme but to supplement it by increasing awareness and 
encouraging reporting of ADRs within hospitals. Local schemes also aim to 
minimise the factors discussed earlier which may deter potential reporters from 
making an ADR report (see Box 1.1). 190' A number of examples of local reporting 
schemes have been published in the literature and although methods of reporting 
may vary between institutions, most operate on similar principles (Box 
2.44.48.49.50,51X 
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Box 2.1: Requirements for the operation of a typical 
local ADR reporting scheme 
Identified operators of the scheme 
System for reporting (card, telephone, computer) 
Feedback to reporters 
Centre for collation of reports 
Information sources to research and evaluate ADRs 
Funding 
Multidisciplinary involvement and co-operation 
2.3 ADR reporting at the Royal Liverpool University Hospital. 
40 
In 1985, a local scheme was introduced at the Royal Liverpool University Hospitals 
(RLUH), the 'Green Card' scheme. 44 Still in operation, the scheme has resulted in 
an increase in the number of ADR reports to the Pharmacy department and a 
subsequent increase in reports to the CSM / MCA. 53 However, if the reported 
incidences of ADRs experienced by hospital in-patients3 and ADR related hospital 
admissions4 are compared to the number of patients treated by the RLUH each 
year, under-reporting of ADRs remains a cause for concern in the hospital. 
'Green Cards' are available on all wards and dinics, and with few details required 
can be completed by any member of the hospital staff and sent to the pharmacy 
department. Yellow Card reports are more complex, difficult and time consuming to 
complete which has been shown to have an adverse effect on reporting rates. 
'Green Cards' used at the RLUH and similar cards in other local schemes tend to be 
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more basic in their design that makes it faster and simpler to report an ADR. A 
number of variations on the 'Green Card' exist, and examples of information 
required to be included on such cards are shown in Box 2.2. A 'Green Card' used at 
the RLUH is provided in Appendix 5. 
Box 2.2: Details required for locally designed 
ADR report card or for telephone reporting 
Patient name 
Patient hospital ID number 
(Addressograph if possible) 
Location of patient 
Name of suspect drug(s) 
Details of suspected reaction(s) 
Name of reporter 
Status of reporter (profession) 
Contact number / address 
Factors which facilitate the operation of a program such as the 'Green Card' 
scheme are listed in Box 2.3. 
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Box 2.3: Factors facilitating the operation of a 
local ADR reporting scheme 
Low cost 
Simple to operate 
Easy to maintain 
Easily available in patient areas (for example wards, 
clinics and casualty departments) 
Minimum impact on pre-existing workload 
Highly visible 
Constantly publicised 
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At the RLUH, once the pharmacy department has received a report, either the drug 
information pharmacist or ward pharmacist retrieves the patients medical records. 
An ADR investigation form is completed including patient details, concurrent 
illnesses, vital organ function and known drug allergies (Box 2.4). The investigation 
form also provides information for completion of Yellow Cards should a report be 
appropriate. 
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Box 2.4: Details be included in ADR report form on review of patient 
medical records 
f Patient age, sex (pregnancy) and weight (if appropriate) 
f Medication details including: 
f Dose, route of administration, duration of therapy, indication 
f Drug allergies 
f Previous exposure to the drug(s) 
f Details of self medication 
e Biochemical / haematological status (where relevant) 
e Reason for admission 
" Other illnesses 
" Details of the reaction including: 
f Whether symptoms resolved on drug withdrawal or dose 
reduction 
f Whether re-challenge was performed 
f Whether corrective treatment was prescribed 
f Timing of the reaction after exposure 
I" Whether the patient's medical condition could have contributed to the 
ADR. 
0 Outcome 
The appropriate literature sources (Box 2.5) are examined for previous reports of 
the reaction and details entered onto the ADR research form. The ADR team 
comprising the Drug Information Pharmacist and a Senior Registrar in Clinical 
Pharmacology then reviews the completed report. The ADR is evaluated and a 
decision is made determining the likelihood (or causality) that the suspect drug 
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caused the reaction. Clinical judgement is used to determine causality at the RLUH, 
however, an alternative method may be the use of algorithms. These algorithms 
consist of a series of questions concerning the circumstances surrounding the ADR 
which when evaluated, give an indication of the likelihood that the reaction was or 
was not an ADR. A variety of algorithms have been published of which Naranjo's 
appears to be the most commonly cited as it is reasonably reliable and simple to 
use. U. S. 58.57 
Box 2.5: Examples of literature sources for researching ADRs 
" CSM / MCA (ADROIT database) 
" British National Formulary 
" Compendium of Data Sheets and Summaries of Product Characteristics 
" Martindale: The Extra Pharmacopoeia 
19 Medline 
I* The Internet 
" Meyler's Side Effects of Drugs 
" Davies' Textbook of Adverse Drug Reactions 
" Industry / Pharmaceutical Manufacturers 
" Royal Pharmaceutical Society of Great Britain 
" Specialist centres, for example, children's hospitals 
" Drug Information Centres 
Severity of reaction is also important as it often determines whether a report is 
submitted to the CSM / MCA. Use of clinical judgement to determine severity of 
reactions may be appropriate although categories of reaction severity are well 
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defined in the Iiterature. 48'5' Reactions at the RLUH are categorised as `serious' or 
'non-serious' in accordance with CSM / MCA criteria (see 1.14). 
In conjunction with whether the suspect drug is in the black triangle' category or if 
the reaction is `serious' or unusual, a decision is made as to whether a report to the 
CSM / MCA is appropriate. Reports are then allocated a reference number and 
filed. Following evaluation of the report, an acknowledgement letter is sent to the 
reporter giving details of their report, whether a Yellow Card was sent to the CSM / 
MCA and a brief summary of previous similar reports where appropriate. 
At the RLUH, a number of methods of providing feedback to potential ADR 
reporters are used. These include publicising the success of the scheme through 
committee minutes, the hospitals 'Drugs And Therapeutics' committee newsletters, 
pharmacy department newsletters and directorate memorandums. The scheme is 
further promoted via staff training sessions and promotional talks all of which are 
important methods of raising awareness of the scheme and hopefully, increasing 
reporting rates. 
2.4 Reporting at other institutions. 
Similar schemes are in operation or have been in adopted in other institutions. At 
the John Radcliffe Hospital, Oxford, locally designed Yellow Cards have been 
placed at the end of each patients bed with the intention of eliminating the problem 
of locating cards to make an ADR report Cards were checked each day by the 
ward pharmacists and although no longer in operation, the scheme was successful 
in generating an increase in the number of Yellow Cards-46'a° 
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Retrospective coding of patients pathologies during in-patient episodes by medical 
records has also resulted in identification of ADRs. This was achieved by 
retrospective review of patients' medical records and prescription charts for 
evidence that an ADR has occurred and also by identifying patients' records 
endorsed with coding (for example, International Classification of Disease (ICD) 
codes) signifying the occurrence of an ADR. 59'00 Telephone models have been 
developed to facilitate reporting of ADRs. 51 The advantage of reporting by this 
method is that no forms are required and telephones are readily accessible on most 
wards and clinics. Participants may prefer personal contact and where relevant, 
may have the opportunity to obtain advice from the drug information department 
concerning the suspected ADR. In other hospitals, schemes have been 
implemented in the outpatient setting with encouraging results. 51 Report cards may 
also be placed in other areas of the hospital, for example, casualty departments or 
theatres. 
For hospitals with limited resources or staff, it may be possible to adapt schemes so 
that a minimal impact is made on workload by altering current procedures. For 
example, adaptation of pharmacy intervention monitoring programmes to cover ADR 
monitoring may allow collection and collation of ADR data by pharmacists without 
greatly altering current practice. 
2.5 Reporting of reactions to newly marketed agents. 
Schemes to increase the reporting of ADRs to black triangle' drugs have been 
evaluated. '*" A scheme in which newly marketed drugs were highlighted by the 
use of `sticky labels' placed on prescription charts was implemented at the Northern 
General Hospital, Sheffield. 50 Lists of these drugs were also circulated and the 
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scheme was publicised in the hospital's 'Drugs and Therapeutics' bulletins. 
Although the scheme failed to make a large impact on the number of Yellow Card 
reports, were the increases in reports to occur on a national level, then such 
initiatives may prove to be somewhat more worthwhile. 
A similar study was conducted at the Nottingham City Hospital, resulting in an 
appreciable increase in the number of ADRs reported to the CSM / MCA via the 
Yellow Card Scheme. 49 In addition to the measures effected in the Northern 
General study, dispensed containers were marked with labels to highlight the fact 
that the drug was under intensive surveillance by the CSM / MCA. 
2.6 The role of computers. 
The future of adverse drug reaction monitoring will undoubtedly change as the role 
of computers in hospitals evolves. Computers are currently involved in biochemical, 
haematological, microbiological, prescribing, dispensing (including the detection of 
drug-drug interactions and potentially drug-disease interactions), medical 
information and administrative activities. Cross-referencing of these functions will 
provide a powerful tool with which to monitor the safety of drugs. Preliminary 
studies examining this aspect of ADR monitoring have already produced 
encouraging results. 81.02.03 
2.7 Use of data from local schemes. 
Primarily, the data from local schemes have been used to contribute to national 
pharmacovigilance schemes. In-house, collation of ADR data may facilitate the 
identification of trends or problems which may be preventable or highlight the need 
for stricter monitoring of certain drugs. As a result of one study, digobn fact sheets 
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were produced and placed in the appropriate patients' medication file. As a result of 
the same project, a limit of seventy two hours duration was placed on the use of 
parenteral ketoralac and information from the scheme resulted in deletion of oral 
ketoralac from the hospital formulary. °D Changes in drug administration procedures, 
implementation of new prescribing policies, promotion of awareness of ADRs, 
modification of patient education procedures and drug ordering systems and 
therapeutic drug monitoring procedures were all implemented in some hospitals as 
a result of ADR data collected via local schemes. " 
2.8 The importance of local schemes 
There is no doubt that local ADR reporting schemes make a positive contribution to 
the identification and reporting of ADRs. A number of different models for reporting 
schemes have been published in the literature. Departments wishing to develop a 
scheme may choose whichever model may complement their clinical operations. 
Their design should overcome some of the problems associated with under- 
reporting and facilitate the development of an ADR reporting culture. The scheme 
must be continuously promoted and provision of feedback to reporters is essential. 
The schemes should also improve pharmaceutical care by identifying prescribing 
issues within hospitals, ensuring ADRs are processed effectively and efficiently and 
contributing to pharmacovigilance. Pharmacists are well placed and have the 
necessary skills with which to carry out these important functions. Formal 
involvement in the Yellow Card Scheme now means that pharmacists have a major 
role to perform in pharmacovigilanoe. 
In order to investigate and assess the contribution pharmacists are making and 
could make to pharmacovigilance in the UK, this study was initiated. 
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Chapter 3: Aims and objectives of the study 
The previous chapters have described some of the limitations of spontaneous 
ADR reporting in the UK. Given that pharmacists' training is becoming 
increasingly clinically orientated, pharmacists have the potential to make a 
significant contribution to pharmacovigilance initiatives on a local and national 
basis. During the design of the program of studies for this thesis in 1996, 
pharmacists were not recognised as official reporters of ADRs to the Yellow 
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Card Scheme. Thus, the initial focus of this thesis was to evaluate and identify 
roles for pharmacists in ADR reporting and an in local ADR reporting schemes. 
This was to be achieved using a national postal questionnaire survey and a 
prospective evaluation of the local ADR reporting scheme at the RLUH 
described in section 2.3. In addition, it was intended to conduct a prospective 
investigation of the problems associated with ADR-related admissions and an 
investigation of the potential for using computerised data to monitor and report 
ADRs. The results of these studies could then be used to identify potential roles 
for pharmacists. 
The introduction of reporting for pharmacists described in section 1.19 and 
which took place in 1997 presented an opportunity to widen the proposed plan 
of research. The focus of this thesis therefore altered slightly to include an 
evaluation and assessment of pharmacists' involvement in and contribution to 
the Yellow Card Scheme using both qualitative and quantitative methodology. 
The initial survey of hospital pharmacy departments' involvement in ADR 
reporting was repeated to evaluate the impact that this development had on the 
operation of local or in-house schemes. 
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The overall aim of the thesis was therefore met by a series of related, but self- 
contained studies, which gradually built up a comprehensive picture of ADR 
reporting by hospital pharmacists in the UK. 
Specifically, the aims of the thesis were: 
1. To identify hospital pharmacists' current involvement in ADR reporting. 
The objectives for this phase of the study were; 
To investigate and assess the involvement of hospital pharmacy 
departments in ADR reporting, and factors influencing the existence of local 
ADR schemes. 
" To assess influences upon and the number of reports received by local ADR 
schemes. 
" To ascertain the influence of the Yellow Card Scheme on hospital pharmacy 
departments' involvement in local schemes. 
2. To identify potential roles for hospital pharmacists in ADR reporting in 
in-house or local ADR reporting schemes. 
The objectives for this phase of the study were; 
To develop and evaluate a computer database to record, analyse and report 
ADRs. 
" To assess methods of improving reporting rates of a local or in-house ADR 
reporting scheme. 
" To investigate the transfer of data from secondary to primary care concerning 
ADRs that patients may have suffered while in hospital. 
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3. To investigate pharmacists attitudes to, and knowledge of ADR 
reporting. 
The objectives of this phase of the study were; 
" To ascertain the extent to which hospital pharmacists have become involved 
in ADR reporting. 
" To assess pharmacists' attitudes to, and knowledge of, the Yellow Card 
Scheme and to compare it with those of medical staff assessed in previous 
studies. 
" To identify pharmacists' concerns about the Yellow Card Scheme and to 
identify factors that could encourage pharmacists to report ADRs. 
4. To investigate in areas in which ADRs have a significant impact and 
identify potential roles for pharmacists. 
The objectives of this phase of the study were; 
" To assess levels of reporting of ADRs for clinically significant ADRs in ADR- 
related admissions. 
9 To collate data about the nature of ADR-related admissions. 
To identify areas in which pharmacists could contribute to the reduction in 
impact and frequency of ADRs.. 
These four areas of research are closely linked to the model of clinical 
pharmacy practice in the UK. Such a model is illustrated in Figure 3.1 in which 
ADR-related activities are the focus. 
Chapter 3: Aims and objectives 
Figure 3.1: Flow chart illustrating model of clinical pharmacy. 
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Chapter 4: An investigation into adverse drug reaction reporting by 
hospital pharmacy departments in the United Kingdom. 
4.1 Introduction 
A number of examples of local reporting schemes have been published in the 
literature (see Chapter 2). Types of reporting system vary between institutions 
although most operate on the principle that reports are made to the pharmacy 
department using locally designed forms or by telephone. 
The aim of this phase of the thesis was, by surveying randomly selected hospital 
pharmacy departments throughout the United Kingdom, to assess the extent of 
involvement of pharmacy departments in ADR monitoring schemes and to 
highlight innovative practices within such schemes. 
4.2 Method 
A questionnaire was devised, covering a wide range of issues including size of 
hospital and pharmacy departments, roles of pharmacists employed by 
departments, existence of ADR reporting schemes and where appropriate how 
such schemes operate. The questionnaire was piloted at 15 hospitals and as a 
result, minor alterations were carried out to the wording of the questionnaire. 
Two hundred hospitals, out of an estimated 1000 hospitals in the UK, were 
selected at random from two databases. One hundred were selected from the 
United Kingdom Drug Information Pharmacists Group (UKDIPG) and a further 
one hundred from the directory in the Chemist and Druggist Annual (excluding 
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any hospitals selected from the UKDIPG). 65,06 Hospitals were selected from the 
UKDIPG as it was felt that hospitals with drug information facilities may be more 
likely to have ADR schemes and therefore provide more information about the 
methods used in operating such schemes. 
The questionnaire, a covering letter (Appendix 1) and a prepaid envelope with 
which to return completed forms were sent to randomly selected hospital 
pharmacies in July 1996. Envelopes were addressed to the `Clinical Services 
Manager' as it was felt that these individuals would be, in some respect, largely 
responsible for the operation of these schemes. For hospitals without a Clinical 
Services Manager, it was anticipated that the questionnaire would be completed 
by a pharmacist with clinical services input. 
Questionnaires were distributed in July 1996 and were returned over the 
following two months. Returned questionnaires were entered onto a database 
and analysed using the Epi-Info Version 6.3.67 Analysis of results included 
frequency evaluations, comparison of mean values and cross tabulations in 
which x2 tests were applied. P values of s 0.05 were taken to be statistically 
significant. 
4.3 Results 
Of the 200 hospitals surveyed, 172 (86%) responded. No significant difference 
was observed in response rate from hospitals selected from the UKDIPG (84 
responses (84%)) and those selected at random from the Chemist and Druggist 
register (88 responses (88%)) (f =0.66, p=0.4). No significant difference 
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between the two groups was observed in terms of the number of pharmacists 
employed by each department (x2=5.45, p=0.14) and the number of 
departments operating a local ADR monitoring scheme (x2=0.8, p=0.2) although 
hospitals in the UKDIPG group tended to have a larger number of hospital beds 
((2=6.97, p=0.07). As expected, one significant difference was observed 
between the two groups, in that departments in the UKDIPG group were 
significantly more likely to have a Drug Information Pharmacist (2=20.0, 
P<0.0001). 
4.3.1 Surveyed hospital demographics 
Distribution of the size of the respondent hospitals is shown in Figure 4.1. 
Figure 4.1. Distribution of hospital size (n=172) 
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Of these 172 hospitals, 102 (59.3%) were part of larger NHS trusts, 58 (33.7%) 
were affiliated to university medical schools and 27 (15.7%) had a Clinical 
Pharmacology department within the hospital. An ADR specialist nurse was 
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employed by 1 (0.6%) hospital. The distribution of the number of pharmacists 
employed by each department is shown in Figure 4.2. 
Figure 4.2. Distribution of number of pharmacists per department 
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4.3.2 Involvement in ADR reporting schemes 
Pharmacy departments were analysed according to their involvement in the 
provision of drug information services and ADR monitoring schemes, the results 
of which are shown in Table 4.1. Although it might be assumed that the 10 ADR 
specialist pharmacists were responsible for the organisation of local ADR 
schemes, this was not true; only 6 (60%) were employed by departments with a 
local ADR reporting scheme. The four who were not associated with local 
schemes were based in hospitals with drug information centres suggesting that 
this may have some association with their role. 
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Table 4.1. Activities related to Drug Information and ADR monitoring 
performed by surveyed departments 
Activity (n = number of responses per question) Number participating 
in activity 
Designated drug information pharmacist (n=171) 131 (76.6%) 
Designated drug information centre (n=169) 124 (73.4%) 
ADR reporting scheme (n=172) 26 (15.1%) 
Designated ADR specialist pharmacist (n=171) 10 (5.8%) 
Participants were also asked about formal mechanisms for documenting and 
communicating data concerning ADRs that had occurred in their hospital (Table 
4.2). Although few respondents indicated that mechanisms for documentation 
and communication of ADR data existed in their departments, it is possible that 
some were unaware of such mechanisms that may exist outside the pharmacy 
department. A computerised data base of ADRs, was maintained by 2 (7.7%) 
departments of which one hospital used the database as part of an in-house 
intervention collection. 
UVt RQOOL ýýý CITY 
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Table 4.2. Formal mechanisms of documentation and communication of 
details of ADRs (n=172) 
Mechanism yes 
Documentation in patients' notes 4(2.3%) 
Communication to patients' general practitioners 3(1.7%) 
Communication to patients' community pharmacists l (O. 6%) 
Data collection forms, for the purpose of evaluating identified ADRs, were used 
by 25 (14.5%) departments of which 16 (64%) were involved in a local scheme. 
Having identified an ADR, 2 (1.2%) respondents used an algorithm (see section 
2.3) to decide whether to report an ADR to the CSM / MCA. Clinical judgement 
was used by 83 (48.3%) respondents and 157 (91.2%) discussed the reaction 
with medical staff. Other methods of deciding to report ADRs included 
discussion with senior pharmacists (1 (0.6%)) and reporting all reactions to 
unlicensed medicines (1 (0.6%)). 
4.3.3 Hospitals having ADR reporting schemes 
Of the 172 responding hospitals, 26 (15.1%) had an ADR reporting scheme. 
Schemes were organised by pharmacy departments in 21 (84%) cases, Clinical 
Pharmacology Departments in 2 (8%) cases and in single instances (4%), 
schemes were operated either by senior medical staff alone or by a combination 
of pharmacy and Clinical Pharmacology Departments. 
Reports of suspected adverse drug reactions were made to pharmacy 
departments in a number of ways, with some departments using a combination 
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of methods. Locally designed cards were used by 16 (61.5%) departments, 
telephone reporting was used by 10 (38.5%) departments and CSM / MCA 
Yellow Cards were used by 8 (30.8%) departments. No other methods were 
reported. The CSM / MCA `Yellow Card' category included 4 departments 
involved in the Northern Regional pilot scheme investigating participation in the 
Yellow Card Scheme by pharmacists. 21 Personnel allowed to report via such 
schemes differed between establishments (Figure 4.3). Some departments 
allowed reporting by 'Anyone', whereas some departments were more selective 
(see discussion). 
Figure 4.3. Staff groups permitted to participate in local ADR reporting 
schemes (n=26) 
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For those units using `Yellow Card' reporting, pharmacists and other professions 
were not always included in these schemes as, at the time of the survey, only 
doctors and dentists were allowed to submit 'Yellow Cards' direct to the CSM / 
MCA with the exception of the Northern Regional scheme (see section 1.19). 
Hospitals were also asked, where possible, if they could provide examples of 
locally designed cards or ADR investigation forms. Cards were provided by 7 
(26.9%) departments and ADR investigation forms were provided by 2 (7.7%) of 
hospitals. These cards tended to be similar in design with only basic information 
being required to make a report. Patient details, suspect drug, brief details of 
the suspected reaction and details of the reporter were required for most 
reports. 
Participants having an ADR reporting scheme were also asked if feedback was 
supplied to reporters. Feedback was 'always' provided by 8 (30.7%) 
departments, 'never by 3 (11.5%) departments, 'on request only' by 3 (11.5%) 
departments and 'for selected reports only' by 9 (34.6%) departments (the 
remainder did not answer). The nature of feedback to reporters varied with 16 
(80%) of those providing feedback informing the reporter whether a Yellow Card 
had been sent to the CSM / MCA or of the likelihood that a reaction had 
occurred. An indication of the incidence of reported reactions was fed back to 
reporters by 15 (57.7%) schemes. Departments were also questioned about the 
methods of publicising ADR schemes within the hospital. Of the 26 hospitals 
having an ADR scheme, 16 (61.5%) hospitals actively publicised their scheme 
using methods described in Figure 4.4. Other methods of promoting the 
scheme included co-operation with clinical audit (1 (3.8%)) and lecturing to 
doctors during their induction week (1 (3.8%)). 
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Figure 4.4. Methods of publicising ADR schemes within hospitals (n=26) 
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N. B. 'D&T' newsletter refers to hospitals' Drug and Therapeutics Committee 
newsletters 
4.3.4 Numbers of ADR reports received by local schemes 
Some respondents declined to state the number of ADR reports received each 
year. Of the 15 who did, the number of reports received each year ranged from 
0-526 (mean 52.3± 115.3, median 20). Of these reports, the number that were 
submitted to the CSM / MCA each year ranged from 0-30 (mean 9.8± 8.5, 
median 9.0) (Figure 4.5). 
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Figure 4.5. Number of ADR reports received and subsequently forwarded to 
the CSM / MCA by local ADR schemes 
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Overall, just over one third of reports were forwarded to the CSM / MCA (mean 
36.6% ± 30.5, range 0-100%, median 27%). Despite having a scheme, hospital 
7 received no reports. For hospitals 13,14 and 15 in Figure 4.5, Yellow Cards 
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were used to report ADRs and all reports were subsequently sent to the CSM / 
MCA. 
4.3.5 Possible Influences on numbers of ADR reports. 
The number of reports received by a scheme was not influenced by the size of 
hospital in terms of number of beds (p=0.3) or the number of pharmacists 
(p=0.06), the presence of a drug information pharmacist (p=0.4) or the presence 
of a clinical pharmacology department (p=0.3). 
Although no extraordinary reasons appeared to exist for the substantially larger 
number of ADR reports received by hospital number 4, the hospital appeared to 
be ideally equipped to operate an ADR scheme. The hospital was very large 
(>1200 beds), had a correspondingly large number of pharmacists (>21), had a 
drug information pharmacist and centre, employed an ADR specialist 
pharmacist, had a patient help line, allowed reporting by most hospital staff via 
card or telephone and promoted the scheme throughout the hospital. 
The departments that publicised the existence of local ADR reporting schemes 
received significantly higher numbers of ADR reports (mean 73; median 25) than 
those that did not (mean 14, median 5) (Mann-Whitney test, p=0.04). The 
presence of a specialist ADR pharmacist resulted in a significantly larger 
number of ADR reports being received by the scheme (Mann Whitney, p= 
0.05). Those having an ADR pharmacist received a mean of 146 reports 
(median 50) in comparison to a mean of 21 reports (median 15) for departments 
without an ADR pharmacist. Hospitals providing feedback to reporters received 
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a significantly larger number of ADR reports (mean 73; median 25) than those 
not providing feedback (mean 13; median 5) (Mann-Whitney test, p=0.04). 
4.3.6 Hospitals without local ADR reporting schemes 
The reasons why hospitals did not have ADR reporting schemes are shown in 
Figure 4.6. 
Figure 4.6. Reasons why a local ADR scheme does not exist (n=143) 
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Other reasons for the absence of a scheme included a hospital which used 
incident forms to record ADRs (1 (0.7%)), 'Yellow Cards' being freely available in 
BNFs (1 (0.7%)), and the fact that pharmacists were excluded from the 'Yellow 
Card' ADR reporting scheme (2 (1.4%)). 
Of 146 departments having no scheme, 113 (77.4%) said they would consider 
implementing schemes in their hospital. Of these, 90 (79.6%) said they would 
utilise reporting by locally designed card, 66 (58.4%) said they would use 
telephone reporting, and 6 (5.3%) said they would co-ordinate 'Yellow Card' 
reporting. Other methods of preferred reporting included via the Hospital 
Information System (HIS) (1 (0.9%)) and via E-mail (1 (0.9%)). Despite having 
no specific or dedicated ADR reporting scheme, 127 (87.0%) hospitals used 
intervention monitoring. Of these hospitals, 92 (72.4%) recorded interventions 
concerning ADRs of which 83 (90.2%) used the data collected to report ADRs to 
the CSM / MCA. For hospitals indicating that size of departments had an 
influence on the existence of a scheme, significantly more were from smaller 
hospitals ((2=29.98, p<0.0001). Conversely, for hospitals indicating that number 
of staff was an important factor, there was no significant trend in larger or 
smaller numbers of staff. 
4.3.7 Possible influences of other factors on the existence of a local 
ADR scheme and their significance 
From the results of the survey, it did not appear that size of hospital in terms of 
the number of hospital beds (p = 0.5) or number of pharmacists (p = 0.1), had 
any significant influence on the existence of a local ADR reporting scheme. For 
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hospitals stating that number of staff was an important factor in relation to the 
absence of a scheme, there was no significant trend towards either larger or 
smaller numbers of staff (p=0.44). The hypothesis that the presence of a 
designated drug information pharmacist or centre would result in an increase in 
the proportion of hospitals having a scheme was not substantiated; in fact, a 
trend, although not significant (p=0.3), suggested the reverse. However, 
hospitals having a Clinical Pharmacology department were significantly more 
likely to have a local ADR reporting scheme in operation (x2=5.17, p=0.04) whilst 
a similar association was not true for hospitals affiliated to a medical school 
(p=0.15) 
4.3.8 Monitoring of newly marketed agents 
18 (10.4%) departments operated schemes to monitor adverse effects of newly 
marketed drugs, that is those marked with inverted black triangles in the British 
National Formulary, Data Sheet Compendium and on promotional material. Of 
these, 3 (16.7%) departments operated schemes in conjunction with a local 
ADR scheme. Methods of monitoring these drugs included highlighting them on 
prescription charts (13 (72.2%)), highlighting dispensing containers for these 
drugs (4 (22.2%)) and monitoring specific drugs for adverse effects (5 (27.7%)). 
4.4 Discussion 
From the results of the survey, it can be shown that there is less pharmacy 
involvement in ADR activities in the UK than in the US; 15% of this sample of 
UK hospitals were involved in ADR monitoring, compared with 8O. 7% and 
96%00 of surveyed American hospitals in 1992. The American Society of 
Chapter 4: Initial hospital pharmacy survey 69 
Hospital Pharmacists has taken a leading role in the development of pharmacy 
involvement with ADR reporting, publishing a number of articles and 
programmes to help pharmacists become more informed about ADR monitoring 
and reporting. As stated in Chapter 1, this approach appears to have resulted in 
hospital pharmacists becoming the most frequent reporters of serious ADRs to 
the FDA. Since the introduction of ADR reporting in the UK, the Royal 
Pharmaceutical Society of Great Britain is yet to offer a similar service to its 
members. 
For hospitals with ADR reporting schemes, few major differences existed in the 
operation of local ADR reporting schemes. Most departments allowed more 
than one discipline to participate in their ADR scheme. It has been shown that 
different professions report different types of ADR. 70 A multi-disciplinary 
approach is therefore more likely to result in a larger quantity and wider variety 
of reports than one profession alone, particularly as it is not the responsibility of 
one individual to report an ADR that a patient may suffer. 
It was unclear from the results of the study whether patients were allowed to 
participate in local schemes. The design of the questionnaire allowed 
respondents to indicate that either 'Anyone' could report via their local scheme 
or to indicate that patients or individual categories of hospital staff were allowed 
to report via their scheme by ticking the appropriate box. For those opting to tick 
individual professions rather than 'Anyone', none included 'Patients'. It is 
therefore possible that selection of 'Anyone' implied 'Any member of staff rather 
than including 'Patients'. This may particularly be the case as 'Patients' may not 
have access to local reporting cards or telephone numbers in order to make an 
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ADR report. Nevertheless, patients are an important source of ADR information 
and should be encouraged to report suspicions of ADRs. 
The results suggest that having a pharmacist to co-ordinate, operate and 
promote a scheme may increase the number of reports and raise the profile of 
the scheme. The nature and role of the ADR specialist pharmacist in hospitals 
which did not have an ADR reporting scheme was not clear. However, all 10 
ADR pharmacists were from centres who had a drug information centre, which 
suggests some involvement in this area. 
The most frequently used method of reporting was via locally designed card. 
'Yellow Cards' were used by some departments although they may present 
some disadvantages in that they are more complicated to fill in than the local 
reporting cards obtained from this survey which are simpler to complete. 
Telephone reporting was also a frequently cited method and is also simpler to 
carry out than completion of a `Yellow Card'. 
Promotion of local schemes varied between departments and the more 
successful schemes tend to be those promoted within the hospital. Whether 
departments whose local schemes had collapsed due to lack of interest had 
effectively promoted their scheme within their hospitals is unknown. A lack of 
feedback concerning previously submitted ADR reports has been identified as a 
reason for failure of staff to report further ADRs. Most departments having an 
ADR scheme provided some degree of feedback to reporters. This acts as both 
feedback and promotion and may also inform participants in ADR reporting 
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schemes that their report is both appreciated and making a valuable contribution 
to surveillance schemes. 
Some hospitals involved in the Northern Regional scheme stated that they did 
not have a local reporting scheme; conversely other hospitals in the same 
scheme stated that they did have a local scheme. This may be due to the 
subjectivity in which the answer to the question was decided upon or 
alternatively due to the degree of involvement of the departments in promoting 
the regional scheme and concurrent local ADR reporting activities within their 
hospitals or departments. 
Reporting of ADRs to newly marketed drugs, that is, those marked with an 
inverted black triangle' is particularly important (section 1.13). The detection of 
rare ADRs, be it due to underlying pathology, drug-drug interactions, delayed 
onset or to their bizarre or unexpected nature, may not occur until long after the 
drug has been marketed. ",? As in-patients are a somewhat captive audience 
and biochemical and haematological data are often available for them, hospitals 
are therefore well placed to monitor for adverse drug reactions. Disappointingly 
few hospitals appear to be taking an active role in monitoring these drugs for 
ADRs. Although the use of many newly marketed agents is restricted by 
hospital formularies, many such agents are used by specialist centres before 
their use is widespread in general practice. 
Few departments had any sort of formal documentation procedure for ADRs or 
any sort of formal communication procedure to patients' general practitioners. 
Furthermore, few hospitals had any sort of investigation form for the evaluation 
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of identified ADRs. ADR documentation and communication is left largely to the 
whims of those caring for the patient. Although it is expected that details of 
patients' ADRs would be documented in their medical records and 
communicated to their general practitioners via the discharge prescription and 
discharge letter, this is often not the case, even for more severe reactions. '13 
ADRs should be processed correctly in order to protect the patient and 
prescriber from the effects of inappropriate re-exposure of the drugs concerned. 
Insufficient information may also prevent a patient being denied medications to 
which they have previously suffered minor adverse effects but could still be 
appropriately prescribed. Patients should also be informed of the name of the 
drug and the nature of their reaction as prescribers may not always have ready 
access to their medical records. 
The results show that a large proportion of ADR reports are not forwarded to the 
CSM / MCA. This survey did not investigate reasons for this but it may be 
assumed that a large number do not satisfy the criteria defined by the CSM / 
MCA. A large number of reports are possibly not reported due to lack of 
information or uncertain causality. However, it would be of interest to investigate 
these reports to determine if common ADR reports appear and also if a 
significant number of reports that should be reported to the CSM / MCA are not 
being made. 
Few departments used a computer to develop a database of ADR reports 
received by the pharmacy department. Such a database may be used to 
produce basic analyses of reports and to identify trends occurring within the 
hospital or frequent types of reaction. The database could also be programmed 
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to produce several reports from a single data set, for example, a letter for the 
GP giving details of the reaction, a label and letter for the patient's medical 
records, a report for the Drug and Therapeutics Committee and a report for the 
patient's community pharmacist (see Chapter 8). 
Despite the fact that 84.9% of the hospitals in this sample did not have an ADR 
reporting scheme, a large number of departments indicated that they would 
consider implementing an ADR scheme. The proposed introduction of Yellow 
Card reporting for pharmacists (which was published after this survey was 
completed) may have prompted departments to introduce ADR reporting 
schemes and may have changed the attitudes of the many respondents who 
had said they would not consider implementing such a scheme and also those 
whose schemes had failed in the past. 
For hospitals with limited resources or staff, existing activities may be altered to 
collect ADR reports. Telephone help lines for patients were under-used as 
methods of obtaining ADR data especially as they may be one of the few 
opportunities that patients may have to report ADRs. Intervention monitoring 
could also be used to a greater extent without greatly altering the methods or 
forms used to collect the necessary data and could be used as a form of 
reporting scheme for pharmacists within their own department. 
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5.1 Introduction 
75 
The previous chapter described an investigation into the activities of hospital 
pharmacy departments in ADR monitoring in July 1996. This study was carried out 
at a time when hospital pharmacists were not allowed to report via the Yellow Card 
Scheme. Hospital pharmacists were invited to join the Yellow Card Scheme in April 
1997. A follow up survey was undertaken in July 1998 to assess whether this 
change in practice had affected the extent to which hospital pharmacy departments 
were involved in in-house schemes and to further explore some of the issues 
addressed in the initial study. 
5.2 Aim and objectives 
The aim of the study was to assess the impact the introduction of Yellow Card 
reporting for hospital pharmacists had on the operation of local ADR reporting 
schemes. The objectives of the study were: 
" to determine the number of hospitals having local schemes in comparison to the 
previous study 
" to determine the number of reports received by these schemes and forwarded to 
the CSM / MCA in comparison to the previous study 
" to identify methods by which the schemes operated 
" to identify factors influencing whether hospitals operated a local scheme in 
comparison to the previous study 
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" to identify the number of reports received by schemes in relation to the number 
of pharmacists and the number of hospital beds in each hospital and to use this 
data as a marker of effectiveness of each scheme. 
5.3 Method 
A structured questionnaire was designed in which the issues addressed in the 
previous (1996) study were re-examined. The questionnaire was not identical to the 
one used previously; some questions were excluded and some new questions were 
included. Additional information sought included precise numerical data on the 
number of in-patient beds and pharmacists per hospital in order to calculate reports 
per bed and reports per pharmacist. Particular attention was paid to the operation of 
local ADR schemes and related activities and potential changes in the number of 
ADR reports made to the CSM / MCA by each pharmacy department. The issue of 
whether patients could report ADRs via local schemes, which the previous 
questionnaire failed to clarify, was also addressed. Since reporting had been 
introduced for pharmacists, the questionnaire asked for details of education and 
training that departments had carried out, in order to assess its impact on the 
numbers of reports made to the CSM / MCA. 
In the previous study, one hundred hospital pharmacy departments had been 
selected from the UK Drug Information Pharmacists Group (DIPG) directory, and a 
further one hundred from the Chemist and Druggist Directory (C&DD) (excluding 
hospitals already selected from the DIPG). 65 Hospitals had been selected from the 
DIPG directory as it had been anticipated that hospitals with drug information 
departments might be more likely to have an ADR monitoring scheme and would 
therefore provide more data. In fact, this was found not to be the case. 
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The pre-piloted questionnaire, a covering letter and a pre-paid envelope was sent in 
July 1998 (16 months after the introduction of reporting by hospital pharmacists) to 
the same 200 hospital pharmacies as in the previous study (Appendix 2). Follow up 
letters and questionnaires were issued to non-respondents one month later. The 
questionnaire was addressed to the clinical services manager in each pharmacy 
department, as this approach in the previous study had resulted in an 86% 
response rate. For hospitals without a clinical services manager it was expected that 
the questionnaire would be completed by somebody with clinical input to the 
departments operation. Returned questionnaires were collated and evaluated 
using Epi Info version 6.3.6' Analysis of results included frequency evaluations, 
comparison of mean values (± standard deviation) using the Mann Whitney test and 
cross tabulations in which chi squared tests were applied. Ps0.05 or less was 
selected to indicate statistical significance and all values were calculated at 95% 
confidence intervals. 
5.4 Results 
Of the 200 hospitals surveyed, 153 (76.5%) responded. Of these, three hospitals 
had been dosed or had merged with another hospital since the previous study. 
These three were returned uncompleted and therefore excluded from the study. 
Therefore, of 197 possible responses, 150 (76.1%) responded. 
5.4.1 Validity of results: comparison lbr the two surveys. 
The response rate was 76.5%, a significant difference (p=0.01, x2 = 6.29) in 
comparison to the response rate of the previous study (86% (172 / 200)). Overall, 
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there were no statistically significant differences in the demographics of the 
responding hospitals between the two studies. The size distribution of responding 
hospitals is shown and compared with the previous study in Table 5.1. 
Table 5.1: Distribution of hospital size 
Number of <400 401-800 801-1200 > 1200 Data not 
hospital beds supplied 
Number of 51 (34%) 67 (44.7%) 22 (14.7%) 7 (4.7%) 3(2%) 
hospitals 198 
(n=150) 
Number of 63 (38.7%) 78 (45.3%) 24 (13.9%) 6 (3.5%) 1 (0.6%) 
hospitals 196 
(n=172) 
NB. Some percentages may not add up to more than 100% due to rounding up 
The distribution of the number of pharmacists employed by each department is 
shown in Table 5.2. Of the hospitals responding, 45 (30%) were affiliated to a 
university medical school (58 (33.7%) previously), 19 (12.7%) had a Clinical 
Pharmacology department (27 (15.7%) previously) and 1 (0.7%) hospital had an 
ADR nurse (1 (0.7%) previously). 
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Table 5.2: Distribution of number of pharmacists per department 
Number of <10 11 - 20 21 - 30 >30 Data not 
pharmacists per supplied 
department 
Number of 73 (48.7%) 58 (38.7%) 8 (5.3%) 6(4%) 5(3.3%) 
departments '98 
(n=150) 
Number of 85 (49.4%) 66 (38.4%) 12 (7.0%) 6 (3.4%) 3(l. 7%) 
departments 196 
(n=172) 
NB. Some percentages may not add up to 100% due to rounding up 
5.4.2 Comparison of DIPG and C&DD groups. 
No significant difference in response rate was observed between the hospitals 
selected from the DIPG (76 / 150 responses, 50.7%) or from the Chemist and 
Druggist directory (74 / 150 responses, 49.3%). Comparison of the average number 
of hospital beds per hospital between the DIPG and C&DD groups revealed a 
similar profile (no significant difference) however, hospitals in the DIPG had a 
significantly larger number of hospital pharmacists (DIPG mean 13.8 ±8.9, C&DD 
mean 10.5 ±10.1, p=0.001). As expected, hospitals from the DIPG group were 
significantly more likely to have a drug information pharmacist (p<0.001, x2 = 21.51). 
No significant difference was observed between the DIPG and C&DD groups with 
regard to the presence of a local ADR reporting scheme (p=0.9). Therefore, they 
can be analysed as a single sample for the purposes of this chapter. 
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5.4.3 ADR specialist pharmacists. 
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ADR specialist pharmacists were employed by 14 departments and hospitals having 
an ADR scheme were significantly more likely to have an ADR pharmacist than 
those without such a scheme (p=0.01, x2 = 5.78). Duties of ADR specialist 
pharmacists where hospitals had an ADR scheme included co-ordination of ADR 
reporting, education of staff, co-operating with clinical pharmacology departments 
and assessing ADR reports, whether alone or in conjunction with medical staff. In 
hospitals where ADR reporting schemes were absent, the roles of the ADR 
specialist pharmacists were similar and included education and training with regard 
to ADR reporting, co-ordinating data collection and queries about ADRs and 
responsibility for overseeing ADR reporting. Hospitals with an ADR pharmacist had 
a significantly larger number of hospital beds (mean 806.2, ± 420.0) in comparison 
to hospitals without (mean 546.2, ± 288.6, (p=0.03)). Similarly, hospitals with an 
ADR pharmacist had a significantly larger number of pharmacists (mean 21.8, 
±18.1) in comparison to hospitals without (mean 11.2, ±7.6, (p=0.01)). 
5 . 4.4 Involvement in ADR schemes. 
The involvement of pharmacy departments in the provision of drug information 
services and ADR monitoring schemes is shown and compared with the previous 
study in Table 5.3. Telephone help lines for patients were operated by 41 (27.3%) 
hospitals and of these 17 (41.7%) departments used the help lines to report ADRs 
to the CSM / MCA. 
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Table 5.3: Pharmacy departments' drug information and ADR monitoring 
activities: Comparisons between surveys. 
Activity I position 1998 (n=150) 1996(n=172) P value 
Designated DI pharmacist 79.3%(119) ; 76.6% (131) 0.6 
Designated DI centre 75.3% (113) `73.4% (124) 0.7 
ADR reporting scheme *18.9% (28) 15.1%(26) 0.4 
Designated ADR specialist 9.3%(14) 5.8% (10) 0.1 
pharmacist 
+ Data not supplied by one respondent 
* Data not supplied by three respondents 
Few departments (4 (2.7%)) had any procedures for documenting ADRs in patients' 
medical records. Only 1 (0.7%) department had any procedure for reporting ADRs 
to general practitioners (which involved a section on the discharge letter to explain 
the reasons for stopping drug therapy) and none of the departments had a 
procedure for communicating this information to patients' community pharmacists. 
A comparison with the previous study is shown in Table 5.4. 
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Table 5.4: Formal mechanisms of documentation and communication of 
details of ADRs. Comparison between surveys. 
1998 (n=150) 1996 (n=172) P value 
Documentation in patients' 2.7% (4) 2.3% (4) 0.8 
notes 
Communication to patients' 0.7% (1) 1.7% (3) 0.4 
general practitioners 
Communication to patients' -00/0(0) 0.6% (1) 0.4 
community pharmacists 
* Data not supplied in one response 
5.4.5 Hospitals having ADR reporting schemes. 
Of the hospitals surveyed, 28 (18.7%) stated that a local scheme was in operation, 
a non-significant increase in comparison to 26 (15.1%) departments in the previous 
study (p=0.6). There was no significant change in terms of which departments 
within hospitals organised local schemes. Of the 28 hospitals having a local 
scheme, 24 (85.7%) were operated by pharmacy departments only, 1 (3.6%) 
scheme was operated by clinical pharmacology alone and in 2 (7.2%) cases, the 
scheme was operated jointly between pharmacy and clinical pharmacology 
departments. The remaining hospital did not state who operated their scheme. To 
assess their quality or suitability for forwarding to the CSM / MCA as Yellow Cards, 
ADR reports were screened by `pharmacists only' in 9 (32.1%) cases, `pharmacists 
and medical staff in 6 (21.4%) cases and `medical staff only' in 2 (7.1%) cases. 
The remainder did not comment. 
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Reporting methods were similar to the previous study with some departments using 
multiple methods. CSM / MCA Yellow Cards were used by 11 (39.3%) 
departments, telephone and CSM / MCA Yellow Cards were used by 9 (32.1%) 
departments, locally designed cards, telephone and CSM / MCA reporting forms 
were used by 5 (17.9%) departments, 2 (7.1%) used locally designed cards only 
and 1 (3.6%) department used a combination of local cards and CSM / MCA cards. 
In comparison to the previous study, numbers of schemes using locally designed 
cards fell from 16 to 8 while those using CSM / MCA Yellow Cards increased from 8 
to 27. Only one hospital had developed a computer database for their scheme, 
which was used to record and report on ADRs reported via the local scheme. The 
personnel allowed to participate in schemes varied between establishments. A 
notable difference between the present and the previous study was that 
pharmacists were now involved in all local schemes. An issue unclear from the first 
study was whether patients could report ADRs via hospital schemes. In this survey, 
of 28 respondents indicating that they operated a local scheme, 7 (25%) indicated 
that patients could report ADRs as part of a local scheme. 
Feedback was provided to reporters by 25 (92.6%) of the 27 respondents who 
answered this question. Analysis and comparison of the numbers of reports 
received by departments who did and did not provide feedback were therefore of 
little value. Of the 25 departments, feedback was 'always' provided in 10 (40%) 
cases, 'on request in 7 (28%) and 'for selected reports only' in 9 (36%). Of these, 7 
(28%) respondents felt that providing feedback was 'very important, 13 (52%) 
'important', 2 (8%) 'of little importance' and 1 (4%) 'of no importance'. 
Local schemes were publicised by 16 (57.1%) of the departments having such 
programs. Methods included an ADR newsletter in 3 (10.7%) departments, Drug 
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and Therapeutics Committee Newsletter in 8 (28.6%), posters in 7 (25%) and 
stickers on the cover of BNFs in 1 (3.6%) hospital. 
In response to an open question asking for general comments about their schemes, 
respondents appeared somewhat negative about the impact their schemes were 
having: 
"Hoping to improve things with new DI pharmacist" 
"Its rubbish really, were too short staffed to do anything better" 
"Plan to implement a better scheme" 
"Present scheme not a great success, a more formal scheme may be better" 
" Scheme not actively promoted due to staffing difficulties" 
Other respondents reported that they promoted the existing Yellow Card Scheme 
rather than using locally designed cards: 
"Not a local scheme as such, more a local procedure" 
"DI collates Yellow Card reporting" 
"Scheme generally acts to promote Yellow Card reporting to staff' 
6.4.6 Numbers of reports received and made to the CSM / MCA. 
Of the 28 departments having a local scheme, 18 provided details on both the 
number of local ADR reports and Yellow Card reports which they received and 
submitted to the CSM / MCA, while 3 departments only stated the number of Yellow 
Card reports they sent to the CSM / MCA. The number of local ADR reports ranged 
from 3- 180 reports (mean 24.4, ± 42.6). In comparison to the previous study, the 
mean number of local ADR reports received by pharmacy departments was reduced 
from 52.3 ±112.7 in 1996 to 24.4 ± 42.6 reports in 1998, a non-significant difference 
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(Mann-Whitney, p=0.29). Local schemes received a mean of 0.02 local reports per 
inpatient bed per year (± 0.041, median 0, range 0 -0.15) and a mean of 0.01 CSM / 
MCA reports per inpatient bed per year (± 0.03, median 0, range 0-0.14). 
However, in the previous study, the mean number of reports per department was 
skewed by the fact that one hospital had received 526 local reports. No equivalent 
number was reported in this survey. Without this outlying figure, the mean values 
for local reports per pharmacy department in 1996 and 1998 were 26.8 (± 29.8) and 
24.4 (± 42.6) respectively (p=0.4). Numbers of reports received by local schemes in 
this study are shown in Figure 5.1. 
Figure 5.1: Numbers of ADR reports received by local schemes and reported 
to the CSM I MCA 
Despite the fall in the number of local ADR reports received, a non significant 
increase was found in the number of Yellow Card reports to the CSM / MCA from a 
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mean of 9.5, ± 8.2 reports in 1996 to a new mean of 15.3 ± 22.4 reports (range, 3- 
100) per department in 1998 (Table 5.5, p=0.8). 
Table 5.5: Comparison of ADR reports made in 1996 and 1998. 
Local Reports Yellow Card reports 
1998 (n=21) 1996 (n=15) 1998(n=21) 1996 (n=15) 
Total number 4401 1046 312 156 
of reports 
received by 
schemes 
Mean number 24.4 52.3 14.8 9.8 
of reports 
received by 
schemes 
Std dev. 41.4 115.4 21.9 8.5 
Range 3-180 0-526 3-100 0-30 
Median 10 20 69 
Of a total of 446 local ADR reports made to participating departments, 312 (70.0%) 
were forwarded to the CSM / MCA, a significantly higher percentage than the 14.9% 
in the previous study (p<0.001, x2 = 165). The distribution of the number of reports 
made to the CSM / MCA by the surveyed hospitals is shown in Figure 5.2. 
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Figure 5.2: Distribution of reports to the CSM I MCA 
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5.4.7 Influences of other factors on the existence of a local scheme. 
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Hospitals were more likely to have a local scheme if they were affiliated to medical 
schools (p=0.03, x2 = 4.61) or a drug information pharmacist (p=0.05, x2 = 3.68). In 
the previous study, neither of these factors appeared to influence the presence of 
schemes (p=0.15 and p=0.3 respectively). Unlike the previous study (p=0.04, x2 = 
5.17), there was no significant evidence that hospitals having a clinical 
pharmacology department were more likely to have an ADR scheme than those 
without (p=0.3) although fewer hospitals in this survey had such a department. ADR 
schemes were associated with larger hospitals as judged by the number of hospital 
beds (mean 820.6, ± 382.5) in comparison to hospitals without a scheme (mean 
518.8, ± 264.1, (p<0.001)). Similarly, there was an association between hospitals 
with an ADR scheme and the total number of pharmacists in the department (mean 
0-10.11-20 21-30 31-40 41- 50 51-100 
Number of reports to the CSM 
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17.1, ±12.4 (p=0.003)) in comparison to hospitals without (mean 11.3, ± 8.6, 
(p=0.003)). 
5.4.8 Influences on numbers of ADR reports. 
The number of methods available to potential reporters appeared to increase the 
number of both local and CSM / MCA reports for each scheme although due to the 
small sample sizes, a statistical significance for this was unobtainable (Table 5.6) 
(p=0.2 and p=0.6 respectively). 
Table 5.6: 
scheme ( 
Influence of increasing numbers of reporting methods per 
n=18). 
Number Number of Mean Median Mean Median 
of departments number number number number 
reporting of local of local of CSM / of CSM 
methods reports reports MCA MCA 
used. (Standard reports reports 
deviation) (Standard 
deviation) 
1 11 12.0 10 9.6 7 
(± 1 0.1) (± 8.4) 
2 or 37 44.0 22 20.7 6 
(± 62.9) (± 30.2) 
There was no significant difference in the number of reports received by schemes in 
terms of the number of professions of staff available to report, although the mean 
number of local reports was higher in the group allowing three or more professions 
to report (Table 5.7). 
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Table 5.7: Influence of increasing numbers of professions able to report 
per scheme (n=21) 
Number of Number of Mean Median Mean Median 
different departments number number number number 
professions having of local of local of CSM I of CSM 
able to number of reports reports MCA MCA 
report different (Standard reports reports 
professions deviation) (Standard 
reporting deviation) 
1 or 2 11 11.6 10 14.0 10 
(± 8.8) (±12.1) 
3 or more 10 37.3 10 15.8 5 
(± 56.5) (±30.0) 
Publicising schemes through Drug and Therapeutics Committee newsletters or 
posters and stickers on BNFs resulted in a increase in the numbers of local reports 
received by schemes (mean number of reports 38.2, ± 60.3, median 10) in 
comparison to those who did not (mean number of reports 13.4, ±10.3, median 10) 
although this difference was not significant. Publicising schemes also appeared to 
increase in the numbers of CSM / MCA reports received by schemes (mean number 
of reports 20, ± 28.7, median 7) in comparison to those who did not (mean number 
of reports 9.2, ± 9.1, median 5) although similarly, this difference was not 
significant. 
Chapter 5: Follow up survey 90 
5.4.9 Hospitals without an ADR reporting scheme. 
Hospitals without a scheme were asked to respond about any future plans to 
introduce schemes in their departments and hospitals. Of the 120 respondents, 15 
(12.5%) said they had definite plans to introduce a scheme in their hospital, 40 
(33.3%) had probable plans to introduce a scheme and 65 (54.2%) said they had no 
plans to introduce a scheme. Responses correlated significantly with the number of 
staff within the department (p=0.01). Those having 'definite' plans to introduce a 
scheme employed a mean of 19.1 pharmacists, those having 'probable' plans 
employed a mean of 11.6 pharmacists and those with 'no' plans employed a mean 
of 9.3 pharmacists. The presence of a drug information pharmacist significantly 
increased the likelihood that a scheme would be adopted (p=0.05, x2 = 5.84). 
However, the presence of an ADR specialist pharmacist did not (p=0.5). 
5.4.10 Monitoring of newly marketed agents. 
Of the 150 respondents, only 8 (5.4%) hospitals had schemes for monitoring newly 
marketed or black triangle drugs. Of these, 6 highlighted these drugs on 
prescription charts and 4 departments marked the containers in which these drugs 
were dispensed. Lists of these drugs were circulated to either the hospitals wards 
or to their pharmacists by 2 of the eight departments. Schemes had been 
implemented by 2 (1.4%) other departments but had been abandoned due to their 
ineffectiveness. 
5.4.11 Education and training. 
Of the departments responding, 94 (62.3%) had arranged education or training 
activities on adverse drug reaction monitoring for their departments. Of these, 79 
(83.1%) had organised workshop or discussion sessions, 77 (81.9%) had distributed 
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the CSM / MCA information pack to pharmacists, 23 (24.5%) had held formal 
lectures and 7 (7.5%) had initiated local schemes and discussed issues relating to 
their implementation. Representatives of 4 (4.3%) departments had been sent to 
regional study days on the introduction of ADR reporting for pharmacists. 
Those departments with greater numbers of pharmacists (mean 14.0 ± 10.3) tended 
to organise education or training activities compared with those with fewer 
pharmacists (mean 8.6 ± 6.2) not having such sessions (p<0.001). All but one 
department who provided information on the numbers of local and CSM / MCA ADR 
reports processed per scheme had organised education and training. Other 
significant influences on education and training activities included the presence of a 
local scheme (p<0.001, x2 = 12.44), specialist ADR pharmacist (p=0.02, x2 = 4.98) 
and a drug information pharmacist (p=0.03, x2 = 4.88). 
5.5 Discussion 
This study was conducted to evaluate the impact that the introduction of reporting 
via the Yellow Card Scheme by hospital pharmacists has had on the operation of 
local or in-house ADR reporting schemes. In the previous study, 80.1% of 
respondents from hospitals without a local scheme said they would consider 
introducing a local scheme. Clearly the introduction of hospital pharmacist reporting 
did not provide the impetus for such developments (although in this study, 12.5% of 
those responding said their departments had 'definite' plans to implement a scheme 
and 33.3% had 'probable' plans). Furthermore, schemes that have been introduced 
have been unsuccessful in generating large numbers of ADR reports. 
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In the United States of America, operating ADR reporting schemes is a requirement 
for hospitals to become accredited with the Joint Commission on the Accreditation 
of Healthcare Organisations. 46 Furthermore, pharmacists have been allowed to 
report as part of the Food and Drug Administrations spontaneous reporting system 
"MedWatch" for a number of years. Similar research has demonstrated that 
80.7% and 96%69 of surveyed American hospitals operated local or in-house 
schemes compared to 18.9% departments within this survey, a difference explained 
by the above reasons. However, it is clear that the importance of ADR monitoring 
has a lesser profile in the United Kingdom. 
There have been no innovations in the methods by which ADRs are reported via 
local schemes; however, the results suggest that increasing the number of methods 
available improves reporting rates. The fact that 11 (39.3%) departments of the 28 
having a local scheme used CSM / MCA Yellow Cards alone, and comments 
received concerning their operation, suggest that some departments are using 
these cards as part of a local procedure rather than locally designed scheme. This 
could also explain the increase in the proportion of reports forwarded to the CSM / 
MCA, that is, reports are only made in the first place if the reporter considers them 
appropriate for reporting as a Yellow Card report to the CSM / MCA, unlike some 
schemes where reporters are asked to report any suspected reaction. 12 These 
'procedures' primarily involved co-ordination of Yellow Card reporting either by the 
hospital as a whole or by the pharmacy department itself. Such a scheme would 
place minimal demands on the department, encourage and increase awareness of 
reporting and reduce duplication and paperwork. In addition, the increase in the 
proportion of Yellow Cards submitted to the CSM / MCA could be due to a change in 
the proportion of reports originating from hospital pharmacists; however, this 
information was not collected as part of this study. Nevertheless, it is encouraging 
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that the number of Yellow Card reports submitted to the CSM / MCA has increased, 
albeit non-significantly. Staffing difficulties within the NHS further compound the 
problem of underreporting of ADRs in hospitals with local schemes. 74 While 
healthcare professionals are working in pressured environments, staff are forced to 
prioritise their work and as ADR reporting has no imediate gain to the patient at that 
time, it is possible that it is neglected for more pressing activities. 
From the small numbers of departments allowing patients to report, it is clear that 
patients have very little opportunity to report ADRs without directly consulting a 
doctor or other healthcare professional. Other research has shown that patients are 
concerned about ADRs (potential or actual) and that they were the most frequently 
cited reason for calling a medicines information help line. 75 The Consumers 
Association has also voiced concerns about the public's awareness and ability to 
participate in ADR reporting schemes. 76 It is important that some provision is made 
for patients to enquire about or report ADRs to healthcare professionals in a 
position to give them appropriate advice and that these reports are used to promote 
drug safety. 
Reporting of ADRs to newly marketed drugs, that is, those marked with an inverted 
black triangle, is particularly important given the limitations of clinical trials. The 
detection of rare ADRs, be they due to underlying pathology, drug-drug interactions, 
delayed onset or to their bizarre or unexpected nature, may not occur until long after 
the drug has been marketed. 71.72 It was somewhat disappointing that little activity 
had developed in the monitoring of the black triangle or newly marketed agents in 
the two years since the initial survey. Given the paucity of ideas concerning 
methods of monitoring these agents, it is improbable that any major inroads in this 
area will develop in the near future. The increasing use of computer assisted 
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prescribing may provide a solution to this, in that reporting processes can be built in 
to such programs prompting prescribers to report suspicions of ADRs. 
Underreporting of ADRs was once again identified as a problem affecting local 
schemes. The combined number of inpatient beds for those hospitals having a 
reporting scheme was 22,156 beds. If the average inpatient episode lasts between 
one to two weeks, then it is not unreasonable to assume that this could account for 
up to or over one million patients treated at these hospitals each year. Assuming 
the data provided by Lazarou et a14 correct and can be applied to this sample, if 
6.7% of these patients have suffered a serious ADR then the 410 local ADR reports 
received over a year by local schemes represents a small fraction, far less than 
0.1% of the potential 'serious' ADRs that might be reported to the local schemes 
and an even smaller fraction of those reactions which were reported to the CSM / 
MCA. This is substantially lower than previous estimates of the extent of under 
reporting. 18 Less than two thirds of departments had provided any sort of education 
or training activities concerning ADR reporting for pharmacists and this could have 
contributed to the lack of reporting 
There had been no change in the number of hospitals having systems in operation 
to record ADRs in patients medical records and report them to either their general 
practitioner or to their community pharmacist. This is perhaps particularly surprising 
given the growing importance that many institutions are currently attaching to 'risk 
management and clinical governance. " Although it is expected or assumed that 
details of patients' ADRs are documented in their medical records and 
communicated to their general practitioners via the discharge prescription and 
discharge letter, this is often not the case, even for more serious reactions. 73 Not 
surprisingly, general practitioners also perceive this transfer of information as 
Chapter 5: Follow up survey 95 
inadequate. 78 Patients and prescribers should be protected from the effects of 
inappropriate re-exposure of the drugs concerned. Alternatively, patients may be 
mistakenly denied medication to which they have previously suffered adverse 
effects but could still be appropriately prescribed in a situation where other drugs 
may be less suitable or effective. 79,80, 
Issues concerning quality within the NHS are currently increasing in importance as 
the concept of clinical governance gains momentum. Some studies evaluating the 
impact of ADRs have concluded that many ADRs are predictable and 
preventable. 81'82 Data from local ADR schemes could be used to evaluate the 
impact ADRs have on quality within hospitals or similar healthcare institutions. 
Since organisations are to be accountable for "continuously improving the quality of 
their services and safeguarding high standards of care", monitoring of ADRs to 
assess their impact has been defined as a key area. The National Institute for 
Clinical Excellence (NICE) is intended to set standards concerning the management 
of clinical situations and the utilisation of clinical interventions in which the 
management of ADRs would appear to be a core issue. 20 Furthermore, as reporting 
to the CSM / MCA is confidential, it is not possible for hospitals to collate data 
concerning ADRs within their institution without some in-house system for collecting 
and collating reports. 
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Chapter 6: Attitudes of hospital pharmacists to adverse drug 
reactions and the Yellow Card Scheme: A qualitative study. 
6.1 Introduction 
A review of the first year of reporting demonstrated that reports submitted by 
hospital pharmacists had made a valuable contribution to the Yellow Card 
Scheme. In terms of the quality of reports, significantly fewer required follow up 
by the CSM / MCA than those reports submitted by hospital doctors However, 
the numbers of reports submitted by hospital pharmacists had been somewhat 
lower than expected. 83 
6.2 Aims 
The aim of this study was to investigate the attitudes of hospital pharmacists to 
ADR reporting, to identify any concerns they may have about this new role and 
to assess their attitudes to the CSM / MCA and the Yellow Card Scheme. 
6.3 Methods 
All major hospitals (n=13) within the Mersey CSM / MCA RMC catchment area 
were contacted and asked for permission to interview three clinical pharmacists. 
Chief Pharmacists were first contacted by letter outlining the purposes and 
nature of the study. Departments were then contacted by telephone to arrange 
a convenient time for face to face interviews if permissable. 
Interviews were focused on subject areas which were incorporated into a semi- 
structured questionnaire (Appendix 3). The questionnaire was based on similar 
research tools examining the attitudes of community pharmacists84 and medical 
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practitioners2021 to ADR reporting and was designed to assess pharmacists' 
attitudes to the Yellow Card Scheme, reporting of ADRs, reasons why they may 
not report ADRs and to assess their concerns about this new role. 
Interviews were piloted on five hospital pharmacists from outside the RMC and 
the structure amended prior to the main data collection phase of the study. 
Some dosed questions were changed to open questions and some questions 
were clarified. The same individual interviewed all pharmacists with interviews 
lasting approximately thirty minutes. The interviewer, who had previous 
experience in this methodology, prepared for the interviews through training 
sessions and literature review. ' 
Interviews were tape-recorded and transcribed into a word processing package, 
Microsoft Word, then exported to and analysed using WinMax Pro. 85 This 
program facilitates the collation of data using code words, categories or phrases 
with the intention to identify themes and issues raised during the interviews. 
Examples of code words or phrases include "black triangle drugs", "CSM / MCA", 
"Education and training", "Under-reporting' and "increasing reporting". These 
themes and issues are illustrated using verbatim quotes. 86 Two assessors 
carried out analysis individually and then jointly. Each interviewee was assigned 
an interview number for purposes of analysis and reporting comments (P1 - 
P38). 
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6.4 Results 
Demographics of interviewees. Interviews were completed with 38 
pharmacists from 13 hospitals (in one hospital, only two pharmacists were 
available for interview). Interviewees had been qualified for a mean of 8.1 years 
(± 6.6 years, range 1-30 years). Of those interviewed, 8 (21.1%) were currently 
undertaking diplomas in clinical pharmacy, 15 (39.5%) had completed a diploma 
in clinical pharmacy of whom 6 had extended their studies to MSc, while 11 
(28.9%) had no postgraduate qualifications. 'Other miscellaneous 
qualifications were held by 4 (10.5%) pharmacists. The interviews covered a 
wide range of issues and themes concerning the Yellow Card Scheme and a 
wide range of opinions and viewpoints were elicited from the interviewees. 
6.4.1 Attitudes towards the current Yellow Card Scheme fror reporting 
ADRs 
The Committee on Safety of Medicines. The CSM / MCA was criticised by a 
few interviewees for its lack of user friendliness or customer orientation: 
P25: "I think they're a classic government organisation, its not easy to get 
through to the right person at the right time. They should adopt more of a 
pharmaceutical industry, medical information type approach, where there is 
always somebody available to take a call. They're typically a government 
organisation and not enough customer focused. " 
Widespread dissatisfaction with the manner in which the CSM / MCA had 
resisted pharmacist reporting was expressed. The idea that pharmacists were 
Chapter 6: Attitudes to ADR reporting: qualitative study 100 
allowed to report ADRs because numbers were dropping rather than because of 
their professional capabilities was expressed: 
P4: "I was a bit peeved in a way that pharmacists were not regarded as 
competent enough to fill some form of ADR report. " 
P14: "I think the idea of getting pharmacists to report was because the number 
of reports had gone down, rather than them saying, `we'll let pharmacists report 
because they'll be really, really good at it". " 
A few pharmacists appreciated the CSM / MCA's concerns about pharmacist 
reporting: 
P8: °l could see where they where coming from in certain ways. You know, I 
could see that they have a vested interest as well, in not being swamped with 
masses of information which is of a dubious nature.... " 
Pharmacists felt that the CSM / MCA could encourage reporting by feeding back 
information about previously reported reactions and numbers and origin of 
reports in a more frequent and informative manner. 
P12: 7 you saw some examples of things people had reported and outcomes, 
if there was a positive outcome of it then I think that would encourage you to 
'port them, you'd know the benefits of fopoi1ing. " 
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P17 "I certainly would be interested in what comes out of our hospital and what 
proportion of it is ft m pharmacists. That information is probably not as readily 
available as I'd like it to be. I'd be interested what the national figures were so 
you could benchmark yourself against that and hope to increase it. " 
6.4.2 Regional Monitoring Centres. 
Pharmacists' opinions of the local CSM / MCA RMC varied depending on their 
proximity with the unit and the nature of previous contact, if any. Those who 
had used the unit had found it be useful and that knowing the staff on a 
personal basis and its local situation, encouraged them to use it. Those who 
had not used the RMC were largely ambivalent about its purpose and presence. 
Pharmacists appeared to be unclear as to the exact role of the RMCs: 
P34: "I dont really know what sort of role they fulfil at all. I think perhaps they 
should be giving more of the education that we need. To be honest I didn't even 
know there was one. " 
6.4.3 The Black Triangle Intensive Monitoring Scheme. 
Pharmacists were knowledgeable and largely positive about the benefits of the 
black triangle scheme. The fact that any suspected reaction should be reported 
removed many of the concerns about whether a report should be made. 
Reporting of minor reactions to black triangle drugs. Pharmacists had mixed 
views about whether a drug's status in terms of the black triangle, would 
encourage them to report minor or less important reactions; 14 (36.8%) said 
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they would, 10 (26.3%) said they would not and the remainder said that it would 
depend on the circumstances at the time of the reaction. Whether a reaction 
was listed in the product's Data Sheet or Summary of Product Characteristics 
appeared to be an important factor in deciding whether to report: 
P25: "It depends on what kind of drug it was, if it was a completely new 
chemical entity yes I would. " 
6.4.4 Crlterla for reporting. 
Pharmacists had mixed opinions about the criteria for reporting ADRs. 
Pharmacists who had participated in education and training sessions appeared 
to be either more knowledgeable or less concerned about the criteria for 
reporting ADRs whereas other pharmacists, particularly those newly qualified, 
expressed concerns about reporting inappropriately. 
P12: "I'm not sure when to report and when not to so i and up being 
overcautious really, you know, because you don't want to just start sending in a 
form for everything so... " 
P10: "I think the criteria are pretty good actually. I think its easier in a hospital 
situation knowing more accurately what to report because of things like, what 
extends hospital stay or what causes admission. I suppose, if you're not seeing 
patients from that situation, then things might be harder to fit into the criteria. " 
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P11: "It's perhaps not clear to other pharmacists or even clinicians who've not 
had additional training. They tend to focus on black triangle drugs and don't 
report well known reactions. " 
P9: Well in theory they're okay but once you get down to it its not so easy and 
there are some cases where it's a bit unclear. What's not serious to the CSM / 
MCA might well be serious to the poor sod that's got to put up with it! I mean 
some things that medics think, and we think patients should put up with, aren't 
really all that pleasant and it's easy to overlook that. I probably use my own 
interpretation of what the criteria are if I'm honest. " 
P1: "Because I'm newly qualified I would seek advice from other members of 
the department. If they were of the opinion that it wasnY worth reporting then 
probably wouldn't - I'd listen to them. " 
6.4.5 Comments on the Yellow Cord. 
Pharmacists were generally satisfied with the layout and required content of the 
Yellow Card. Lack of space for additional medication was the only problem 
identified on a number of occasions although some pharmacists correctly 
identified the option to put this information on the back of the card or on an 
additional sheet. Pharmacists were generally unconcerned by the use of a 
separate reporting card for pharmacists. Many thought it appropriate because 
the CSM / MCA would want to compare pharmacists' reports with other 
professions and to audit the implementation of the scheme. Some pharmacists 
did not approve of the use of separate cards and the fact that Yellow Cards 
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were not available in the BNF was also highlighted. As a result, a minority of 
pharmacists felt their participation in the Yellow Card Scheme was not fully 
supported by the CSM / MCA and that they were perceived as "second class" 
reporters. 
6.4.6 Participation In the scheme to date. 
Of those interviewed, 15 (39.5%) had not reported an ADR via the Yellow Card 
Scheme, 7 (18.4%) had reported a single ADR, 12 (31.5%) had reported 
between two and four reports and only 4 (10.5%) had reported 5 or more ADRs. 
Pharmacists had reported a mean of 1.8 Yellow Cards (t 2.1, range 0-8). Most 
pharmacists commented that their contribution had been somewhat less than it 
could have been. Many pharmacists who had reported one or two Yellow Card 
reports had done so shortly after the scheme had been launched and had not 
reported once the 'novelty' had wom off: 
P3: "I did one early on, just after it started, I think I made mote of an effort 
because we had just been allowed to report. " 
P21: al think there's probably more that I've missed but I think pressure of work 
... I've either not picked them up or not reported them. " 
There was no real consensus as to why pharmacists had reported some 
reactions and not others suggesting that the decision is often made either on a 
whim or depending on the circumstances that pharmacists find themselves in at 
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the time. Many were stimulated to report by reactions that had been to a black 
triangle drug, had resulted in hospital admission or had been particularly 
serious. Others had reported less notable reactions that complied with the CSM 
/ MCA criteria or reported because doctors had been unwilling to do so: 
P20: "Probably the severity. The one I remember clearly was a child who 
ended up on intensive care with Steven's Johnson Syndrome..... " 
P30: "The one where a patient was accidentally re-challenged with the drug 
and had the same reaction -I felt very definite about that, it was very.... worth 
reporting. " 
6.4.7 Relations with medical stafff. 
Overall, the fact that doctors receive a copy of their ADR report did not concern 
pharmacists. Most stated that they would not report an ADR without either 
informing the patient's doctor or discussing it with them first to obtain a second 
opinion: 
PJO: "I work in a team anyway so I'm quite happy for the doctor to know. In fact 
I'd probably mention that I was filling a form in. " 
P15: Well I always generally discuss it with them anyway, if only to get their 
feeling as to whether it was or not. " 
However, many pharmacists were concerned about reporting ADRs in situations 
where they disagreed with the patients doctor about whether an ADR had 
Chapter 6: Attitudes to ADR reporting: qualitative study 106 
occurred or should be reported via a Yellow Card. One suggestion was that the 
option to report in confidence should be included in the reporting protocol: 
P9: "I think if there's disagreement you should be allowed, as a healthcare 
professional to make up your own mind and to be able to report something 
without having to get permission. " 
6.4.8 Causality of reactions. 
Pharmacists had some concerns over the certainty that a reaction had occurred 
and some would be deterred from reporting reactions that were unlikely or 
somewhat bizarre. Many suggested that they would contact the patient's doctor 
or discuss it with colleagues to obtain a second opinion before reporting. Some 
pharmacists were also conscious of the CSM / MCA's concerns about 
inappropriate reports and were reluctant to report potentially implausible 
reactions: 
P28: 'People aren't prepared to report unless they're 90% certain it is a reaction. 
I think we should be encouraging reporting between 50% and 90%, that sort of 
area because I'm sure a lot don't get reported. That's where we come in 
ieaI y.... " 
P18: 'Probably Pd consult with the doctor and see what their opinions were. It 
could be something clinical that you don? actually know about that patient But 
if they can't really establish why its happening, yea, !b probably iepoit. " 
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P30: "I'd have to pretty certain about something before I reported it. You'd have 
to be fairly sure it was a reaction to that drug but if it was a black triangle drug I'd 
probably report with a note saying this seems a bit strange to me but for all I 
know there could be ten more people sending in the same reaction, I mean 
every reaction's a little unusual the first time it happens. " 
Several pharmacists commented that ADRs were identified by chance rather 
than by a deliberate approach: 
P17: "There are an awful lot of things that we have to do when we go out onto 
wards and therefore its a bit serendipitous if we pick them up. I would say a lot 
of the ones we do report, are the ones that are reported to us. Sometimes 
patients will mention something or sometimes someone will say, "do you think 
this is a side effect? '"' 
P37: "I don't think they're pointed out for us, I think its more something you tend 
to spot. I mean I would look at, if something's crossed off for no obvious reason, 
I'd look at that and I'd find out why. Or, if someone's prescribed calamine or 
chlorpheniramine, look and see if they had a rash from a drug or something.... 
more often than not, if something's been stopped suddenly. " 
6.4.9 Modvadon in reportng. 
Most pharmacists stated that they felt motivated to report ADRs in principle 
although as demonstrated by their participation in the scheme, practice did not 
reflect this. Others were less enthusiastic about the scheme: 
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P13: 1 don't feel demotivated, so by inference, i suppose / am motivated. I just 
need to think about it. " 
P16. I'd like to think I'm committed to it. You know, when the opportunity 
arises I would feel motivated to do something about it. I don't think it's 
something we should tum our back on. " 
P23: "ADRs is not something I feel terribly motivated towards, which I do 
recognise is a bad thing because they do need to be repotted. " 
6.4.10 Patient confidentiality. 
Pharmacists were unconcerned about reporting patient details in terms of 
confidentiality. They were generally aware that information from Yellow Cards 
was treated in confidence and that they could report without identifying the 
patient, if required. 
&4.11 Attitudes towards hospital pharmacists' role in reporting via the 
Yellow Card Scheme. 
In response to their submission of a Yellow Card, pharmacists were generally 
unconcerned regarding the nature of feedback provided by the CSM / MCA and 
most stated that an acknowledgement letter or quantification of previous reports 
would suffice. One paediatric pharmacist commented that the data were of 
limited use as it was not categorised by age. Most were satisfied with the 
current provision of information, that is, details of numbers of previous reports, 
with few requiring further information. Pharmacists were concerned about the 
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quality of their report with many suggesting that it would be beneficial for them 
to be provided with feedback on the quality of their report. However, some 
expressed concern that individual feedback about inappropriate reports would 
dissuade people from reporting again and suggested the use of generic 
feedback: 
P27: "Ceitainly if they though my report was rubbish I'd want to know and I'd 
use that positively. If you don't, then you're going to carry on reporting rubbish 
in blissful ignorance for ever more. " 
A few pharmacists expressed the opinion that using the information that the 
CSM / MCA provides via drug analysis prints and individual case reports placed 
a responsibility to the user to contribute to that database or illustrated the 
problems associated with underreporting. Some commented that they used this 
data in their day to day practice: 
P3: "It's not till you use the data, you know, you've got it on the screen that you 
think perhaps I should do more. You think at the end of the day, it doesn't mean 
a lot when you put it into context, its only out of so many that haven't been 
reported. " 
When asked about Current Problems in Pharmacovigilance, nearly all 
pharmacists were enthusiastic about its content and format. Most pharmacists 
said they read it and that the brief and informative manner in which items were 
presented encouraged them to read it. Many commented that they used the 
information in practice: 
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P11: "I think I've used it in arguments, well not arguments, more discussions 
really with clinicians to back yourself up, for example the recent one with 
cisapride, we were discussing that just recently on a ward round. it soft of 
backs up your argument, that is, if the CSM / MCA are worried, then we should 
be too. " 
6.4.12 Reasons for under-reporting. 
Pharmacists were reluctant to report well known reactions despite their 
awareness of the need to do so: 
P4: if you saw something serious then you might think, lets get something 
filled in here, whereas, if its something that you know is regularly reported on, 
then you might not. " 
Many pharmacists quoted pressure of work as the reason for their lack of 
participation in the scheme. Most stated that it was a lack of time preventing 
them from identifyng ADRs in practice that was the problem rather than the time 
required to complete a Yellow Card: 
P2: "Its something that's taken a back seat because of the circumstances in our 
department. There's a limited number of staff within the system and other 
priorities have taken the lead. " 
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P3: "You might see an ADR but you come back from the wards and you get 
thrown into something straight away and once you've left it, then it never gets 
done. " 
Some pharmacists stated that they had yet to accept it as part of their everyday 
practice and that it was not one of their main priorities: 
P23: "... when I look at the things I need to do in one day its not something 
that's very high on my list. " 
Some pharmacists were concerned by their lack of clinical knowledge and felt 
that this was an area where doctors could assist them: 
P16: We're not doctors and I think some of my colleagues folget that 
sometimes. My diagnostic skills are male, female, bald, young, fat, thin and 
that's it. If I wasn't sue I'd seek some help or confirmation from the doctor. " 
P15: Wes, it sometimes bothers me that I might not have a total grasp of the 
condition the patients have but on the other hand, I know I can do a better job 
when it comes to drug details so I donut know... it's a bit of a balance really. " 
6.4.13 Education and training. 
Training was identified as an issue that would increase reporting and awareness 
of ADRs. Pharmacists who had been on the CSM / MCA RMC study day found 
the course beneficial. A deeper understanding of the Yellow Card Scheme and 
its purpose and intricacies appeared to motivate pharmacists either to report or 
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to be more concerned with participating in the scheme and its importance. 
Many stated that they had attended educational sessions as a pre-registration 
trainee or as a diploma student but that little had happened since then: 
P28: "Yes when we were first able to report we did a lunchtime seminar on 
ADRs and encouraging pharmacists to report and what we could do and also 
trying to get doctors to report. But that was a one off event really. " 
P11: "Certainly the study day made me more aware and more likely to report. 
Unfortunately I'm the only one from our department who's been and as far as 
know, they've not run another one and 1 think maybe if we got more pharmacists 
on that, that would help. " 
Pharmacists suggested that departments could encourage them to report ADRs 
by increasing time on the wards, development of a local scheme and by raising 
it as an issue within the department via departmental meetings: 
P24: "After we had a talk you were more aware of them, but that was a year 
and a half ago and we've not had anything since and perhaps we should do 
more regularly. It possibly needs other sessions or a six monthly review to see 
what people are reporting and how many just to keep people aware of what's 
going on. " 
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6.4.14 The concept of a fee. 
All pharmacists were generally opposed to the concept and a number expressed 
concern about inappropriate reporting. Although some stated that financial 
reward would be most welcome, many were concerned that reporting ADRs was 
a professional issue and should not be financially driven: 
P16: "A fee? Well I suppose it would stimulate some interest. It would be 
disappointing that we were needed to be paid to do something like that. " 
6.4.15 Local schemes. 
Pharmacists involved in local schemes stated that they found they were 
encouraged to report ADRs. Local schemes were useful for collating data within 
a hospital and for ward staff to communicate reports via official channels. 
Schemes were also described as sifting mechanisms for ADR reports from a 
quality control aspect. Some pharmacists in hospitals without schemes 
expressed a desire for their hospital to initiate one. 
6.4.16 Pharmaceutical companies. 
Pharmacists felt that drug companies were helpful in dealing with their ADR 
related queries and many commented that they were far more prompt than the 
CSM / MCA in providing written information. Although many were aware that it 
was a legal requirement, almost all pharmacists felt antagonised by the requests 
for further information from drug companies. 
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6.4.17 Professional responsibility. 
Pharmacists generally agreed that reporting was a professional responsibility 
and felt that it was an important part of their role: 
P13. "You're involved in the safe, effective and economic use of drugs. A part 
of that is the possibility that it might cause adverse effects and you've got to 
manage that. Reporting should be expected, it should be the norm. " 
6.4.18 Att/tudes towards the Introduction of reporting for hospital 
pharmacists. 
The introduction of direct reporting for pharmacists. The introduction of 
reporting for pharmacists was seen as a positive development by the majority of 
those interviewed. Many felt it was appropriate considering pharmacists' 
knowledge of drugs. In some cases, pharmacists had been involved in reporting 
ADRs either as part of a local scheme, assisting doctors to complete reports or 
merely obtaining a doctor's signature prior to submitting reports themselves. It 
was widely felt that reporting for pharmacists should have been introduced much 
earlier. The role of the Royal Pharmaceutical Society of Great Britain was 
perceived to have been disappointing in the introduction and subsequent 
promotion of the scheme: 
P16: "l think they're (the RPSGB) very lax in their approach to developing a 
proper professional approach... but they've taken too much of a back seat on it. 
Chapter 6: Attitudes to ADR reporting: qualitative study 115 
Things like this that we should embrace, maybe they've not done and provided 
as much support as there should have been. " 
6.4.19 The processes involved In the introduction of reporting. 
Pharmacists were generally dissatisfied with the process of the introduction of 
reporting. Many felt that there had been little publicity about the development 
and a number of pharmacists also commented that there had been little follow 
up after the introduction of reporting: 
P14: "... it just sort of came in. Everyone was sent booklets about it but there 
wasn't a huge amount of fanfare about it. " 
P17: ".... there seemed to be little consultation, one minute we couldn't and the 
next minute we could. Maybe I missed a lot of the pre-press about It, it seemed 
to suddenly happen rather than evolve. " 
Conversely, a minority of pharmacists was satisfied with the level of information 
provided: 
P 15: "'It was well publicised and I think the material that we got was sufficient 
for us to get on with it. " 
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6.4.20 CSM / MCA Information Pack 
The information pack designed to support the launch of pharmacist reporting 
was well received by pharmacists. Many had retained the pack as an 
information resource and used in as a training resource: 
P28: "1 thought it was quite basic but 1 wasn't sure we needed anything else 
quite frankly. /think it illustrates what you should report and what you shouldn't, 
I felt I knew most of it quite honestly but there again I thought it was a good 
reminder to everybody. " 
Approximately half of those interviewed considered themselves ill-prepared to 
participate in the scheme when it was introduced. Some seemed prepared to 
'have a go' while others were reluctant to report when they were unsure of 
exactly what was required. Some stated that their previous involvement in the 
completion of reports had prepared them for this role. 
M. 21 Final thoughts - viewpoints. 
Pharmacists were asked to give their final thoughts or observations on the 
scheme. Most felt that promotion of the scheme was important to encourage 
pharmacists to participate: 
P17: Well I hope it continues and I hope we continue to build up our role in it 
as the level of reporting that's coming out so far is pretty discouraging, j was 
under the impression that we weren't doing too badly but I know we could 
certainly do a lot better.... " 
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P18: "I think it is everyone's responsibility. You can't say its just pharmacists, it 
needs input from everybody. " 
P19: "Pharmacists don't seem to have taken up the challenge of showing that 
they are an important source of spotting ADRs. Possibly they're not in the right 
place at the right time, they're not as involved with the patient enough. " 
P25: I think its something that will grow into practice. It should be built into pre- 
reg. training, basic grade training and even diploma training. It will be 
interesting to see what the quality and amount of'epoffing is like in a few years 
rime. " 
6.5 Discussion. 
Despite the campaign for ADR reporting for pharmacists continuing for over ten 
years, 32 it was considered that its introduction was precipitous and that since 
then, it had been poorly publicised and promoted. Since its introduction, 
hospital pharmacists' participation in the scheme appears to have been 
somewhat sporadic. However, it is worth noting that the initial level of doctors' 
participation in the Yellow Card Scheme was also somewhat slow to reach the 
level of reporting that exists today. 87 The CSM / MCA generally has a poor 
image with hospital pharmacists in terms of its accessibility and perceived 
opinion of pharmacists' role in reporting. However, feedback by the CSM / MCA 
on individual reports was generally thought of as satisfactory and the Current 
Problems in Pharmacovigilance publication was highly regarded. 
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Only 42% of those interviewed had submitted more than a single Yellow Card 
report and a similar percentage had reported none at all. Whilst hospital 
pharmacists acknowledge ADR reporting as part of their professional role, it is 
not yet considered as part of their daily practice. A number of factors appear to 
be dissuading pharmacists from participating in the scheme. These include 
clinical factors such as uncertainty about the significance of a reaction and a 
lack of clinical knowledge. Collaborative reporting, combining doctors' clinical 
knowledge and pharmacists' pharmaceutical expertise should provide an ideal 
basis for quality ADR reporting. Pressure of work was also quoted as a 
deterrent to reporting; a factor that has not been helped by current recruitment 
difficulties. " These difficulties may have been a contributory factor as to why 
departments have done little to promote reporting and why ADR reporting does 
not rank as a high priority. Initial schemes for education and training were 
perceived as having been successful, however, eighteen months after the 
introduction of reporting, on-going training needs had not been fully addressed 
either by the CSM / MCA, their RMCs, the RPSGB or by individual hospital 
pharmacy departments. 
Hospital pharmacists did not consider that receiving a fee would increase 
reporting, in contrast to the opinions of community pharmacists. " This issue has 
been addressed previously by a CSM / MCA working party which concluded that 
the concept of having a sizeable fee might encourage reporting of trivial 
reactions while a small fee would not be a spur to reporting 86 The layout of 
Yellow Card reporting forms was deemed satisfactory and the concept of a 
separate card for pharmacists was acceptable. Availability of Yellow Cards was 
sometimes a problem, which could be overcome by the inclusion in the BNF of 
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an all purpose Yellow Card rather than one for use by doctors and dentists 
alone. The role of pharmaceutical companies should be addressed in 
pharmacovigilance as the negative views expressed by pharmacists about the 
nature and extent of follow up by company based medical information centres 
are in some cases deterring pharmacists from utilising a potentially important 
information source. However, pharmaceutical companies are currently legally 
obliged to follow up reports of ADRs with the reporting healthcare professional. 
6.6 Limitations of this study. 
The sample was restricted to main hospitals within the CSM / MCA Mersey 
Region. Potentially, there may have been differences in the responses received 
from hospital pharmacists in smaller hospitals. As interviews were conducted 
with only 38 of an estimated 200 hospital pharmacists employed in the CSM 
Mersey catchment area, caution should be exercised in the extrapolation of 
results to the rest of the population. However, this phase of the study is the first 
to collect qualitative data about ADR reporting by hospital pharmacists and has 
provided some insight into the processes affecting their participation in the 
Yellow Card Scheme. 
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Chapter 7: Attitudes of hospital pharmacists to adverse drug 
reaction reporting and knowledge of the Yellow Card Scheme. 
7.1 Introduction 
The previous chapter describes the qualitative approach used to identify 
pharmacists' attitudes to ADR reporting. This chapter describes a quantitative 
survey in which the attitudes and knowledge of hospital pharmacists to the 
Yellow Card Scheme are assessed using quantitative methods and compared 
with previous studies examining the views of medical practitioners. 2 -` 
7.2 Aim 
The aim of this component of the study was to investigate the attitudes of 
hospital pharmacists to ADR reporting and their understanding and knowledge 
of the Yellow Card Scheme. 
7.3 Method 
On annual registration with the Royal Pharmaceutical Society of Great Britain 
(RPSGB), pharmacists are asked to indicate the branch of the profession in 
which they practice. From the RPSGB computer database, in which 
approximately 7000 hospital pharmacists are listed, 600 were randomly 
selected. These pharmacists were sent a postal questionnaire, a covering letter 
and a prepaid envelope with which to return the completed questionnaire. Four 
weeks later, a second mailing of the questionnaire was distributed to all 600 
pharmacists to encourage non-respondents to participate in the study. 
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The questionnaire was similar to that used in previous studies examining the 
attitudes of medical practitioners to ADR reporting. 2021 The previous qualitative 
study was also used to formulate the questionnaire (Appendix 4). " 
Pharmacists' knowledge of the Yellow Card Scheme, attitudes to reporting, 
reasons why they may not report ADRs and concerns about this new role were 
included in the questionnaire. A list of hypothetical ADRs was included and 
pharmacists were asked to indicate whether or not they would report them, a 
method similar to that used by Bateman at al. 21 The number of hypothetical 
reports for which pharmacists would report / not report in agreement with CSM / 
MCA criteria was recorded; a method reported by other workers. 90 A senior 
member of the CSM / MCA reviewed the questionnaire prior to its distribution 
and comments and suggestions were incorporated into the questionnaire. 
The questionnaire was piloted on 20 randomly selected hospital pharmacists of 
whom 12 (60%) responded. A follow up mailing was not distributed. One 
question was identified as ambiguous and altered accordingly. The' pilot study 
also identified one retired pharmacist and one not in hospital practice. Enquiries 
to the RPSGB revealed that the database did include pharmacists not actively 
involved in hospital practice and those who had retired. The sample size 
selected initially was 500, but was increased to 600 to allow for such 
pharmacists. 
Data from this survey were compared with studies performed by Belton et a12° 
and Bateman et a1.21 Responses in the survey by Bateman et al were 
categorised into six sub-groups of medical practitioners. For the purposes of 
this study and to simplify comparisons, these categories were merged and re- 
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calculated as a single numerical value and percentage of the total number of 
respondents. 
Data were analysed using the Statistical Package for Social Sciences (SPSS for 
MS Windows version 9). Data are presented as mean t standard deviation 
(where appropriate) and statistical analysis was performed by chi-squared tests, 
linear and logistic regression, accepting p50.05 as significant. In all logistic and 
linear regressions, non-significant predictors (p>0.05) were removed one at a 
time, until only significant predictors (ps0.05) remained. 
Factors influencing respondents to report the 6 hypothetical cases in 
accordance with CSM / MCA criteria were assessed using logistic regression. 
Three predictors were used, that is, whether a new drug was involved, whether 
the reaction was not well recognised and whether the reaction was serious. A 
decision to report or not report each individual reaction (regardless of 
concordance with CSM / MCA criteria) was used as the dependent variable. 
Factors influencing respondents to have participated in the Yellow Card Scheme 
were also assessed using logistic regression. Five predictors were used, that is, 
age, length of time in hospital practice, previous education and training, whether 
pharmacists practised in a CSM / MCA RMC and whether pharmacists 
considered themselves well informed about the Yellow Card Scheme when it 
was launched. Whether pharmacists had reported via the Yellow Card Scheme 
or not, was used as the dependent variable. 
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Factors influencing pharmacists to comply with CSM / MCA criteria were 
assessed using linear regression. Four predictors were used, that is, age, 
length of time in hospital practice, previous education and training and whether 
pharmacists had ever reported an ADR via the Yellow Card Scheme. The total 
number of reports that pharmacists would or would not report in accordance with 
CSM / MCA criteria was used as the dependent variable. 
7.4 Results. 
7.4.1 Demographics. 
Following distribution of 600 questionnaires, 322 (53.7%) were returned. 
Seventeen respondents (2.6%) stated that they were retired or no longer 
practising as hospital pharmacists, and were thus excluded. The age of the 
remaining respondents (n=305) ranged from 22 - 65 years (mean 36.1 ± 9.1 
years) and number of years qualified ranged from 1- 42 years (mean 13.7 ± 9.1 
years). Respondents' time in hospital practice ranged from I- 34 years (mean 
11.2 ± 7.1 years). Of those surveyed, 85 (27.8%) practised in an area covered 
by one of the CSM / MCA RMCs, 109 (35.7%) were not in a RMC, and 106 
(35.1 %) stated they did not know (4 (1.3%) did not respond). 
7.4.2 The Yellow Card Scheme and phanrnacovlgllance. 
Of those surveyed, 296 (97.0ßb) knew that they were allowed to report ADRs via 
the Yellow Card Scheme. Of these, 224 (75.7%) knew about the scheme from 
reports in the Pharmaceutical Journal, 117 (39.5%) via departmental meetings 
or announcements, 113 (38.2%) through discussion with colleagues and 153 
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(51.7%) had received a copy of the CSM / MCA Information Pack. A small 
number of pharmacists (frequency less than 10 in each case) stated that they 
had heard about the scheme through the Centre for Pharmacy Postgraduate 
Education (CPPE) scheme, postgraduate education courses, drug information 
training days and pre-registration training. Of those surveyed, 172 (56.0%) 
considered that they had been adequately informed about the launch of the 
scheme, while 72 (23.6%) did not, and 60 (19.7%) could not remember. A 
Yellow Card report had been submitted to the CSM / MCA by 78 (25.6%) of 
those responding. Overall (that is, reporters and non-reporters), the 305 
pharmacists returning questionnaires had reported a total of 217 Yellow Cards 
(mean per pharmacist 0.7 ± 2.4 Yellow Cards, range 0- 30). Pharmacists that 
had reported ADRs had submitted a mean of 2.8 ± 4.2 Yellow Cards. 
Pharmacists were asked, using an open question, to explain what they 
understood by an inverted black triangle' placed next to a medicine. 
Responses varied with 171 (56.1%) pharmacists stating that it was a new drug 
and that all reactions should be reported, while 97 (31.8%) stated that it was 
either a new drug or stated that all reactions should be reported. The remainder 
either did not answer (n=25 (8.2%)) or did not know (n=12 (3.9%)). Asked 
whether the CSM / MCA wished to receive 'only proven ADRs', 284 (94.0%) 
correctly stated this was false, only 2 (0.7%) stated this was true and 16 (5.3%) 
did not know. Pharmacists were also asked to identify the nature of reports the 
CSM / MCA wished to receive for specific groups of drugs (Table 7.1). In 
comparison to medical practitioners surveyed by Belton et al. 20 and Bateman at 
a/ 21, answers were similar between the groups. However, pharmacists were 
less aware of the criteria for reporting vaccines than doctors in the Bateman et 
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al study. 21 but comparable to those surveyed by Belton at a!. 20 The reasons for 
this discrepancy are unclear. 
Table 7.1: Appropriateness for CSM I MCA reports 
Category All Serious No Don't Bateman Belton et 
(correct reactions reactions reactions Know at all all 
response) (n=1181) (n=261) 
Newly 97.7% 0.7% 0.0% 1.6% 93.1% 97 % 
marketed 
agents' (298) (2) (0) (5) (1100) (253) 
(all 
reactions) p<0.003 [3% were 
(n=305) not sure] 
Established 6.6% 91.4% 0.7% 1.3% 93.7% 95%4 
products 
(serious (20) (278) (2) (4) (1107) (248) 
reactions) 
(n=304) [3% were 
not sure] 
Vaccines 56.3% 23.0% 0.7% 20.1% 77.2% 59% 
(all 
reactions) (171) (70) (2) (61) (912) (155) 
(n=304) 
P<0.0001 [26% 
were not 
sure] 
Herbal 36.2% 15.8% 4.6% 43.4% N/A NA 
drugs 
(all (110) (48) (14) (132) 
reactions) 
(n=304) 
1. Percentage and number answering statement correctly 
2.6% agreed with statement "Only serious reactions to new products"; 7% were not 
sure. 
3.47% agreed with "AII suspected reactions to established products", 19% were not 
sure. 
Rounding up means percentages are greater than 100% 
N. B. P values were calculated using x2 tests comparing responses from either 
Bateman of a/ or Belton of a/ with pharmacists' responses 
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Pharmacists were asked to identify the purpose of the Yellow Card Scheme 
from 6 statements (Table 7.2). Pharmacists generally knew the purpose of the 
scheme but many incorrectly thought that the scheme could be used to calculate 
the incidence of ADRs and that safe drugs could be identified through the 
scheme. In comparison to the surveys of medical practitioners , 
20.21 pharmacists 
were less aware of the real purposes of the scheme and significant differences 
existed in answer to four of the questions posed. 
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Table 7.2: Purpose of the Yellow Card Scheme 
Question Yes No Don't Bateman Belton 
(Correct Know et all et all 
response) (n=1181) (n=250) 
To enable safe 41.0% 46.0% 13.1% 33.8% 21% (52) 
drugs to be 
identified (No)2 (122) (137) (39) (400) [15% not 
(n=298) sure] 
p<0.0001 p<0.0001 
To measure 82.5% 14.2% 3.3% 56.9% 22% (56) 
the incidence 
of ADRs (No) (249) (43) (10) (872) [10% not 
(n=302) sure] 
p<0.0001 p=0.01 
To identify 75.2% 10.6% 14.2% 84.2% 73% (183) 
factors 
prodlsposing (227) (32) 
patients to 
ADRR (Yes) 
(n=302) 
(43) (994) [21 % not 
sure] 
p=0.0003 
To identify 98.0% 0.3% 1.6% 99.2% 98% (244) 
previously 
unrecognised (299) (1) (5) (1171) [2% not 
ADRs (Yes)2 sure] 
(n=305) 
To obtain 62.5% 17.9% 19.6% NA 71% (178) 
information 
about the (188) (54) (59) 122% not 
characteristics sure] 
of reactions 
(yes) p=0.03 
(n=301) 
To compare 65.1% 19.4% 15.5% 59.9% NA 
the adverse 
effects of (198) (59) (47) (707) 
drugs in the 
same 
therapeutic 
class (Yes) 
(n 304) 
1. Number and percentage answering correctly 
2. Rounding up means percentages may not equal 100% 
N. B. P values were calculated using x2 tests comparing responses from either 
Bateman et a/ or Belton et a/ with pharmacists' responses 
Chapter 7: Attitudes to ADR reporting - quantitative survey 129 
7.4.3 Attitudes to reporting. 
Pharmacists were asked to state whether they agreed or disagreed with the 
statements about ADR reporting (Table 7.3). 
Table 7.3: Attitudes to ADR reporting 
Statement Agree Disagree No Bateman et 
opinion all 
(n=1181) 
ADR reporting is a 86.1% 5.0% 8.9% 94.8% (1119) 
professional obligation 
for pharmacists (260) (15) (27) p<0.0001 
(n=302) 
One ADR report makes 2.0% 94.7% 3.3% 15.5% (183) 
no dWerence to the 
Yellow Card Scheme (6) (287) (10) p<0.0001 
(ns303) 
All serious ADRs are 0.0% 98.4% 1.6% 19.1% (226) 
Identified by the time a 
drug is marketed (0) (299) (5) p<0.0001 
(n=304) 
Yellow Cards are too 9.5% 72.7% 17.8% 50.6% (598) 
complicated to fill in 
n=304) (29) (221) (54) p<0.0001 
It I. adequately clear to 56.0% 34.0% 10.0% NA 
me what I should and 
should not report to the (168) (102) (30) 
CSM I MCA 
(nm300) 
1. Percentage and number agreeing with statement 
2. Would report if there was an easier method' 
3. Did not feature in survey by Belton et al 
N. B. P values were calculated using x2 tests comparing responses from 
Bateman et a/ with pharmacists' responses 
, ý: ýý - t_. 
` 
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While over half of the doctors surveyed by Bateman et alp' felt that Yellow Cards 
were too complicated to fill in, only a tenth of pharmacists agreed with this 
statement. Significantly fewer pharmacists thought that "one Yellow Card made 
no difference to the scheme" and none thought that "all serious ADRs are 
identified by the time a drug is marketed". When asked whether ADR reporting 
should be compulsory, 152 (49.8%) stated that it should (despite the fact that 
only a quarter had reported), 131 (43.0%) stated that it should be voluntary, and 
22 (7.1%) were either unsure or did not respond. There was no significant 
difference between reporters and non-reporters opinions as to whether reporting 
should be compulsory or voluntary (x2= 1.5, p=0.5). 
7.4.4 Pharmaceutlcal Manufacturers 
Of those surveyed, 260 (85.2%) had, on at least one occasion, contacted a 
pharmaceutical manufacturer for information concerning a suspected ADR. Of 
these, 248 (95.4%) had been sent forms or documents from the pharmaceutical 
company to be completed as a result of their enquiry. Sixty seven (27.0%) 
stated that these requests would deter them from contacting companies in 
future. 
7.4.5 Reporting ADRs. 
pharmacists were asked what would influence them in deciding whether to 
report an ADR (Table 7.4). High proportions of pharmacists and medical 
practitioners 202, $0 would be encouraged to report serious or unusual reactions 
or those related to new products although the proportion of pharmacists quoting 
these reasons was significantly higher than the medical practitioners. However, 
Chapter 7: Attitudes to ADR reporting - quantitative survey 131 
the largest difference was that over four fifths of pharmacists would be 
encouraged to report an ADR if they were certain a reaction had occurred in 
comparison to half of those surveyed by Bateman of al. 21 
Table 7.4: Factors encouraging pharmacists to report an ADR 
Factor Agree Disagree Bateman Belton at al 
at all (n=261) 
(n=1181) 
The reaction is of 99.3% 0.7% 80.2% 95% (247) 
a serious nature (947) 
(n=280) (278) (2) [2% not sure] 
P<0.0001 
P=0.001 
The reaction is 98.6% 1.4% 95.0% 89% (232) 
unusual (1122) 
(276) (4) [9% not sure] 
(n=280) p'0.008 
p<0.0001 
The reaction is to 99.3% 0.7ß6 90.4% 91% (237) 
a new product (1068) 
(n=280) (278) (2) [7% not sure] 
P<0.0001 p<0.0001 
Certainty that the 82.4% 17.6% NA 49% (129) 
reaction is true 
ADR (229) (49) [31 % not sure] 
(n=278) 
p<0.0001 
The reaction is 12.7% 87.3% 60.0% NA 
well recognised (709) 
for a particular (35) (241) 
agent p<0.0001 
(n=276) 
1. Number and percentage agreeing with statement 
2. Respondents asked to state 'Important' / 'Unimportant'/ 'Not sure' 
3. Respondents asked if 'Severity' is an important factor in deciding to send in 
a Yellow Card. 
N. B. P values were calculated using x2tests comparing responses from either 
Bateman at a/ or Belton at a/ with pharmacists' responses 
Over a third of those surveyed had, at some time, either not reported an ADR 
knowing that a doctor was going to report it (107 (37.2%)), or had completed a 
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Yellow Card for a doctor to sign (65 (22.6%)). Of those surveyed, 126 (43.8%) 
had access to CSM / MCA information in either microfiche or CD-ROM format in 
their department, while 48 (16.7%) did not know. CSM / MCA data had been 
used by 200 (69.4%) pharmacists in their evaluation of potential ADRs. Of 
those responding, only 125 (43.4%) knew that patients' doctors or consultants 
received a copy of their report from the CSM / MCA. 
Pharmacists were asked to state the factors that might discourage them from 
reporting ADRs (Table 7.5). Significant differences existed between 
professions in terms of deterrents to reporting. Of those surveyed by Belton et 
a!, 20 significantly fewer were deterred from reporting by a lack of time or concern 
about submitting an inappropriate report although more were deterred by a lack 
of report forms. In comparison to those surveyed by Bateman et a!, 21 
pharmacists were significantly more likely to be deterred by a lack of time but 
less concerned by the absence of a fee or concern that reporting would 
generate extra work. 
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Table 7.5: Reasons for not reporting ADRs 
Reason Agree Disagree Bateman et 
all (n-1181) 
Belton et al 
(n=260) 
Concern that a doctor gets 9.0% 91.0% NA NA 
a copy of my Yellow Card 
(n'279) (25) (254) 
Lack of confidence in 16.2% 83.8% NA NA 
discussing the ADR with 
the prescriber (45) (233) 
Apprehension about 33.7% 66.3% NA 8%' (20) 
sending in an [10% were not 
inappropriate report (94) (185) sure] 
(n=279) 
p<0.0001 
Lack of time to fill in a 45.2% 54.8% 27.7% (327) 21% (54) 
report [17% were not 
(n=279) (126) (153) p=0.005 sure] 
P<0.0001 
Concern that a report will 17.6% 82.4% 29.3% (346) NA 
generate extra work 
The absence of a fee for 5.0% 95.0% 15.0% (177) NA 
reporting ADRs 
(n-279) (14) (265) p<0.0001 
Lack of time to actively 56.8% 43.2% NA NA 
look for ADRs while in 
clinical practice (158) (120) 
(n-278) 
Level of clinical knowledge 32.3% 67.7% NA NA 
makes it difficult to decide 
whether or not an ADR has (90) (189) 
occurred 
(n=279) 
Don't feel the need to 40.9% 59.1% NA NA 
report well recognised 
reactions (114) (165) 
(n=279) 
Pharmacists Yellow Cards 9.7% 90.3% NA 21 %s (55) 
not available [5% were not 
when needed (27) (252) sure] 
(n-279) 
D=0.0002 
1. Number and percentage agreeing with statement 
2. Reporting results in 'badgering by the CSM 
3. Responses were 'Yes' / 'No' / 'Not Sure' 
4. Actual question "Doctor fears he / she may appear foolish about reporting a 
suspected reaction". 
5. Actual question referred to "report forms" 
N. B. P values were calculated using %'tests comparing responses from either 
Bateman et ai or Belton et a/ with pharmacists' responses 
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Pharmacists were provided with a list of hypothetical ADRs and asked to state 
which ones they would report to the CSM / MCA (Table 7.6). 
Table 7.6: Reporting reactions 
Reaction Agree Disagree Don't know 
Jaundice with frusemide 
(nm273) 
72.5% 
(198) 
12.5% 
(34) 
15.0% 
(41) 
Headache with venlafaxine' 
(n=271) 
47.6% 
(129) 
38.4% 
(104) 
14.0% 
(38) 
Cold extremities with B- 0.4% 96.0% 3.6% 
blockers 
(1) (265) (10) 
(n=276) 
Thrombocytopenia with 41.5% 49.8% 8.7% 
heparin 
(115) (138) (24) 
(n=277) 
Nausea with montelukast' 70.1% 18.6% 11.3% 
(n=274) (192) (51) (31) 
Gastrointestinal bleed with 33.1% 60.8% 6.1% 
diciofenac 
(92) (169) (17) 
(n=278) 
'Symbols were not included in the questionnaire 
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Of the five examples that were (applying the CSM / MCA criteria) appropriate for 
a Yellow Card report, pharmacists would, overall, report a mean of 3.7 (± 1.7) 
ADRs. Significantly fewer would report headache with venlafaxine than nausea 
with montelukast (p<0.001) and significantly fewer would report 
thrombocytopenia with heparin and a gastrointestinal bleed with didofenac than 
jaundice with frusemide (p<0.001). A significant difference also existed between 
the number of respondents that would report the didofenac and heparin 
reactions (p<0.05). 
Pharmacists' scores of appropriately stating they would report reactions in 
accordance with the CSM / MCA criteria were assessed using linear regression. 
Pharmacists who had previously reported, and had previously undertaken 
education and training were found to be significantly and positively associated 
with participation in the scheme (p<0.0001). Logistic regression demonstrated 
that pharmacists would be significantly more likely to report reactions that were 
serious, to new drugs or that were not well associated with that drug (p<0.0001). 
7.4.6 Educadon and training. 
Some form of education and training concerning ADRs had been received by 
109 (37.9%) pharmacists. Of those who had received training, 74 (67.9%) had 
attended departmental meetings, 11 (10.1 %) had attended a CSM / MCA study 
day / evening, 8 (7.3%) had attended formal teaching sessions (pre-registration 
training and postgraduate education), 5 (4.6%) had undertaken CPPE distance 
learning packages and 7 (6.4%) had attended training led by drug information 
pharmacists or centres. Those who had undertaken training were significantly 
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more likely to have reported an ADR (p<0.0001), scored significantly higher on 
the criteria for reporting (p=0.001), would be more likely to report more of the 
example scenarios (p<0.0001) and a trend suggested that they knew more 
about the purposes of the Yellow Card Scheme (p=0.07). Those who 
considered themselves adequately informed about the launch of Yellow Card 
reporting for pharmacists were also significantly more likely to have participated 
in the Yellow Card Scheme (p<0.001). Education and training was the only 
positive predictor identified using logistic regression that influenced pharmacists 
to report (p=0.001). 
7.4.7 Increasing reporting. 
When asked how ADR reporting could be improved (open question), 
pharmacists gave a wide variety of responses. The most frequently cited 
comments included education, training and study days or evenings (62), more 
time to spend on wards with patients (31), more feedback, reminders and 
increased awareness (21), encouragement from managers and departments 
(13), increased collaboration with prescribers and participation on ward rounds 
(12), increased accessibility of Yellow Cards and cards specifically designed for 
the use of pharmacists (13) and more publicity in journals about the scheme (8). 
Other proposals (frequency less than 7) included on-line access or telephone 
based reporting, development of local initiatives, increased confidence in 
dealing with medical staff, making reporting a professional responsibility, a fee 
for reporting, ADR specialist pharmacists and increasing awareness among 
other professionals that pharmacists could report ADRs. 
Chapter 7: Attitudes to ADR reporting - quantitative survey 137 
7.5 Discussion. 
7.5.1 Response rate. 
The response rate is arguably higher than figures indicate. The number of 
hospital pharmacists in the UK has been reported at 4500 full time equivalents, 
thus, the 7000 pharmacists on the RPSGB database is somewhat overstated. 91 
It is probable that a significant proportion of those surveyed would not have 
been eligible for the survey and that not all pharmacists' registered address is 
their current address. This survey's sample of respondents represents 
approximately 5% of the hospital pharmacists registered in the UK, a higher 
proportion than the studies involving medical practitioners used for comparison 
in this chapter. 20' 1 
7.5.2 Knowledge of, and participation In the Yellow Card Scheme. 
The aim of this study was, using a postal questionnaire, to evaluate the attitudes 
and knowledge of hospital pharmacists to the Yellow Card spontaneous ADR 
reporting scheme. Pharmacists were generally aware of the purposes of the 
scheme and which ADRs should be reported but lacked knowledge in specific 
areas. Pharmacists were less aware than their medical colleagues2021 of the 
purpose and usefulness of the information collected by scheme and reasons for 
this are unclear. This may have important implications as to why the majority of 
pharmacists in this study would not report the recognised but serious reactions 
shown in Table 7.6. Paradoxically, the review of the first year of hospital 
pharmacists' reporting suggested that well recognised but serious reactions 
constituted the majority of Yellow Card reports that were made in practice. °3 
This analysis also showed that overall, they reported a significantly lower 
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proportion of black triangle drugs than their medical counterparts (p<0.0001) but 
that the proportion of serious reactions reported to these agents was 
significantly higher (p=0.01). 83 Combined with responses obtained from this 
questionnaire and the qualitative work described in Chapter 6,89 this suggests 
that pharmacists are either reluctant to report minor reactions to these agents 
(also a finding of the previous chapter) or do not perceive the contribution this 
data can make to post-marketing surveillance as important. 
7.6.3 AWtudes to reporting. 
With regard to attitudes to ADR reporting, none of the pharmacists thought all 
serious ADRs were identified by the time a drug is marketed in comparison to 
the 19.1% in the Bateman et al study. 21 This is possibly due to high profile 
withdrawals of drugs prior to this survey, for example, troglitazone° and the 
reclassification of terfenadine. 16 That significantly less pharmacists thought that 
Yellow Cards were too complicated to fill in than doctors could reflect cultural 
differences between professions. It was encouraging that a large majority of 
those surveyed consider reporting to be a professional obligation and that half 
thought reporting should be compulsory. Since only a quarter of those 
responding had reported an ADR, this may have been to add an incentive to 
report. Over two thirds of pharmacists had used CSM / MCA data in their clinical 
activities, suggesting that the majority of pharmacists find it of use, despite their 
failure, or reluctance to contribute to the database itself. 
Regarding factors influencing reporting, nearly all pharmacists would be 
encouraged to report if a reaction was serious, to a new product or an unusual 
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reaction which was similar to the findings of other studies. 20'2' Paradoxically, 
over three quarters stated that they would be encouraged to report if they were 
certain it was a true ADR while previously in the questionnaire, almost all 
respondents knew that the CSM / MCA did not only want to receive reports of 
proven reactions. 
7.5.4 Factors discouraging reporting. 
In terms of factors discouraging pharmacists from reporting, none of the 
proposed reasons appeared to discourage the majority of pharmacists, with the 
exception of a lack of time in clinical practice. The proportion selecting this 
reason and also a lack of time to complete reports was significantly higher than 
that found in previous work (Table 7.5, p<0.001)2021 °0 and probably reflects 
different working practices between the professions and current recruitment 
difficulties within the pharmacy profession. 74 Time was also the most frequently 
cited factor that would improve pharmacists' involvement in ADR reporting in 
response to an open question and some felt that departments and managers 
could help by allowing them more time and encouraging them to participate in 
this activity. However, whether this would work in practice is debatable, as there 
are probably many clinical activities for which pharmacists consider themselves 
to have insufficient time. 
A fee was not considered to be an incentive to report. This issue has been 
addressed previously by a CSM / MCA working party which concluded that the 
concept of having a sizeable fee might encourage reporting of trivial reactions 
while a small fee would not be a spur to reporting. 86 Research in an Irish 
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hospital has shown that the use of a fee can stimulate reporting and that 
reporting rates drop once the fee has been withdrawn. 22 Pharmacists also 
stated that participation in ward rounds might aid their identification of ADRs and 
result in increased reporting of reactions that doctors might not be willing to 
report. Participation in ward rounds by pharmacists has been shown to result in 
a decrease in the number of adverse drug events (including ADRs) experienced 
by patients. 93 
7.5.5 Reporting of examples. 
In terms of reporting from the examples of reactions given, three quarters of 
those responding stated they would report jaundice with frusemide, an unusual 
and serious reaction, but only half would report thrombocytopenia with heparin 
and only a third would report a gastrointestinal bleed with didofenac. This 
supports the view that most pharmacists would not report well known, albeit 
serious, reactions but would report unusual ADRs. A disparity was observed in 
whether pharmacists would report a minor reaction to the black triangle drugs 
venlafaxine (headache) and montelukast (nausea) and the reason for this is 
unclear. This difference could be explained by either the longer period 
venlafaxine has been marketed, or that montelukast is part of a new therapeutic 
class, or a combination of the two. 
Clearly, and despite a good knowledge of the CSM / MCA guidelines for 
established drugs, pharmacists are somewhat selective in the reactions they 
consider report worthy. As stated earlier, analysis of the first year of reporting 
by hospital pharmacists identified differences in reporting in comparison to their 
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medical counterparts with regard to new drugs but that the proportion of 
serious reactions reported for these agents was significantly higher. 83 
Combined with responses obtained from this questionnaire, this suggests that 
pharmacists are either reluctant to report minor reactions to these agents (also a 
finding of the qualitative work described in Chapter 6) or do not perceive the 
contribution this data can make to post marketing surveillance as important. 
Pharmacists clearly consider that new reactions, ADRs to new drugs and 
serious reactions as incentives to report. 
7.5.6 Education and training. 
The findings of this survey demonstrate that education and increased 
awareness are required to improve pharmacists' knowledge of, and increase 
participation in the Yellow Card Scheme and to improve their perceptions of the 
importance of pharmacovigilance, also a finding of other workers regarding 
Dutch medical practitioners 90 The infrastructure for the delivery of postgraduate 
education and training is well established within the pharmacy profession. In 
particular, the Centre for Postgraduate Pharmacy Education (CPPE) and 
College of Pharmacy Practice (CPP) have produced and delivered postgraduate 
education for a number of years, including material relating to ADRs. The role 
of the RPSGB and the CSM / MCA should also be reviewed in terms of the 
nature of promotion of the scheme and should perhaps take a more proactive 
and visible role. It was of some concern that only half of those responding had 
used the information pack. 
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Chapter 8: The development of HAROLD: a computer-based system 
for the recording and reporting of adverse drug reactions reported 
via a hospital pharmacy based local ADR reporting scheme. 
8.1 Introduction 
A number of articles have been published in the pharmaceutical press 
concerning the increasing use of information technology for pharmacy - related 
applications. 62,03"79,94"950,979" 10° Activities that were previously cumbersome, 
repetitive or time consuming may now be completed with significant 
improvements in efficiency and effectiveness. Computers have an important 
role in prescribing and dispensing activities, including the detection of drug-drug 
interactions and drug-disease interactions. Furthermore, computers are 
involved in monitoring and reporting of pathological tests and are at the forefront 
of medical information and administrative activities. 
This chapter describes the development and introduction of a computer 
database to record, analyse and report adverse drug reactions (ADRs) at the 
Royal Liverpool University Hospitals (RLUH). 
8.2 Why the database was set up 
At the RLUH, audit work within the hospital had revealed that a number of 
reported ADRs were neither adequately documented in patients' medical 
records nor communicated to the patients' general practitioners via standard 
discharge letters or discharge prescription forms. 73 It was therefore decided to 
introduce an ADR notification programme at the RLUH to ensure that all ADRs 
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reported via the 'Green Card' scheme were recorded in patients' medical 
records and that an endorsement of the ADR was made on the cover of 
patients' medical records. It was also intended to ensure that the details of any 
ADRs should be passed on to patients' GPs. 
Recent advances in the development of the 'Green Card' scheme and an 
increase in the level of participation of the hospital staff resulted in an 
increasingly large number of reports being. received by the pharmacy each 
month. As a result, the workload raised by the scheme had risen significantly, 
placing an increasing encumbrance on the operators of the 'Green Card' 
scheme. The extra anticipated workload imposed by the new notification 
program, combined with other pressures, cast doubt upon the feasibility of new 
system. It was therefore decided to develop a system which could be simple to 
co-ordinate, utilise minimal time resources and result in an appreciable 
improvement in current operation of the scheme. As a result, the Hospital 
Adverse drug Reaction On-Line Database (HAROLD) was developed. 
8.3 Selection and requirements of the database 
A number of database systems have been set up for use in adverse drug 
reaction monitoring and a number of different programmes have been used. 
Articles have been published describing the use of Epi-Info, dBASE and Alpha 
Four in clinical pharmacy activities. 97" °6, °°, 10° The database required by the 
RLUH needed to allow simple, uncomplicated design, simple data entry and 
automatic generation of reports. The system was also required to be able to 
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generate reports of a suitable quality for the purposes of communicating data to 
other healthcare professionals. 
The database chosen for use at the RLUH was Microsoft Access (version 2.0). 
This package was widely available as part of Microsoft Office Professional, 
which was widely used throughout the United Kingdom and is simple to use 
once the operator had become familiar with its basic functions. Access could be 
cross-linked with Microsoft Word (a word processing programme), Microsoft 
Excel (a spreadsheet / statistical package) and other Microsoft programmes and 
could automatically generate reports with relative ease. 
8.4 The programme 
The system was operated on a standard personal computer with Microsoft 
Windows 3.1, and Microsoft Access 2.0 or higher. The hardware used to run 
the program needed at least 8 Mb of RAM and approximately 65Mb of hard disk 
space. On opening the database, operators may select tables, forms, reports 
and queries about data already entered into the system. 
8.5 Commands and data entry 
It is beyond the scope of this chapter to discuss in detail the development of the 
database itself. However, Access has detailed 'Help' facilities and Wizard' 
functions which provide step by step instruction in a number of activities within 
the program. Once the operator is familiar with the programme, operation of 
Access is relatively straightforward. A number of hospitals and educational 
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establishments offer instructional courses in the operation of Access while many 
others have computer help desk facilities. 
Once the database has been set up, the practical application of the database is 
relatively simple to operate. Staff can be trained to use the database in a matter 
of minutes. Following data entry, Access will run queries and produce reports. 
Data may also be copied to Microsoft Excel for numerical and statistical 
evaluation if required. 
8.6 Involvement in the `Green Card' scheme 
Details of ADR reports were entered into HAROLD from the data collection 
forms. From this data, HAROLD automatically produced a number of pre- 
programmed reports: 
"A summary of 'Green Card' ADR reports for the Trusts 'Drug and 
Therapeutics Committee'. This provided a brief description of each ADR 
reported via the 'Green Card' scheme, the suspect drugs, whether or not they 
are under intensive CSM / MCA surveillance, and whether a Yellow Card had 
been sent to the CSM / MCA. The reporter's profession was also included. 
" An acknowledgement letter to the reporter. This provided basic background 
information to their suspected ADR including the number of CSM / MCA 
reports of the ADR and whether the reaction was well documented or 
otherwise. Where appropriate, reporters were also advised as to whether a 
report has been sent to the CSM / MCA via the Yellow Card Scheme. As 
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stated earlier, it was felt that provision of such information is vital in 
encouraging staff to continue their participation in the scheme. 
" An information sticker was generated by the database. This was placed on 
the cover of patients' medical records to alert hospital staff that the patient 
may be sensitive to a particular drug and that a letter giving further details of 
the reaction may be found inside the medical records. In the event of the 
letter being lost or removed, the stickers also carry an ADR reference number 
which may be used to obtain further details from the pharmacy department. 
"A letter to be placed inside the patient's notes advising potential prescribers 
of the nature of the ADR. This letter also included a reference number with 
which the reader may obtain further details of the ADR from the Pharmacy 
Department. 
"A letter to the patient's GP advising them of the patients details, details of 
the ADR and the suspect drug. Similarly, the telephone number of the 
department's drug information department and an ADR reference number 
were provided for the GP to make further enquiries if necessary. 
"A 'Yellow Card' substitute was generated by the computer for reports that 
needed to be forwarded to the CSM / MCA. All information fields listed on 
official Yellow Cards were included in the computer generated report. A 
contact number and ADR reference number were also included in the report 
so that further information may be obtained from the Pharmacy department 
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on request. Since the introduction of HAROLD a number of such reports 
have been submitted to the CSM / MCA. 
"A sticker was also produced which was placed on a card similar to those 
used in patient medication record registration cards. This is given to the 
patient to show to their doctor, dentist or pharmacist when receiving 
medication in the future. This aimed to prevent the patient being re-exposed 
to medicines to which they have previously suffered an ADR. 
Data entry may be performed in a matter of minutes. All reports may be 
subsequently generated by HAROLD in a fraction of the time required to 
produce the same reports manually. 
8.7 Other uses 
HAROLD was also designed to be used to detect trends in ADR reporting and 
reporter status and to analyse data where appropriate. It was anticipated that 
the improvements made to the `Green Card' scheme, the use of HAROLD and 
the information provided to the hospital staff and GPs, would encourage further 
involvement in ADR reporting by all concerned. 
8.8 Future uses 
Future developments for the program may include the interfacing of HAROLD 
with on-line information, for example, the British National Formulary, Martindale, 
the Internet, the CSM / MCA database and Medline. This would allow faster and 
perhaps more efficient literature searching to be performed for ADR related 
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queries and would save time consuming and often tedious tasks. This may be 
particularly true if more than one drug is suspected of causing the reaction or 
alternatively, if a suspect drug is not easily identified from a patient's symptoms. 
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Chapter 9: Evaluation of changes to an in-hospital (`Green Card') 
adverse drug reaction reporting scheme. 
9.1 Introduction. 
Local schemes serve a number of purposes which have been described in 
Chapter 2. If the reported incidences of ADRs experienced by hospital in- 
patients and ADR related hospital admissions are compared to the number of 
patients treated by the hospital each year, then it is likely that there is a large 
number of ADRs occurring in the hospital that are never reported and 
subsequently identified by the in-house scheme. 
In order to tackle the problem of under reporting, changes to the 'Green Card' 
scheme were implemented (detailed below). This chapter describes the impact 
of these changes and the evaluation of the reports received by the scheme. 
9.2 Methods. 
The 'Green Card' scheme was introduced in 1985 and shortly after, wall 
mounted holders for 'Green Card' report forms were issued to all wards. 
However, it became apparent that few of these holders remained in their original 
position and that little had been done to promote the scheme for a number of 
years. In December 1996, the following changes were made to the ADR 
reporting scheme in an attempt to improve the numbers of reports received; 
" Re-issuing wall mounted 'Green Card' report form holders with attached, 
explanatory posters, to all wards and clinics at the hospital (Appendix 5). 
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" Placing of a reminder to report suspected ADRs, on the front cover of all 
British National Formularies issued by the pharmacy department. 
" Distribution of a Drug and Therapeutics Committee newsletter discussing the 
purpose of, and promoting the 'Green Card' scheme. 
" Recruitment of specialist nurses for a nurse reporting study with reports being 
forwarded to the 'Green Card' scheme. 
" Holding a short training and awareness session for doctors and for 
pharmacists who were asked to promote the scheme. 
" Promotion of the scheme in the hospital formulary. 
All reports were entered onto the HAROLD computer database and both an 
experienced clinical pharmacist and a clinical pharmacologist assessed each 
report. Use of two algorithms to determine the likelihood a reaction had occurred 
was considered more scientific than the use of global introspection. For a 
subjective approach, Venulet and Ten Ham's algorithm (a series of semi 
structured questions) was used. 57 For an objective approach, Naranjo's 
algorithm (a series of rigid, dosed questions) was used. " This involves the 
calculation of a score for each reaction which is then compared to a banded list 
of likelihoods that reactions have occurred, for example, probable or unlikely. 
Data were further categorised with regard to: 
" Classification of the organ system affected by the ADR using a classification 
method obtained from the CSM / MCA Mersey Regional Monitoring Centre 
(unpublished). 
" Drug dass using the categories listed in the British National Formulary. " 
" Severity (serious / non-serious)" 
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" Causality (the likelihood a reaction had occurred [Ten Ham's57 and 
Naranjo'sTM methods]) 
9 Whether the reaction was a type A or a type B reaction120 
" Origin of the report (profession, speciality and location) 
9 Whether the product was under intensive post marketing surveillance (black 
triangle scheme) 
" Whether the report resulted in a Yellow Card report to the CSM / MCA 
Correlation between the two causality ratings was determined by Spearman's 
rank correlation. Reactions were assessed and classified independently for each 
category. Data were exported to Epi Info Version 6.0 for statistical analysis 
including simple frequency evaluations and cross tabulations employing chi 
squared tests. 67 P values of 0.05 or less were considered to be statistically 
significant. 
9.3 Results. 
Reports were analysed for 1997 in which a total of 181 reports were received by 
the scheme compared to an average of 84 reports for each of the previous 11 
years (Figure 9.1). 
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Figure 9.1: Number of ADR reports received by the `Green Card' scheme at 
the RLUH since it began in 1985 
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Of the patients experiencing ADRs that were reported, 102 (57.6%) were 
female, 75 (43.4%) were male. In comparison, of the total number of patients 
treated at the RLUH in the same year, 51.7% were female, 48% were male. The 
mean age of patients experiencing an ADR was 56.6 years ± 18.5 years (range 
10 - 91 years). The increase in the number of reports corresponded with a large 
increase in the number of staff reporting once only, and a small increase in the 
number of staff reporting on more than one occasion (Figure 9.1). No significant 
increase in reporting was noted for doctors; however, there was a large rise in 
the number of pharmacists reporting and a particularly large rise in the number 
of nurses reporting (Figure 9.2). 
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Figure 9.2: Number of `Green Card' ADR reports made by individual 
professions per year 
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Cross-checking established that no duplicate 'Green Card' reports were received 
by the scheme in 1997. Analysis of the number of pharmacists, nurses and 
doctors employed by the Trust in relation to the number of reports made by each 
group also showed that pharmacists reported significantly more ADRs per 
pharmacist than nurses and doctors (x2 test, p<O. 05) (Table 9.1). 
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Table 9.1: ' Green Card' ADR reports: Breakdown by profession. 
Profession % of the % of % of % of % of No of 
total reports reports reports reports reports 
(n= No. of reports made by made by made by made by per 
staff in received each each each the top 3 staff 
RLUH) by the profession profession profession reporters group. 
scheme that were that were that were in each 
made by 'serious'2 forwarded to black group 
each as Yellow triangle 
profession Cards2 agents2 
Pharmacist 44.8% 61.7% 51.9% 13.6% 51.9% 4.7 
(n=17) (81) (50) (42) (11) (42) 
Nurse 32.6% 32.2% 67.8% 39.0% 40.7% 0.03 
(24) 
(n-1723) (59) (19) (40) (23) 
Doctor 21.5% 53.8% 56.4% 15.4% 20.5% 0.09 
(8) 
(n=417) (39) (21) (22) (6) 
Other' 1.1% 50% 50% 50% N/A N/A 
(n=2) (2) (1) (1) (1) 
Totalas 100% 50.3% 58.0% 22.7% N/A N/A 
(181) (91) (105) (41) 
P values NA p<0.01 p0.22 p<0.01 N/A p<0.000 
1 
1. Includes one aromatherapist and one pharmacy technician report. 
2. Percentages are calculated from the number of reports made by each profession 
shown in column 2 (for example, 61.7% of pharmacist reports were serious) 
3. Percentage calculated from the total number of reports. 
Reports were made by 89 members of hospital staff, that is, less than 4% of 
those eligible to do so. Of the reports, 63 (34.8%) were made by the top 5 
reporters in the hospital (three pharmacists and two (specialist) nurses). The 
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substantial influence of the three most frequent reporters for each profession is 
illustrated in Table 9.1. For pharmacists, over half (51.9%) of the reports 
received came from three of those reporting, for nurses, 40.7% came from three 
reporters but for doctors, the proportion was much less (20.5%). Of the 52 
wards and clinics from which reports arose, over half (54.7%) came from just 12 
units (23%). In terms of specialities within the hospital, the 'Medicine' and 
'Surgery' directorates accounted for the majority of the reports (51.4%), 
reflecting the distribution of the Trust's case mix. 'Skin and appendages' and 
'gastrointestinal' reactions accounted for 98 (54.1%) reports while the remainder 
were divided between 13 other classes of reaction (Figure 9.3). 
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Figure 9.3: Number of reports per disease group 
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(7.0%) reactions and drugs used in rheumatic diseases and gout, for 11 (5.9%) 
reactions. The remainder was divided between 27 different categories of drugs. 
Of the reported reactions, 3 (1.7%) were instances where two drugs were 
suspected of having caused an ADR through an interaction and in 4 (2.2%) 
cases, the reporter suspected one of two drugs (that is, in total, 188 drugs were 
suspected of causing 181 reactions). In 4 (2.3%) instances, patients 
experienced two suspected reactions, each reported on a separate 'Green 
Card'. Of almost 600,000 in-patients and outpatients treated at the RLUH in 
1997, ADRs were reported for only 177 (0.03%) patients. Extrapolating data 
from previous studies, (that is, 5% of patients admitted to the hospital will have 
suffered an ADR, 4 and 6.7% of inpatients will experience a serious ADR), in the 
study period, approximately 30,000 patients may have been admitted due to an 
adverse drug reaction and 40,200 may have had a serious adverse drug 
reaction while a hospital inpatient. 
9.3.1 Black triangle drugs (BTDs). 
BTDs accounted for 40 (22.1 %) reports. Nurses reported a higher proportion of 
reactions to BTDs than pharmacists and doctors (X2 14.09, p<0.001) (Table 9.1). 
Of the 23 BTD reports from nurses, 22 were from specialist nurses. A 
significantly greater number of reports concerning BTDs (27 (67.5%)) were 
classified as `serious' in comparison to non-black triangle drugs (65 (46.8%)) (X2 
5.71, p=0.02). All 40 BTD reports were reported to the CSM / MCA as Yellow 
Cards. 
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9.3.2 `Serious' and `Non-serious' reactions 
Using CSM / MCA criteria, 91 reactions were judged as being 'serious' and 90 
as 'non serious' (Table 9.1). A higher proportion of reports from pharmacists 
(61.7%) were classified as 'serious' reactions when compared with reports from 
nurses (32.2%) and doctors (53.8%) although this was not significant (x2 14.12, 
p=0.07). 
9.3.3 Yellow Carl reports. 
A total of 105 Yellow Cards were sent to the CSM / MCA (Table 9.1). A higher 
percentage of reports from nurses were forwarded to the CSM / MCA as Yellow 
Cards than those from doctors and pharmacists, although the differences were 
not significant (X2 5.73, p=0.22) (Table 9.1). Of the Yellow Card reports sent to 
the CSM / MCA as a result of the 'Green Card' scheme, two were identified by 
the CSM / MCA as duplicates, having been submitted directly by the reporters. 
9.3.4 Causality. 
Causality assessment of the reports is shown in Tables 9.2 and 9.3. Using 
Venulet and Ten Ham's57 and Naranjo'e methods, significant differences in 
causality were observed between the different professional groups that reported 
(r 20.24 and 13.8 respectively, p=0.03 for both methods). Using both methods, 
nurses reported the highest proportion of `probable / likely' or 'definite' reactions 
(76.2% and 55.2%) in comparison to pharmacists (61.8% and 43.8%) and 
doctors (43.7% and 23.1 %). A significant correlation was observed between the 
2 methods of causality assessment (R, value of 0.6 (p<0.001)) indicating a 
degree of consistency between the two methods. 
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Table 9.2: Classification of likelihood that an ADR had occurred by reporters profession 
using Venulet and Ten Ham's method. 
Reporters Certain Probable I Possible Unlikely Conditional Unlikely 
status Likely / I 
Unassessable Unessessable 
Doctors 7.7% (3) 36.0% (14) 25.6% (10) 5.1 % (2) 17.9% (7) 7.7% (3) 
(n=39) 
Nurses 8.5% (5) 67.7% (40) 15.3% (9) 0.0% 6.8% (4) 1.7% (1) 
("=59) (0) 
Pharmacists 19.8% (16) 42.0% (34) 16.0% (13) 4.9% (4) 11.1%(9) 6.2% (5) 
(rý81) 
Others 0.0% (0) 50% (1) 0.0% (0) 0.0% 50%(1) 0.0% (0) 
(n=2) (0) 
'Total 13.3% (24) 49.2% (89) 17.6% (32) 3.3% (6) 11.6% (21) 5.0% (9) 
(W-181) 
Percentages are calculated from the number of reports made by each profession, that is, the n values 
in column I (for example, 7.7% of doctors reports were 'Certain') 
'"Percentage calculated from the total number of reports. 
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Table 9.3: Classification of likelihood that an ADR had occurred 
by reporters profession using Naranjo's method. 
Reporters Definite Probable Possible Unlikely 
status 
Doctors 0.0% (0) 23.1% (9) 74.4% (29) 2.6% (1) 
(n=39) 
Nurses 5.1% (3) 50.1% (30) 47.5% (28) 0.0% (0) 
(n=59) 
Pharmacists 3.7 (3) 40.1% (33) 55.6% (45) 0.0% (0) 
(n=81) 
Others 0.0% (0) 50% (1) 50% (1) 0.0% (0) 
(nag) 
*Total 3.3% (6) 40.3% (73) 56.9% (101) 0.55% (1) 
(n=181) 
'Percentage calculated from the total number of reports. 
Percentages are calculated from the number of reports made by each 
profession, that is the n value in column 1 (for example, 23.1 % of doctors reports 
were 'Probable') 
9.3.5 Type A and B reactions. 
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Of the reported reactions, 89 (49.2%) were type A and 92 (50.8%) were type B 
reactions. There was no significant difference in the proportion of type A and 
type B reactions that were attributed to black triangle and non black triangle 
drugs (p=0.2). Similarly, there was no significant difference between the 
proportion of type A or B reactions that resulted in Yellow Cards (p=0.7). Of the 
type A reactions 45 were 'serious', 44 'non serious' and of the type B reactions 
47 were 'serious' and 45 'non serious'. A larger proportion of reports from 
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pharmacists were type A reactions when compared with reports from doctors 
who reported a larger proportion of the type B reactions (Table 9.4). 
Table 9.4: Type A and B reactions by profession 
Professional status Type A reactions (%) Type B reactions (%) 
Doctors (n=39) 11(28.3%) 28(71.7%) 
Pharmacists (n=81) 48 (59.3%) 
Nurses (n=59) 
Others (n=2) 2 (100%) 
Overall, a significant difference was observed between professions (2 = 10.2, 
p=0.006) suggesting that pharmacists were more likely than doctors or nurses to 
report ADRs of a pharmacological nature. 
9.4 Discussion. 
The 'Green Card' scheme has been criticised in the literature as being 
'cumbersome' and 'not the way forward'. 101 However, experience suggests that 
the scheme increases reporting via national pharmacovigilance schemes and 
encourages awareness of the importance of reporting ADRs amongst the 
hospital staff. While gross underreporting of ADRs is a problem that the 'Green 
Card' scheme has only partly addressed, development of the scheme has 
33(40.7%) 
30 (50.8%%) 29 (49.2%) 
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increased reporting across the professions and allowed some analysis of 
reporting trends within the Trust. The development of an `ADR reporting culture' 
has been suggested as a method of encouraging reporting and increasing 
awareness of ADRs. 20 This issue has been addressed in the USA where 
hospitals are required by the Joint Commission on Accreditation of Healthcare 
Organisations to have procedures for reporting ADRs. 46 
The results of this study show that by promoting in-house or local ADR 
schemes, it is possible to increase the number of reports received by such 
schemes, to encourage individual staff members to report via the scheme and to 
encourage staff to report more than once. This was achieved largely by the use 
of passive methods of promotion, which did not have a significant impact on the 
workload of the staff operating the scheme. However, given the incidence and 
importance of ADRs, departments should consider committing resources to this 
area. The results demonstrate that motivated individuals can make a significant 
contribution to ADR reporting. Enlisting staff on each ward or clinic to act as a 
facilitator for reporting and targeting them with bulletins and information to 
encourage ADR reporting by their colleagues may be a development which 
could significantly enhance ADR reporting rates. 
Pharmacists reported a high number of ADRs in comparison to doctors or 
nurses. Given that the proportion of 'unlikely' or 'possible' reports for 
pharmacists (20.9%) was lower than that for doctors (30.7%) and marginally 
higher than that for nurses (15.3%), it does not appear that pharmacists were 
'trigger happy' in their approach. The majority of reports from pharmacists were 
of type A reactions while in contrast, doctors appeared to report more type B 
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reactions. This suggests that pharmacists might be prepared to report more well 
known or predictable reactions than doctors who tend to report more unusual or 
unexpected reactions. Nationally, a comparison of hospital pharmacist and 
hospital doctor Yellow Card reports has identified a similar pattern. a3 This 
difference in reporting is unlikely to have been influenced by the severity of the 
reaction, given that type A and B reactions identified in this study were of equal 
severity and that doctors and pharmacists reported similar proportions of serious 
reactions. 
The contribution that nurses made to the 'Green Card' scheme was substantial, 
and is in accordance with another study. 70 The higher number reports to BTDs 
made by nurses was largely due to two specialist nurses. The potential 
contribution of specialist nurses is evident and should be explored further. From 
the results, it is dear that other than doctors, nurses and pharmacists, few 
professions are inclined to participate in the scheme. Within those professions 
willing to participate, a minority of staff in each group appears to make the 
majority of the reports received by the scheme. Few reports were received from 
radiologists and anaesthetists and few reports were received from operating 
theatres and the accident and emergency department. Potential for expansion 
of the scheme to other professions, sub sections of medical and nursing staff 
and to clinical areas clearly exists. 
Causality assessment by the methods of Venulet and Ten Ham, which is based 
on a 'best fit categorisation, was preferable to Naranjo's algorithm with the 
reports studied, because of the flexibility that it afforded in judging some 
reactions. Reactions that were evidently 'unlikely' or 'unassessable' using 
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Venulet and Ten Ham's method could still be classified as 'possible' by 
Naranjo's method, and thus the former method was found to be more applicable 
to reports received by the scheme. It is not the aim of the scheme to promote 
reporting of only 'certain' or 'probable' ADRs, as hospital staff are asked to 
report all of ADRs. However, it is encouraging to note that of the 151 reactions 
fully assessed for causality (using Venulet and Ten Ham's method), around 
three quarters were classified as being 'probable' or 'certain'. 
Antibacterial drugs were the most frequent class of drug reported in the scheme 
and this is not surprising given the frequency of their use in general, acute 
hospitals. However, of the 33 reported reactions to antibacterial drugs, 23 
(69.7%) were non-serious (18 reports of skin rashes, (54.5%) and 4 reports of 
gastrointestinal tract disturbances (12.1%)). In comparison, 9 (81.8%) of the 11 
reactions reported for Drugs used in Rheumatic Diseases and Gout were 
classified as 'serious'. Few reports were received for cytotoxic agents, this is 
probably due to the fact that these drugs are regarded as being inherently toxic 
and staff do not consider serious, albeit well recognised reactions unusual 
enough to report. For many other drugs for which ADRs might be expected, for 
example, suiphasalazine, amiodarone or methotrexate, no reports were 
received, while staff seem to be willing to invest time in reporting rashes and 
gastrointestinal upsets secondary to antibiotics. Targeting individual drug 
groups may be of use; however, previous work investigating the highlighting of 
black triangle drugs failed to show any significant increase in reporting. 4" it is 
possible that practical systems will be unattainable until computer-based 
prescribing systems are an integral component of the prescribing of drugs in 
hospital and ADR reporting pathways as part of their capability. 
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Issues concerning quality within the NHS are currently increasing in profile as 
the concepts of clinical governance and risk management gain momentum. 
Other work has shown many ADRs to be predictable and either preventable or 
manageable. 82"102 It has also been demonstrated that inappropriate use of 
medicines is a major cause of ADRs. 81 Use of data from local schemes could 
be used to evaluate the impact that ADRs have on the quality of clinical care 
within the NHS, and perhaps provide avenues to decrease their incidence. 
Such data would enable hospitals to target resources to the areas in which they 
might be expected to have most impact. Risk management also extends to 
preventing inadvertent re-exposure of a patient to a drug suspected of having 
been responsible for the ADR in the past. 10,79,73 The concept of clinical 
governance has been introduced with the intention of setting standards 
concerning the management of clinical situations in which the management and 
reporting of ADRs would appear to be a core issue. " Schemes such as the 
'Green Card' scheme and the data that they provide will prove to be valuable 
tools in the endeavour to attain 'clinical excellence'. 
9.5 Umitations 
Caution should be exercised before extrapolating the findings of the chapter to 
other institutions. The presence of the principal researcher and the knowledge 
that the study was contributing to a research project could have encouraged 
pharmacists at the RLUH to increase their contribution to the scheme beyond 
that which might have been identified under other circumstances. The principal 
researcher also contributed to the ADR reports received by the scheme and 
although the number of reports concerned was not among the highest in terms 
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of reports per individual, this introduces potential bias into the research. The 
influence of individuals motivated to contribute to the scheme is illustrated in 
Table 9.1 and should be considered when considering the application of the 
findings of this research elsewhere. The existence of the scheme prior to its 
'relaunch' is another factor that should be considered since it is likely that many 
of those who reported ADRs via the 'Green Card' scheme were aware of its 
existence before this assessment was carried out. 
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Chapter 10: Communication regarding ADRs between secondary 
and primary care: A postal questionnaire survey of general 
practitioners. 
10.1 Introduction. 
The 'Green Card' scheme has been described in the previous chapter and in 
Chapter 2. Previous audit work at the trust demonstrated that a number of 
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ADRs were neither documented in patients' notes nor communicated to patients' 
general practitioners, even for serious reactions. 7 As part of efforts to increase 
the profile and effectiveness of the in-house 'Green Card' scheme, it is 
proposed that GPs should be issued with a notification form and patients issued 
with an ADR warning card and / or an ADR notification form. 
10.2 Aims 
The aim of this study was to survey general practitioners within the health 
authority in which the Trust is situated to ascertain their views on the current 
transfer of data concerning ADRs and to gauge their opinions on the proposed 
scheme to improve communications between the GP, patient and the hospital. 
10.3 Methods. 
A structured questionnaire using a combination of open and dosed questions 
was designed. Issues relating to communication of data concerning ADRs from 
secondary to primary care and the provision of information to patients were 
included. The questionnaire, a covering letter, a sample notification form 
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(Appendix 6) and a prepaid return envelope were sent to all general 
practitioners within Liverpool Health Authority. One month later, follow up letters 
and questionnaires were redistributed. Data were collated and analysed using 
Microsoft Access version 7.0. 
10.4 Results. 
Of the 270 general practitioners surveyed, 141 (52.2%) responded. Not all 
questions were answered by each respondent. When asked how often they 
saw patients who had experienced an ADR while in hospital, a high proportion 
(46 (33.1%) reported seeing such patients 'occasionally' and 4 (2.9%) reported it 
as a `frequent' occurrence (Table 10.1). Of the 114 (88.4%) respondents who 
saw such patients, 60 (52.6%) felt that instances where no record of the ADR 
existed in patients' discharge documentation happened 'occasionally' while a 
further 15 (11.6%) stated that this occurred frequently. (Table 10.1). 
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Table 10.1: Summary of general practitioners responses 
Frequently Occasionally Rarely Never 
How often GPs see 
patients who have 
suffered an ADR 2.9% (4) 33.1%(46) 54.6% (76) 9.4% (13) 
while a hospital in- 
patient. 
(n=139) 
How often the 
patient tells the 
doctor they have 11.6% (15) 46.5% (60) 30.2% (39) 11.6% (15) 
suffered an ADR but 
no record exists in 
their discharge 
documentation. 
(n-129) 
How often can 
patients name the 
exact drug to which 6.7% (8) 24.6% (29) 58.5% (69) 10.2% (12) 
they have 
previously suffered 
and ADR. 
(n=118) 
How often can the 
patient describe the 
exact nature of the 30.5% (36) 39.8% (47) 28.8% (34) 0.9% (1) 
reaction they 
suffered? 
(n=118) 
How often is 
insufficient 
information supplied 22.6% (30) 37.6% (50) 31.6% (42) 8.2% (11) 
in the discharge 
documentation? 
(n=133) 
How often is the 
total information 
from the patient and 23.3% (31) 45.5% (61) 25.3% (34) 6.0% (8) 
discharge 
documentation 
insufficient to make 
an informed 
decision about the 
consequences of an 
ADR? 
(n=134) 
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10.4.1 Confidence In Information provided by patients 
GPs were asked how often they thought patients could name the exact drug to 
which they had suffered an ADR. A high percentage (81 (68.7%)) stated that 
patients could 'rarely' or'never' name the drug (Table 10.1). Fewer GPs (35 
(29.7%)) felt that patients were unable to describe the nature of their reaction 
(Table 10.1). GPs were asked how confident they were in the information that 
patients gave them. None were 'very confident in this information while 92 
(78.6%) were 'uncertain' or'very uncertain' of this information. A lack of written 
information and uncertainty in verbal information from patients may make it 
difficult for GPs to determine the significance of an ADR a patient has 
experienced in hospital. Almost half of the respondents (61 (45.4%)) stated that 
instances where they had insufficient information to make an informed decision 
about an ADR was an 'occasional' occurrence. A further 31 (23.1%) thought 
that this situated was a 'frequent event (Table 10.1). 
10.4.2 Addltlonal Information required In the ADR notification form. 
The majority of GPs were satisfied with the content of the ADR notification form. 
Only 2 (1.4%) GPs stated that some information provided was unnecessary; 108 
(76.5%) stated that no further additional information was required. In response 
to an open question, 42 (29.8%) GPs thought that additional information was 
required, the nature of which is listed in Table 10.2. 
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Table 10.2: Additional information requested by GPs for 
notification form. 
Additional information Frequency of 
request. 
Dates and duration of reaction 5 
Further advice (management / further action) 5 
Information given to patient 5 
Clinical indication for drug 4 
Other drugs 4 
Treatment for ADR 4 
Severity 4 
Causality 3 
Rechallenge 3 
Dose 2 
Type A or Type B reaction 2 
Outcome 1 
Typical comments included: 
"Dosage, need for further follow up or action. Related drugs which 
should be used with caution. " 
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"Exact nature of adverse reaction, nature of drug concerned, antidote if 
given" 
"How confident is the diagnosis - should the drug be avoided or used 
with caution. " 
"Is the ADR consistent with manufacturers published side effect profile? 
Type of reaction e. g. allergic, idiosyncratic, toxic or drug interaction. " 
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"Relevance to future management" 
"Severity of reaction, any treatment given at the time, information given 
to patient, any follow up necessary by GP. " 
Whether the patient should ever take the same or same class of drug 
ever again. 0 
10.4.3 Should patients receive a copy of the ADR notification form? 
Regarding the notification form, 110 (82.7%) respondents thought that patients 
should get a copy (n=133). However, when asked to comment, GPs had mixed 
views about this proposal (Table 10.3). 
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Table 10.3: Should patients receive a copy of patient notification form 
Should patient receive card: Comment Number of respondents 
Yes: Seen by different doctors 30 
Yes: Patient education 30 
Yes: Patient responsibility 7 
Yes: Time delay 5 
Yes: Improving communication 5 
Yes: Prevents litigation 4 
Yes: Right to know 3 
Yes: Arrange Medic Alert bracelet 2 
No: Cause anxiety or alarm 6 
No: Increases litigation 4 
No: Card better 3 
No: Not able to understand 2 
No: No need if GP has one 2 
No: Patient information leaflet for ADRs 1 
Comments in favour included: 
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"Because sometimes infomlation from the hospital comes late or never at 
all. ' 
"For their safety in future, in case their medical card goes astray. " 
if reaction is severe in case they wish to arrange a Medicaid 
bracelet or similar" 
"It is important that the patient takes responsibility for their health. " 
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"More likely to accept as a significant issue. " 
"Patent awareness very important. They will often confuse information 
they are told and it can be difficult then to re-inform with the correct 
information. " 
"Patients sight to information - they may need this information if they go 
to a hospital elsewhere. 
ff 
"So that they can show to other professionals, for example, dentists. " 
Comments not in favour included: 
"ADR card as below probably of more benefit. " 
"Cause confusion / wont' if they do not understand technical terms. 
They could have a simplified explanation on their discharge letter 
instead. " 
"I don't think it is meaningful to the average patient. 
"Increases likelihood of litigation. " 
"Perhaps a more friendly patient information sheet with understandable 
terminology - less medical. " 
"They need to have some written information, not necessarily a copy of 
the form. " 
"Would like patients to be informed that an adverse reaction had 
occuned and be able to discuss it if concerned but do not feel giving 
patients clinical details is helpful. 0 
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10.4.4 Prov/ding patients with ADR warning cards. 
In response to a proposal to provide patients with a 'credit card' containing the 
name of the drug to which they have experienced an ADR, 135 (97.8%) of 138 
GPs responding thought this would be a useful development with some stating 
that this would be more appropriate than the notification letter. Comments 
included: 
"But they will probably lose it or forget to carry it with them. " 
"Could GPs add to it? - for two way information. " 
"Depends on severity of reaction -a patient could end up with loads of 
cards for minor ADRs. " 
"How will the card be added to? Will only life threatening ADRs be put 
on there? " 
"If there is a severe or unusual reaction perhaps. Otherwise, it seems 
unnecessary. " 
"Useful for patient to know what to avoid. " 
"Useful in emergencies" 
10.4.5 Inclusion of details of the reaction In the war ing card. 
lt was felt by 99 (76.2%) of 130 GPs responding, that the card should contain 
details of the reaction the patient experienced. Specifically, 8 GPs stated that 
the card should contain details of the severity of the reaction, 3 stated there 
would be insufficient space, 2 suggested including the likelihood a reaction had 
occurred and 4 stated that the card should briefly describe the reaction. 
Comments included: 
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"No need for letter to go to patient in this case. " 
"Perhaps should include mild /moderate /severe. " 
"Probably not enough room on the card to be helpful., ' 
"Too much infonnation will confuse or be ignored. 11 
10.4.6 Improving communication. 
When asked how else communication of ADR data could be improved, the 
majority of GPs' comments related to the length of time it takes for discharge 
correspondence to reach them once a patient has been discharged. Thus, 
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many GPs suggested using the telephone, e-mail or facsimile machines to relay 
information as soon as the patient is discharged. A further 11 GPs suggested 
that information should be included in the discharge prescription sheet and 9 
suggested this information be included in the discharge letter. Comments 
included: 
"By fax, phone, e-mail if very significant. " 
"Currently - no great communication, therefore any would be an 
improvement " 
"Do so specially rather than in the typed summary received four or five 
months later. 0 
For serious life threatening events, a telephone call to the GP would be 
helpful. ' 
"It would be helpful if pharmacy could write a discharge summary 
perhaps listing the drugs which we should be wary of using in a patient 
who's had an ADR. 0 
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"Keep the paper work down. " 
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"Tell patient, make them aware that they also have the responsibility to 
avoid this drug! Not solely the doctor/ pharmacy/hospital role. " 
"This should be enough - very useful to see if Yellow Caid was sent or 
not. " 
10.5 Discussion. 
GPs perceive consultations with patients who have experienced ADRs while in 
hospital as a relatively infrequent occurrence. However, on occasions when this 
occurs, information pertaining to the suspected reaction is often absent from the 
discharge documentation. GPs perceive that while patients can usually recall 
the nature of the reaction they experienced, for example, a skin rash or 
anaphylaxis, they are less likely to recall the exact name of the drug which is 
thought to have caused the ADR. Furthermore, when GPs are provided with 
verbal information by their patients, over three quarters of GPs are either 
uncertain or very uncertain that the information is correct. 
Although this study was limited to general practitioners within Liverpool Health 
Authority for the purposes of the 'Green Card' scheme described earlier, 
evidence in the literature suggests that that this not a localised problem. '3, ' ° 
However, care must be taken in interpreting these result in extrapolating them to 
areas where improved methods of communication may already exist. Previous 
work has shown that in many instances documentation and communication of 
data relating to suspected ADRs is neither recorded in patients medical records 
nor communicated to general practitioners. '3*7°, a0 The concept of poor 
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communication between secondary and primary care in terms of both speed and 
quality is not new and has been described many times in the literature. 103.104 
However, data concerning ADRs is rarely included in these studies. Studies 
have also demonstrated that, for a number of reasons including poor 
communication, patients have difficulties managing their medicines post 
discharge. '(* Understanding and recall of information pertaining to their 
medicines is, in some cases, worryingly inadequate. Patients that are unable to 
manage their medicines effectively are at increased risk of therapeutic failure, of 
ADRs and potentially, readmisson to hospital. 
As GPs are unsure of the information that is provided by patients, it is important 
that written information is sent to general practitioners about ADRs that patients 
have experienced while in hospital. This issue is also important in terms of risk 
management in that patients are at risk of being inadvertently exposed to a 
drug(s) to which they have previously suffered an ADR if GPs and / or the 
patient themselves are unaware of the name of the suspect drug. Previous 
work suggests that patients may suffer minor reactions, for example nausea and 
vomiting and conclude that they are allergic to the drug, when in fact, they are 
intolerant and could still be prescribed the drug if no other alternatives were 
available. 106 Methods of communicating such data to patients are not common 
components of ADR reporting programs. 45 This is a situation which has been 
addressed using the HAROLD database (see Chapter 8) to generate reports 
and warning cards. Patients should therefore be provided with written and 
verbal information and be given the opportunity to ask questions and to address 
concerns that they may have about an ADR they have experienced. It was of 
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interest that an equal number of GPs felt that this would either increase or 
decrease the risk of litigation with regard to ADRs patients may experience. 
Many GPs felt that patients should have some written information to show 
healthcare professionals who may not have access to their medical records, for 
example, locum doctors or dentists. Provision of written information for use after 
discharge using a pre-designed form has been discussed in the literature, but 
again, ADRs were not specifically included in the form. 107 Provision of warning 
cards need not be a drain on resources and may be as high or low tech as 
providers wish. The design of the warning card may range from a pre-printed 
card or dispensing label sealed in a plastic pouch to computer generated plastic 
cards. 
Approval for this development had been received from the Trust's Drug And 
Therapeutics Committee and also from the Trusts legal department. It is hoped 
that the scheme will be introduced in the near future. Should the card become 
integrated into Trust practice, it is hoped that prescribers who want their patients 
to receive a warning card will be encouraged to report serious ADRs via the in- 
house 'Green Card' scheme and consequently increase the number of reports. 
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Chapter 11: Adverse drug reactions as a cause of admission to an 
acute medical assessment unit. 
11.1 Introduction 
Previous work has demonstrated that a significant proportion of hospital 
admissions are due to adverse drug reactions (ADRs). A review of studies 
examining ADR-related admissions to hospitals found that on average, 5.5% of 
all hospital admissions result from ADRs. 4 This incidence varied from 0.2% to 
21.7% depending on the population being investigated, for example, elderly 
populations had a higher rate than for surgical patients. Results of previous, 
individual studies examining the incidence of ADR related admissions in general 
medical patients are summarised in Table 11.1.0, 
'00. "0.111.112.113.114,115,116,,, 7,118,119 
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Table 11.1: Studies investigating the admission rate due to ADRs. 
Study Year Study Total Number of Percentage 
sample admissions ADR ADR 
admissions admissions 
Stanton, 1994 Teaching, 691 21 3.0% 
Peterson general 
Rumble et al. medical 
Hallas, Gram, 1992 Teaching, 1999 157 7.9% 
Grodum et al. general 
medical 
Lakshmanan, 1986 Teaching, 834 45 5.4% 
Hershey and general 
Breslau. medical 
Black and 1984 Teaching, 481 30 6.2% 
Somers. general 
medical 
Bergman and 1981 General 285 16 5.6% 
VNihoim medicine 
George and 1980 General 250 10 4.0% 
Kingscombe. medicine 
Ghose. 1980 General 171 11 6.4% 
medicine 
Levy, 1979 Teaching, 2,499 103 4.1% 
Upshitz and general 
Ellakim. medical 
Wood, 1977 General 220 19 8.6% 
Turner and medicine 
Vero. 
Wood, 1975 General 192 13 6.8% 
Turner and medicine 
Vero. 
Hoddinott, 1967 Teaching, 104 3 2.9% 
Gowdey, general 
Coulter and medical 
Parker. 
Sidel, Koch- 1967 General 267 12 4.5% 
Weser, medicine 
Barnett and 
Eaton. 
Seidl, 1966 Teaching, 714 28 3.9% 
Thornton, general 
Smith and medical 
Cluf. 
Chapter 11: ADR related admissions 188 
11.2 Alms 
The purpose of this study was to investigate medical patients admitted to a 
teaching hospital to identify the proportion of admissions that occurred as result 
of an ADR, and to identify the drugs thought to be responsible for these 
admissions. 
11.3 Method 
The study was carried out in the Acute Medical Assessment Unit at a large 
teaching hospital. The unit was created in 1996 to monitor newly admitted 
medical patients with the intention of admitting them to an appropriate ward 
when necessary, or, discharging them for treatment as an out patient or in 
primary care. Two hundred patients were selected on a daily basis using 
randomly generated numbers over a period of two months. Information was 
collected prospectively from newly admitted patients. Data were recorded using 
a data collection form based on the CSM / MCA Yellow Card adverse drug 
reaction reporting form and was identical to that used in the 'Green Card' 
scheme (Appendix 5). Data collected included demographic data, details of 
concurrent illness, drug history details (including over the counter (OTC) 
purchases), and reasons for admission to hospital. Any known drug allergies 
were also recorded. Data were recorded in Microsoft Access Version 7.0 and 
exported to Epi Info Version 6.0 for analysis. A 'p value' of 0.05 or less was 
considered to be statistically significant. 
Where possible, patients' medication history was verified using the medicines 
patients had brought into hospital with them. Where an ADR was suspected or 
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where drug history details appeared to be incomplete, inaccurate or erroneous, 
the patients' general practitioner was contacted to verify the details of the 
patient's drug history. For the purposes of this study, an ADR was defined using 
the World Health Organisation definition: a response to a drug which is noxious 
and unintended and which occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease or for the modification of a 
physiological function. ' Adverse effects of drugs due to deliberate self 
poisoning are excluded from this definition and were not recorded for the 
purposes of this study. 
Patients suspected of experiencing an ADR were followed up five months later 
to determine the outcome of their admission. ADRs thought to have resulted in 
hospital admission were reported to the CSM / MCA using a Yellow Card. The 
likelihood or'causality' that a reaction had occurred was assessed by an 
experienced clinical pharmacist and clinical pharmacologist using Venulet and 
Ten Ham's algorithm 57 and Naranjo's algorithmTM described in Chapter 9. 
Reactions were also classified in terms of reaction type (type A or type B) again 
using previously published criteria. 120 
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11.4 Results 
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Data were collected for 200 patients of which 107 (53.5%) were males and 93 
(46.5%) were females. Ages ranged from 18 to 89 years (mean 58.3 ± 15.8 
years, median 62 years), the distribution of which is shown in Figure 11.1. 
Figure 11.1: Distribution of age of patients admitted to the Acute Medical 
Assessment Unit 
.......................... ................................................................................... _........................................................... 93 
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Of the patients reviewed, 34 (17%) patients described 'drug allergies' including 
19 who claimed they were allergic to penicillin, 5 to co-trimoxazole, while the 
remainder claimed allergies to 13 other medicines. The numbers of drugs 
patients were taking ranged from 0-13, (mean 3.6 ± 2.78 medicines). The most 
common reasons for admission to the unit are listed in Figure 11.2. 
0-30 30-50 50-70 >70 
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Figure 11.2: Frequency of reasons for admission to the AMAU 
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Of the 18 suspected ADRs identified in the study, 15 (83.3%) were judged to be 
responsible for the patient's admission to hospital and 3 (16.7%) were 
coincidental to the patients admission. Two patients (1%) died as a 
consequence of their ADR. The ADRs detected are shown in Table 11.2 
together with their causality assessments. 
0 10 20 30 40 50 60 70 
Number of patients 
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Table 11.2: ADRs detected during study. 
Suspect Drug Doscrfpdwi of Type A Outcome Naranjo Venu/et d Preventable 
suspected ADR or B Tin Ham (Yes / No) 
Warfarin Spontaneous A Discharged two Probable / Certain Yes 
bruising - INR - weeks after Likely 
9.2 admission 
Sotalol *Query congestive A Discharged two Probable / Probable Yes 
cardiac failure weeks after Likely 
admission 
Ibuprofen OTC purchase - A Patient also Possible Possible Yes 
up to eight each being 
day - anaemic. investigated for 
gynaecological 
pathology 
Aspirin GI bleed with A Died 8 days later Possible Probable / Yes 
coffee ground Likely 
vomit 
Bumetanide Hypokalaemia - A Medical records Probable / Certain yes 
potassium unobtainable Likely 
3. Ommol/L on 
admission 
Beclomethasone *Oral candidiasis A Resolved Probable / Certain Yes 
secondaryto following nystatin Likely 
inhaled steroid mouthwash 
Bumetanide Hypokalaemia A Discharged on Probable / Certain Yes 
potassium amiloride Likely 
2.6mmol/L on 
admission. 
Didofenac Epigastric pain A Discharged - Probable / Certain yes 
without Likely 
diclofenac. 
Oxytetracycline Started five days A Discharged on Possible Probable / No 
prior to GI bleed. ranitidine Likely 
Risperidone Chest pain and A Discharged to Possible Unlikely No 
dizziness. Psychiatric 
hospital 
Diclofenac & Gastric pain and A Patient Probable / Probable / Yes 
aspirin heartburn: is discharged on Likely Likely 
taking same medication 
Lisinopril *Cough - patient A ACE inhibitor Possible Probable / No 
on frequent withdrawn Likely 
codeine linctus 
Frusemide and AF secondary to A Died 16 days Probable / Certain Yes 
digoxin hypokalaemia and later Likely 
Propranolol Congestive A Drug withdrawn Possible Possible Yes 
cardiac failure and & treated for CCF 
breathlessness 
Paroxetine. Gastrointestinal B Patient Unlikely Unlikely No 
bleed diagnosed as 
gastric cancer 
Ketoprofen. Exacerbation of A Drug withdrawn - Possible Probable / Yes 
congestive patient Likely 
cardiac failure discharged 
Aspirin Gastrointestinal A Drug withdrawn - Possible Possible Yes 
bleed discharged on 
ranitidine 
Naproxen. Gastrointestinal A Discharged on Possible Probable / Yes 
bleed ranitidine Likely 
*ADR did not directly result in admission 
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Using Venulet and Ten Ham's method, 5' of the 15 ADRs thought to have 
resulted in hospital admission, 10 (66.7%) were identified as being 'probable / 
likely, and 3 (20%) were classified as being possible. Using Naranjo's 
method, s` of the 15 ADRs thought to have resulted in hospital admission, 6 
(40%) were identified as 'probable / likely' and 8 (53.3%) were classified as 
being possible. Of the 18 suspected ADRs, 17 were Type A' reactions and 12 
(66.7%) were judged to have been predictable and to some extent, preventable. 
Patients suspected of experiencing an ADR-related admission were taking a 
mean of 3.9 (± 1.5) different medicines in comparison to those not suspected of 
an ADR taking a mean of 3.6 (± 2.9) different medicines (a non significant 
difference, Mann Whitney U-test, p=0.4). The most common drugs implicated in 
the hospital admission of patients in this study are shown in Table 11.3. All 
reactions identified as a possible cause for hospital admission were reported to 
the CSM / MCA. Only one of the reactions was thought to have been related to 
a product bought over the counter in a community pharmacy. 
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Table 11.3: Drugs causing admission - frequency of 
use. 
Drug class Frequency 
Non steroidal anti inflammatory drugs 8 
(includes 'low dose' aspirin) 
Loop diuretics 3 
Beta blockers 2 
Warfarin I 
Cardiac glycosides 1 
Anti-depressants 1 
Paracetamol 1 
11.5 Discussion 
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The number of patients identified in this study with ADR related admissions is 
similar to that found in comparable populations, that is, teaching hospitals / 
medical admissions. Of particular concern was that 2 (that is 1% of the 
admissions studied) of the identified ADRs resulted in fatalities. Little work has 
been done in this area in the United Kingdom, indeed, relatively none in the last 
ten years, and there is clearly a need for larger studies to be performed. Such 
research is required to identify practical methods by which the incidence of 
preventable or predictable adverse drug reactions can be reduced. 
None of the ADRs that were identified in this study were reported via the Trust's 
in-house 'Green Card' reporting scheme and none were recorded in patient's 
records as being reported to the regulatory authorities (on reporting the ADRs to 
the CSM / MCA, none were identified as duplicates suggesting that this was the 
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case). Important information about a significant number of hospital admissions 
that could be used to influence the management of patients prior to and 
following hospital discharge is not collected. As a result, the opportunity to 
educate prescribers and patients to improve drug use and reduce iatrogenic 
disease is lost. The drugs suspected of causing ADR related admissions, that 
is, diuretics, beta blockers and non-steroidal anti inflammatory drugs (NSAIDs), 
are similar to those reported by other workers 121 and are amongst the most 
commonly prescribed drugs in the UK. Recent work suggests that NSAID 
associated gastrointestinal bleeds are repsonsible for 2000 deaths a year in the 
UK. '22 Increasing awareness amongst prescribers of the common ADRs 
associated with these drugs and ensuring patients are aware of the potential 
problems with their medicines and action to take where appropriate could have a 
significant impact on this problem. 
Studies have shown that many ADR related admissions are preventable; for 
example, one study found that 38.5% of ADRs thought to have caused hospital 
admission were either 'definitely' or 'possibly' avoidable. '23 It has also been 
demonstrated that a relationship to dosage and type (A or B) of ADR appeared 
to be strongly related to preventability. 124,125 It was demonstrated in these 
studies that 73-93% of ADRs are preventable. Inappropriate prescribing is 
responsible for a significant proportion of adverse drug reactions in the elderly. 81 
Despite evidence that many type A reactions are preventable and that a large 
proportion of ADR related hospital admissions are caused by a few lasses of 
therapeutic agents, little action appears to have been undertaken to resolve the 
issue of ADRs and ADR related admissions resulting from the use of these 
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drugs. The number of total hospital admissions and general medical admissions 
is rising (Figure 11.3). 
Figure 11.3 UK general medical admissions, 1989-1998 
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Since this research suggests the proportion of ADR related admissions has 
remained relatively constant, then, the absolute number of ADR-related 
admissions is rising. Methods of reducing the burden of ADR related 
admissions could include improved patient counselling, improved 
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communication between primary and secondary care and improving education 
about the signs and symptoms of ADRs, appropriate prescribing of drugs and 
improving recognition and reporting of ADRs. 123 
Causality assessment by the methods of Venulet and Ten Ham, which is based 
on a 'best fit categorisation, was preferable to Naranjo's algorithm with the 
reports described here because of the flexibility that it afforded in judging some 
reactions. Reactions that were evidently 'unlikely or 'unassessable' using 
Venulet and Ten Ham's method could still be classified as 'possible' by 
Naranjo's method, and thus the former method was found to be more applicable 
to reactions identified in this study. 
Many patients required repeated prompting to divulge details of OTC purchases, 
possibly because they felt they had acted improperly by purchasing medicines 
or because they believed that their OTC purchases were insignificant. Although 
the majority of OTC purchases were largely unimportant from a clinical 
perspective others were indicative of potential problems: for example, a patient 
taking a NSAID had been buying indigestion remedies which could have 
indicated drug induced peptic ulcer disease; a second patient had been taking 
OTC ibuprofen and was found to be anaemic. A further concern was that 2 
(6%) of the patients claiming drug allergies did not know to which drugs they 
were allergic. obtaining accurate drug histories from the majority of patients was 
often difficult and numerous patients were unsure of their exact drug therapy. 
Indeed on examination of patients' own medication which had been brought into 
the hospital, their medicine charts and relation to general practitioners records, 
irregularities were often identified. Again these deficiencies place patients at 
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risk from iatrogenic disease and at risk of omission of important medication. 126,127 
A lack of reporting ADRs to the CSM / MCA and poor identification of ADRs 
suggests that a role for pharmacists in acute medical admissions and in 
monitoring patients for ADR related admissions exists. 
11.6 Limitations. 
This study presents data obtained from predominately elderly adult, medical 
patients at a large teaching hospital, in an area with socio-economic difficulties 
and who were not admitted directly to a specialist ward. Caution should be 
exercised in the extrapolation of these results to other populations including 
surgical or paediatric patients since previous work has demonstrated that the 
sample population may significantly influence the ADR related admission rate. 4 
The high proportion of patients admitted with cardiovascular disease is indicative 
of the well described health problems endemic in the Liverpool area. 128 This 
may also influence the results of this study in comparison to an area with a 
lower incidence of coronary heart disease. The sample population was also of a 
relatively small sample size, although similar in size to some similar, published 
work. 
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Chapter 12: Conclusions 
12.1 ADR reporting schemes 
Despite the evidence that in-house or local ADR reporting schemes can 
significantly increase ADR reporting rates within managed care institutions, few 
are in operation in UK hospitals. At present, the extent to which departments 
wish to involve themselves in the monitoring of ADRs remains the perogative of 
the units concerned. Where schemes are in operation, methods of reporting are 
reasonably similar. Few mechanisms for monitoring newly marketed agents 
exist in either local or national schemes and they do not appear to be 
particularly effective, given the number of reports received by them. Two years 
after the initial survey and a over a year after the introduction of ADR reporting 
for hospital pharmacists via the Yellow Card Scheme, few additional hospitals 
had developed systems for reporting ADRs. It is clear that neither the 
introduction of reporting for hospital pharmacists, nor the association between 
ADR reporting and clinical governance, have significantly encouraged units to 
develop schemes where previously none existed. 
Previous estimates of the proportion of ADRs that remain unreported appear to 
high and somewhat over-optimistic based on the results of this work. While 
anecdotal evidence of commonly occurring or recognised ADRs is abundant, 
data which the CSM / MCA could need to take regulatory action if required, 
remain uncollected. ADR pharmacists appear to make a significant contribution 
to schemes in increasing rates of reporting, education and in operating the 
schemes themselves, and Drug Information pharmacists appear to have a 
similarly important role. Again, despite the demands of clinical governance and 
4ý 
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improving quality in the NHS, few hospitals appear to have any systems in place 
for ensuring that ADRs are appropriately documented in patients' medical 
records and communicated to their primary health care providers (see below). 
The work reported in this thesis demonstrates that education and training have a 
significant effect on pharmacists' participation in reporting via the Yellow Card 
Scheme and so it is disappointing that a significant number of departments have 
provided little or no education or training in this area. 
I2.2 Pharmacists' attitudes to and knowledge of ADR reporting 
Pharmacists have a reasonable knowledge of the Yellow Card Scheme and 
consider it a professional obligation to participate in it. A lack of time appears to 
be a major obstacle to pharmacists reporting ADRs and this problem is likely to 
continue, given the current difficulties in staff recruitment and retention. Despite 
the majority knowing the criteria for reporting ADRs, many pharmacists are not 
prepared to report well recognised and minor reactions and pharmacists appear 
somewhat selective in the reactions they report in some instances, regardless of 
CSM criteria. The lack of leadership and encouragement concerning pharmacist 
ADR reporting from the RPSGB and the CSM / MCA has done little to remind 
pharmacists of the importance of postmarketing surveillance. Under reporting of 
ADRs remains a major problem. 
As stated above, education and training provide a significant positive influence 
on participation in ADR reporting and knowledge of the scheme and this is a 
method by which reporting could be encouraged. The infrastructure for delivery 
ýý°g. 
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of postgraduate education is well established with the College of Pharmacy 
Practice and the Centre for Pharmacy Postgraduate Education continuing 
education schemes having key roles. It is worth noting that when reporting was 
first introduced for doctors and dentists, it took a number of years to reach the 
levels recorded in the late 1980's and early 199O's. 87 It is to be hoped that as the 
scheme continues, pharmacists will become more involved and that 
pharmacovigilance will become an integral part of their clinical activities. 
1 2.3 Local scheme study 
ADR reporting rates through the `Green Card' Scheme at the RLUH have been 
substantially increased, although under-reporting at the hospital remains an 
issue. Analysis demonstrates the substantial contribution that pharmacists 
made to the scheme and identified areas which could be targeted to increase 
reporting. This was achieved through publicity, accessibility and the provision of 
feedback to reporters. With the advent of clinical governance and the wide 
uptake of its initiatives, local ADR schemes may become increasingly important 
for managed care institutions. 
12.4 Transfer of ADR related data 
GPs are dissatisfied with the current provision of information both in terms of 
quality and speed of transfer, which may have serious consequences for patient 
safety. Ensuring patients are aware of drugs to which they may be allergic or 
intolerant through verbal and written methods should minimise such risks. GPs 
were particularly concerned that they should receive information within an 
appropriate period of time following patients' discharge. Given the paucity of 
' ., 
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methods of documenting and communicating this data (Chapters 4 and 5) a role 
for pharmacists exists, which could be supported by the use of a database such 
as HAROLD. 
12.5 ADR related admissions 
This study identified a numerically significant proportion of hospital admissions 
that were related to adverse drug reactions in line with previous studies. While 
the total number of acute medical admissions has increased, the proportion of 
patients admitted as a result of ADRs appears to have remained the same, 
despite a greater awareness of ADRs and issues of drug safety. This research 
suggests that the nature of drugs causing hospital admissions has not greatly 
altered, despite the fact that experience with the wide use of such drugs and 
that awareness of their adverse effects is widely publicised. Pharmacists should 
have a key role in monitoring patients for iatrogenic disease, collating details of 
such instances and providing feedback to prescribers to raise awareness of the 
problems associated with ADR related admissions. 
1Z6 Further research 
Further scope exists for research into the role of pharmacists in ADR reporting. 
With the advent of computerised prescribing, the opportunities for obtaining 
details of ADRs electronically could revolutionise spontaneous ADR reporting. A 
number of hospitals in the UK now have such systems in operation and ADR 
reporting programmes should be built into their design and evaluated. 
Computer-based prescribing and ADR reporting combined would offer 
significant benefits over traditional spontaneous reporting, particularly for black 
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triangle drugs. Reporting would become faster and simpler and medication 
records could provide accurate and comprehensive drug histories. Local 
schemes could then begin to collect data which could be used to influence 
prescribing. 
Issues surrounding ADR-related admissions require further research. Since 
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they cause significant numbers of hospital admissions, further work is required 
to identify methods of predicting and preventing ADR related admissions. 
Larger studies would be required to achieve this. 
12.7 Conclusion 
This thesis has explored some of the issues affecting the role of the hospital 
pharmacist in pharmacovigilance. Local schemes have the potential to 
contribute greatly to pharmacovigilance but probably lack the attention and 
support they require to collect numbers of reports that reflect the number of 
ADRs that are occurring in hospitals should the results of published studies be 
generally applicable. This thesis has identified the level of hospital pharmacists 
and pharmacy departments' participation in local or in-house ADR reporting 
schemes. The factors identified as a result of the findings of this research can 
be used to influence the development of new schemes, or, to enhance existing 
schemes. Appropriate investment in these schemes needs to be encouraged in 
order to increase their effectiveness. Effective transfer of data is also important; 
this thesis demonstrates that in the Liverpool area at least, prescribers are 
dissatisfied with the manner and the timeliness of the information concerning 
ADRs they receive, if at all. This places patients and prescribers at risk from 
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inadvertent re-exposure to drugs suspected of previously causing an ADR. ADR 
related admissions remain a clinically and financially significant problem and 
strategies need to be developed to influence the reduction of their frequency. 
Education of both patients and prescribers is required to reduce this often 
preventable burden on the NHS. 
Pharmacists have positive attitudes to the Yellow Card ADR reporting scheme 
and are aware of its importance and purpose; however, under reporting remains 
a substantial problem. Pharmacists lack confidence in the diagnosis of an ADR 
and appear to have taken a `safety first approach, that is, they tend to report 
well known, albeit serious, ADRs to the CSM / MCA. It is of concern that in the 
eighteen months following the introduction of ADR reporting for Pharmacists via 
the Yellow Card scheme, only a quarter of those able to report, have done so. 
The reasons for under-reporting described in this thesis and elsewhere' are in 
no way insurmountable. Like many aspects of clinical practice, education and 
training are the key initiatives required to enhance reporting of ADRs. The CSM 
/ MCA also need. to convince pharmacists that it is worth reporting ADRs that 
they suspect have occurred rather than ADRs they are certain have occurred. 
Department managers also need to attach more importance to the participation 
of their staff in ADR reporting by encouraging them. 
A lack of leadership and encouragement mean that the CSM / MCA and the 
RPSGB need to take a more proactive approach and encourage potential 
reporters to actively participate in pharmacovigilanoe. If the maximum benefits 
from including pharmacists in the Yellow Card scheme are to be achieved then 
far greater investment is required in the promotion and publication of the 
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scheme to encourage potential reporters to participate. Pharmacists as the 
experts in medicines management have a challenging future as their role 
develops; however, it is important that in these new roles, the basic principles of 
pharmacovigilance and drug safety are not forgotten. 
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Appendix 1: 
Questionnaire and covering and 
follow up letters used in initial 
survey of hospital pharmacy 
departments 
(Chapter 4) 
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Questionnaire to evaluate the role of the hospital pharmacist in adverse 
drug reaction monitoring. 
1.0 About your Hospital 
1.1) Approximately how many beds does your hospital have? Please circle. 
0-400 401-800 801-1200 >1201 
12) Is your hospital part of a larger NHS Trust? Y/N 
If 'NW, please go to question 1.3. 
If 'Yes', approximately how many beds does your Trust have? 
0-500 501-1000 1001-1500 >1500 
1.3) Is your hospital affiliated to a university medical school? Y/N 
1.4) Does your hospital have a clinical pharmacology department? Y/N 
1.5) Does your hospital have a designated Adverse Drug Reaction Nurse? Y/N 
COL About your oharmacv department 
2.1) How many pharmacists are employed in your department? Please circle. 
0-10 11-20 20-30 >30 
2.2) Does your department have an designated drug inforrnabon pharmacist? Y/N 
2.3) Does your department have a designated drug information centre? Y/N 
2.4) Does your department have an designated ADR specialist pharmacist YIN 
2.5) Do you operate a telephone help line for patents to ring in with drug queries? 
YIN 
If ' No', please go to 2.6. 
If 'Yes,, is the telephone help line used to identify and report ADRs? Y/N 
2.6) Do you use an in house data collection form for gathering details (for example, 
patient details and examples of previous reports) of Adverse Drug Reactions that have 
been reported to pharmacy? Y/N 
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2.7) How do you decide to report ADRs via a 'Yellow card' to the CSM? You may tick 
more than one. 
a) Using an algorithm Q 
b) By discussion with a member of the medical staff Q 
c) Using your own clinical judgement Q 
d) Other, please elaborate ................................................................................................. 
............................................................................................................................................ 
2.8) Do you have any formal mechanisms for ensuring appropriate documentation 
of ADRs in the patients medical records? Y/N 
If 'No', please go to question 2.9. 
If 'Yes', please elaborate .................................................................................................. 
.......................................................................................................................................... 
2.9) Do you have a formal mechanism for reporting ADRs to general practitioners? 
Y/N 
If 'No', please go to question 2.10. 
If 'Yes', please elaborate .................................................................................................. 
................................................................................................................................................ 
................................................................................................................................... 
2.10) Do you have a formal mechanism for reporting ADRs to community pharmacists? 
Y/N 
If *No', please go to question 3.0. 
If 'Yes', please elaborate ................................................................................................... 
................................................................................................................................................ 
.................................................................................................................................... 
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3.0) Involvement In 'Local' or'In house' reporting schemes. 
3.1) Do you have a 'Local' or ' in house' adverse drug reaction (ADR) reporting 
scheme? Y/N 
If 'No', please go to question 4.1 
3.2) If 'Yes', and your hospital is part of a multi-centre NHS trust, does this scheme 
operate across all sites? Y/N 
3.3) Who is responsible for the operation of the scheme? You may tick more than one 
category if operated by more than one discipline. 
a) the pharmacy department Q 
b) the clinical pharmacology department Q 
c) other, please state ........................................................................................................ 
3.4) How are ADR reports made. You may tick more than one. 
a) by locally designed card sent to the pharmacy department Q 
b) by telephone to the pharmacy department Q 
c) other ............................................................................................................................. 
.......................................................................................................................................... 
3.5) Who may report via your ADR reporting scheme? If 'Anyone', please ignore other 
categories. Otherwise, you may tick more than one. 
a) Anyone Q 
b) Doctors Q 
c) Nurses Q 
d) Pharmacists Q 
e) Patients Q 
f) Other, please elaborate ................................................................................................. 
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3.6) Do you provide ADR reporters with feedback following their report? 
Always / Never / On request only / For selected reports only 
If 'Never', please go to question 3.7. 
Otherwise, which aspects of information concerning the ADR do you feed-back to the 
reporter? 
a) An indication of the likelihood that the ADR was due to the suspect drug Y/N 
b) An indication as to whether the ADR will be reported as a Yellow Card YIN 
C) An indication of the incidence of the ADR YIN 
d) Other, please elaborate ............................................................................................... 
3.7) Does your department publicise ADR monitoring wilMn the hospital? Y/N 
If No, please go to question 3.8. 
If 'Yes', how is this achieved? You may circle more than one. 
By ADR newsletter Y/N 
By the Drugs and Therapeutics Committee newsletter Y/N 
By promotion of the local scheme within the hospital Y/N 
By posters on wands and in clinics Y/N 
Other, please elaborate ................................................................................................... 
3.8) Do you keep a computer database of ADRs that have occurred in your 
hospital? YIN 
If 'No', please go to question 3.9. 
If 'Yes', for what purposes do you use this database? Please elaborate .......................... 
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3.9) Do you have a particular system for reporting ADRs to new medicines (those 
marked with an inverted black triangle)? Y/N 
If 'No', please go to question 3.10. 
If 'Yes', how does this system for identifying ADRs to black triangle drugs operate? You 
may tick more than one. 
a) By highlighting the drugs on prescription charts Q 
b) Pro-actively monitoring adverse effects of specific drugs Q 
c) Other ........................................................................................................................ 
3.10) Approximately how many ADR reports do you receive from the local reporting 
scheme each year? 
3.11) Approximately how many reports are forwarded to the CSM each as a result of this 
scheme each year? 
Now no to auesdon 5.1 
U Pharmacy departments without a local or'in-house' ADR monitorina 
schom 
4.1) Which issues do you consider to have prevented the operation of an ADR reporting 
scheme in your hospital? You may tick more than one. 
a) Cost of the scheme Q 
b) Size of hospital Q 
c) A lack of perceived need to operate an ADR scheme Q 
d) Staffing Q 
e) Time Q 
f) Implementation of a scheme has never been considered Q 
g) other, please elaborate ................................................................................................. 
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4.2) Would you consider developing an ADR reporting scheme? Y/N 
If 'No' please go to question 4.3. 
if 'Yes', which type of scheme would you consider implementing within your hospital? 
Please place in order of preference. 
a) Locally designed ADR reporting card sent to the pharmacy department 
Q 
b) Reporting of ADRs by telephone to the pharmacy department 
Q 
C) Other ..................................................................................................................... 
4.3) Do you participate in intervention monitoring as part of dinical phaffnacy activities? 
If No, please go to question 4.4. 
Y/N 
If Yes, do you collect data concerning Adverse Drug Reactions? Y/N 
If No, please go to question 4.4. 
If Yes, are'Yellow Cards' ever submitted to the Committee on Safety of Medicines as a 
result of these interventions? Y/N 
4.4) Do you have a particular system for reporting ADRs to new medicines (those 
marked with an inverted black triangle)? 
if'No', please go to question 5.1. 
Y/N 
If 'Yes', how does this system for identifying ADRs to black triangle drugs operate? You 
may tick more than one. 
a) By highlighting the drugs on prescription charts 
0 
b) Pro-actively monitoring adverse effects of specific drugs Q 
c) Oder ........................................................................................................................ 
Thank you for completing the questionnaire. If you have designed cards or forms for reporting or 
eng data, I would be extremely grateful to you if you could supply me with copies of the forms. 
Please feel at liberty to add any comments at the bottom of this sheet and overleaf. 
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0151-231-2066 
Dear Colleague, 
As a PhD research project, we are investigating adverse drug reactions in 
hospitals and the role of the pharmacist. A major part of our research is to 
evaluate the activities and degree of involvement of pharmacy departments in 
ADR monitoring and reporting throughout the United Kingdom. 
I should therefore be grateful if you could assist us with this research project 
by completing the enclosed questionnaire. It is anticipated that it will take 
approximately ten minutes of your time and that virtually all questions may be 
answered without having to look up any data. Although the questionnaire 
may appear lengthy, the majority of questions are 'Yes / No' or 'Tick box' and 
not all questions need to be answered. Questionnaires maybe returned via 
the 'FREEPOST addressed envelope provided. 
Please note that your responses will be treated with the utmost confidentiality 
and that questionnaires are coded purely to allow follow up of non- 
respondents. It would be greatly appreciated if you could return the 
questionnaire within the next two weeks. 
We understand that your time is very precious, but your co-operation would 
be invaluable and greatly appreciated. 
Thanking you in anticipation of your response. 
Chris Green. BSc(Hons), Pgd. Dip. Prof. D. Mottram. B. Pharm, 
Clin. Pharm, M. R. Pharm. S. PhD, F. R. Pharm. S 
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0151-231-2066 
Dear Colleague, 
Unfortunately, we do not appear to have received a response to the 
questionnaire we sent to you concerning your departments participation in 
adverse drug reaction monitoring. If you have already returned the enclosed 
questionnaire, please ignore this letter and accept our apologies. 
If you have yet to return the questionnaire, we would be extremely grateful if 
you could do so. In order for our survey to be worthwhile, we need to reach a 
reasonable response rate which we have yet to do. 
It is anticipated that it will take about five minutes of your time and that 
virtually all questions may be answered without having to look up any data. 
Although the questionnaire may appear lengthy, the majority of questions are 
`Yes / No' or 'Tick box' and only about half of the questions need to be 
answered depending upon your responses. Questionnaires may be returned 
via the 'FREEPOST addressed envelope provided. 
Please note that your responses will be treated with the utmost confidentiality 
and that they are coded purely to allow follow up of non-respondents. We 
understand that your time is very precious, but your co-operation would be 
invaluable and greatly appreciated, as without it our survey is of limited value. 
Thanking you in anticipation of your response. 
Chris Green. BSc(Hons), Pg. Dip. Prof. D. Mottram. BPharm, 
CIin. Pharm, MRPharmS. PhD, FRPhannS. 
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Questionnaire and covering and 
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survey of hospital pharmacy 
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Adverse drug reaction monitoring: The role of hospital ohanmacles 
1.0 About your Hospital 
1.1) How many in-patient beds does your hospital have? 
1.2) Is your hospital affiliated to a university medical school? 
1.3) Does your hospital have a clinical pharmacology department? 
1.4) Does your hospital have a designated Adverse Drug Reaction Nurse? 
If 'Yes', what is the role of this nurse? ............................. 
2.0) About Your pharmacy department 
Y/N 
Y/N 
Y/N 
2.1) How many full time equivalent pharmacists are employed in your hospital 
pharmacy department? 
2.2) Does your department have an designated drug information pharmacist? Y/N 
2.3) Does your department have a designated drug information centre? Y/N 
2.4) Do you operate a telephone help line for patients to contact with drug information 
queries? Y/N 
If 'Yes', are ADRs identified using the help One, reported to the committee on Safely of 
Maddnes via the Yellow Card Scheme? YIN 
2.5) Does your department have an designated ADR specialist pharmacist? PMaae 
circle one only. 
Full time / Part time / No 
If 'Yes' what is the role of this pharmacist? ....................................................................... . 
................................................................................................................................................ 
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Documentation and communication of ADR data 
2.6) Do you use an in-house data collection form for gathering details of ADRs that have 
been reported to pharmacy (for example, patient details and examples of previous 
iepoits)? Y/N 
2.7) Do you have any formal mechanisms for ensuring appropriate documentation of 
ADRs in patients medical records? Y/N 
If 'Yes', please elaborate ................................................................................................ 
........................................................................................................................................ 
2.8) Do you have a formal mechanism for reporting ADRs to general practitioners? 
Y/N 
If 'Yes', Please elaborate .............................................................................................. 
2.9) Do you have a formal mechanism for reporting ADRs to community pharmacists? 
Y/N 
If 'Yes', please elaborate ................................................................................................... 
3.0) Involvement in `Local' or 'In-house' reoortino schemes. 
3.1) Do you have a 'Local' or'in-house' adverse drug reaction (ADR) reporting 
scheme? Y/N 
If 'No', please go to question 4.1 
3.2) Who is responsible for the operation of the scheme? You may tick more than one 
category if operated by more than one discipline. 
a) the pharmacy department 
b) the clinical pharmacology department 
El 
0 
c) Other, please state ....................................................................................................... 
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3.3) How are ADR reports made. You may tick more than one. 
a) by locally designed card sent to the pharmacy department Q 
b) by telephone to the pharmacy department Q 
c) by CSM Yellow Card Q 
d) Other, please state .................................................................................................. 
3.4a) Who may report via your ADR reporting scheme? Please tick as appropriate. If 
you trek 'Any member of staff, the other boxes may be let blank 
a) Any member of staff Q 
b) Doctors Q 
c) Nurses Q 
d) Pharmacists Q 
e) Radiologists Q 
f) Other, please elaborate ................................................................................................ 
3.4b) Can patients report an ADR via your local scheme? Y/N 
3.5) Do you provide ADR reporters with feedback following their report? Please circle 
Always / Never / On request only / For selected reports only 
3.6) How important is it to feedback to reporters within the local ADR scheme? Reese 
cinde. Very important / Important I Of little importance / Not important 
3.7) Does your department publicise ADR monitoring within the hospital? YIN 
If Yes', how is this publicity achieved? You may tick mae than one. 
a) By ADR newsletter Q 
b) By the Drugs and Therapeutics Committee newsletter Q 
c) Teaching sessions to doctors or nurses Q 
d) By posters on wards and in clinics Q 
e) Other, please elaborate ................................................................................................. 
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3.8) Do you keep a computer database of ADRs that have occurred in your hospital? 
Y/N 
If 'Yes', for what purposes do you use this database? Please elaborate .......................... 
................................................................................................................................................ 
3.9) Who reviews ADR reports before submission to the CSM? Please t ck one only. 
a) Pharmacists only Q 
b) A combination of pharmacists and medical staff Q 
c) Medical staff only Q 
d) Other(s), please state .................................................................................................. 
3.10) What happens to a local ADR report in order for it to be processed and sent to the 
CSM as a Yellow Card report? Please state ...................................................................... 
3.11) Approximately how many ADR reports do you receive from the local reporting 
scheme each year? 
3.12) Approximately how many reports are forwarded to the CSM each as a result of this 
scheme each year? 
3.13 Please use the space below to comment on your particular scheme. Please 
comment on anything that might make your scheme particularly novel or unique. 
................................................................................................................................................ 
................................................................................................................................................ 
Now no to section S. 0 
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4.0 Pharmacy departments without a `local' or `In-house' ADR monitorfno 
scftme. 
4.1) Will you be developing an ADR reporting scheme? Please tick the appropriate 
answer. 
a) We have definite plans to introduce an ADR reporting scheme Q 
b) We have probable plans to introduce an ADR reporting scheme Q 
C) We have no intention of introducing an ADR reporting scheme Q 
please continue to section 5.0 
6.0 Monitorinn newly marketed aaents 
5.1) Do you have a particular system for reporting ADRs to new medicines (those 
marked with an inverted black triangle)? Y/N 
If 'Yes', how does this system for identifying ADRs to black triangle drugs operate? You 
n*y tick more than one answer. 
a) By highlighting the drugs on prescription charts 
0 
bý By highlighting the containers of newly marketed drugs Q 
C) other (please state) ....................................................................................................... 
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6.0 Education and training. 
6.1) Has your department held any training or education meetings to discuss ADR 
reporting since the introduction of Yellow Card reporting for pharmacists? 
Y/N 
If 'Yes' what has this involved? You may tick more than one. 
a) Workshop/ discussion sessions Q 
b) Distribution of CSM information pack Q 
c) Formal lectures Q 
d) Initiation of local schemes and issues relating to implementation Q 
e) Other, please state ................................................................................................... 
Thank you for completing the questionnaire. If you use locally designed cards, I would be 
extremely grateful to you if you could supply me with a copy for the purpose of 
comparison. Please feel at liberty to add any comments at the bottom of this sheet and 
overleaf. 
F-K 
0151-231-2066 
Dear Colleague, 
As a PhD research project, we are investigating adverse drug reactions in 
hospitals and the role of the pharmacist. A major part of our research is to 
evaluate the activities and degree of involvement of pharmacy departments in 
ADR monitoring and reporting throughout the United Kingdom. You may 
remember that we sent you a questionnaire in August 1996. As a result of 
our findings we were able to publish a paper in the International Journal of 
Pharmacy Practice and present a summary of our finding as at the United 
Kingdom Clinical Pharmacy Association Symposium. However, we have 
been asked and are interested to discover whether the introduction of Yellow 
Card reporting for pharmacists has been affected the number of departments 
operating local schemes. 
I should therefore be grateful if you could assist us with this research project 
by completing the enclosed questionnaire. It is very similar to the previous 
questionnaire and it anticipated that it will take approximately five minutes of 
your time and that virtually all questions may be answered without having to 
look up any data. Although the questionnaire may appear lengthy, the 
majority of questions are 'Yes / No' or 'Tick box' and not all questions need to 
be answered. Questionnaires maybe returned via the 'FREEPOST 
addressed envelope provided. 
Please note that your responses will be treated with the utmost confidentiality 
and that questionnaires are coded purely to allow follow up of non- 
respondents. It would be greatly appreciated if you could return the 
questionnaire within the next two weeks. 
We understand that your time is very precious, but again, your co-operation 
would be invaluable and greatly appreciated. 
Thanking you in anticipation of your response. 
Chris Green. BSc(Hons), Pgd. Dip. Prof. D. Mottram. B. Pharm 
Clin. Pharm. M. R. Pharm. S. PhD, F. R. Pharm. S 
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1 5"' August 1998 
Dear colleague, 
Re: Questionnaires and adverse drug reaction reporting 
Unfortunately, we do not appear to have received a response to the 
questionnaire we sent you concerning your department's involvement in ADR 
monitoring and related activities. If you have already returned the 
questionnaire, please do so and accept our apologies. 
If you have yet to return the questionnaire, we would be extremely grateful if 
you could do so. As this is a follow up study, ' we need to attain a similar 
response rate to that of our previous survey. Unfortunately, we are currently 
some way short of this target at the moment. 
We should therefore be grateful if you could, once again, assist us with this 
research project by completing the enclosed questionnaire. it is anticipated 
that it will take approximately five minutes of your time as virtually all 
questions may be answered without having to look up any data. Although the 
questionnaire may appear lengthy, the majority of questions are 'Yes / No' or 
'tick box' and not all questions need to be answered. Questionnaires may be 
returned anonymously via the 'FREEPOST addressed envelope provided 
and it would be greatly appreciated if you could do so within the next two 
weeks. 
We understand that your time is very precious but again, your co-operation 
would be invaluable and greatly appreciated, as without it, our survey is of 
limited value. 
Thanking you in anticipation of your response. 
Chris Green. BSc(Hons), Pgd. Dip. Prof. D. Mottram. B. Pharm, 
Clin. Pharm. M. R. Pharm. S. PhD, F. R. Pharm. S 
1. Green CF, Mottram DR, Rowe P, Brown AM. An investigation into adverse 
drug reaction monitoring by United Kingdom Hospital pharmacy 
departments. International Journal of Pharmacy Practice. 1997; 5: 202- 
208. 
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N. B. If you would like a copy of the article in the International Journal of 
Pharmacy Practice, please fill in the form and return it either with the 
questionnaire or separately to the same address using the FREEPOST 
address below. 
Name ................................................... .... . ................. 
Job Title 
............ . ............................................................ 
Hospital ........................................................................ . 
Hospital Address ........................................................................ . 
Chris Green 
Go School of Pharmacy and Chemistry 
Liverpool 
70 Great Crosshall St 
Liverpool 
FREEPOST 
L3 5UY 
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Hosoital pharmacists and ADR reuortino 
How many years have you been qualified? 
postgraduate qualifications? 
Speciality? 
So you're aware that you can report ADRs via the Yellow Card scheme? 
Have you participated in any education or training with regard to the 
introduction of ADR reporting for pharmacists? 
Did you find that encouraged you to participate in ADR reporting? 
Do you think you're trained in such a way that you go out and look for 
ADRs? 
What do you think about the introduction of ADR reporting for 
pharmacists? 
What was your reaction personally when you discovered you could 
report ADRs via the Yellow Card scheme? 
How prepared did you feel prepared to participate in the scheme when 
pharmacists were officially involved in the scheme? 
Now many ADRs have you reported since the introduction of pharmacist 
reporting? 
What made the ones you reported stand out? 
What concerns do you have about ADR reporting, for example, 
confidence, appropriateness, time, role, legal angle? 
As for reasons why you might not report an ADR, would a lack of time 
prevent you from reporting ADRs? 
týMr 
What about motivation? 
What about a lack of information about a patient? 
What about your' clinical knowledge or lack of diagnostic ability as a 
pharmacist? 
Would the fact that a suspected reaction was unusual or bizarre stop 
you reporting it? 
Does patient confidentiality concern you? 
Are there any other reasons for under reporting that I haven't raised? 
What's the one thing that you would say is deterring you from reporting 
ADRs? 
Obviously the CSM co-ordinates the Yellow Card scheme, how does 
CSM Mersey fit into this ? 
Have you ever contacted CSM Mersey or had any dealings with them? 
Why / not? 
What was your impression? 
What else could they do for you or to encourage you to report? 
Did you receive the Information pack (show pack) regarding ADR 
reporting from the MCAICSM? 
What did you think of the information pack? 
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What do think about current problems? 
The CSM resisted introducing reporting for pharmacists and it was 
widely reported in the PJ. Do you have any views on the adverse 
publicity generated by the CSM concerning ADR reporting for 
pharmacists? 
What do you think about a fee for reporting ADR9? 
The CSM have published criteria concerning what should be reported to 
therm via the Yellow Card scheme. What do you think about them? 
(show copy) 
Pharmacists have to report ADRs using a separate form. Do you have 
any thoughts about this? 
Are you conscious that when you report something that you're reporting 
as a pharmacist and are you worried about what the CSM might think of 
your reports? 
Do you have any thoughts about the structure of the Yellow Card in 
general or how might it be Improved? 
How certain do you think you need to be before reporting an ADR? 
Would you report a reaction you were merely suspicious of being an 
ADR? 
What would constitute a reaction you would consider worthy of 
reporting to the CSM? 
What do you think about the BTD scheme? 
Would you report minor reactions like nausea, rash or cough with a 
black triangle drug? 
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If any, what sort of feedback would you like from the CSM? 
if they wrote back to you and said thanks for your report but we didn't 
feel it was an ADR. How would you feel about that, would it dissuade 
you from reporting another ADR or would it not? 
Do you have any concerns about a copy of your report going to the 
patients doctor? 
Have you contacted any pharmaceutical companies for information 
about ADRs? Describe your experiences and thoughts about them. 
Does the follow up they send deter you from calling them? 
Do you see ADR reporting is a professional obligation? 
A doctor tells you not to report an ADR you are convinced should be 
reported, would you? Why? 
What has your department done to encourage your participation in ADR 
reporting? What could they do? 
What else might encourage you to report ADRs? 
What about an element of competition? 
Does your hospital have a local ADR reporting scheme or procedure? 
What do you think about this? 
Finally, do you have any final or overall thoughts about ADR reporting 
for pharmacists? What about the Yellow Card scheme? is there any 
thing that we have not covered in the questionnaire that you would like 
to discuss? 
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The Yellow Card Scheme and the Hospital Pharmacist 
Section 1: The Yellow Card Scheme and pharmacovigilance 
1. Are you aware that as a hospital pharmacist you can report adverse drug 
reactions (ADRs) to the Committee on Safety Of Medicines (CSM) via the Yellow 
Card ADR reporting scheme? Please tick 
Yes 
El 
No 
EJ 
If `Yes' what alerted you to the fact that as a hospital pharmacist you could report 
ADRs via the Yellow Card scheme? You may tick more than I answer. 
Pharmaceutical Journal articles Q 
Departmental meeting or announcement Q 
Discussion with colleagues Q 
I received a copy of the CSM information pack "Pharmacovigilance: Q 
The Yellow Card Scheme: Information Pack For Pharmacists" 
Other (please specify) 
2. Did you consider yourself adequately informed about the national launch of 
Yellow Card reporting for pharmacists? Please tick 
Yes Q No Q Can't remember 
Q 
3. Have you reported an ADR to the Committee on Safety of Medicines (CSM) 
(either directly or as part of a local ADR scheme) since April 1997? Please tick 
Yes Q No Q 
If 'Yes', how many reactions have you reported? 
4. What do understand by the inverted black triangle (Y) placed next to medicines? 
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5. Which reports does the CSM wish to receive? Please tick the approprilate 
answer for each statement 
a) For newly marketed (black triangle) agents 
All reactions 
Q Serious reactions only 
E] No reactions 
Q Don't know Q 
b) For established products 
All reactions 
Q Serious reactions only 
Q No reactions 
Q Don? know Q 
a) For vaccines 
AR reactions Q Serious reactions only 
E] No ºeacdons Q Don't know E] 
d) For herbal drugs 
All ieactfons 
[] Serious reactions only E] No reactions F] Don't know 
e) Only proven ADRs Q True Q False 
Q Don't know 
6. What is the purpose of the Yellow Card ADR reporting scheme? Please tick the 
appropriate answer for each statement 
To enable safe drugs to be identified Yes 
Q No[] Unsure Q 
To measure the incidence of ADRs Yes 
Q No Q Unsure Q 
To identify factors that might predispose patients 
to ADRs Yes F] No 
O Unsure[] 
To identify previously unrecognised ADRs Yes 
Q No Q Unsure Q 
To obtain information about the characteristics of 
particular reactions Yes 
Q No Q Unsure Q 
To compare adverse effects of drugs within 
the same therapeutic dass Yes 
Q No Q Unsure Q 
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7. Please state whether you agree or disagree with the following statements about 
ADR reporting. Please tick the appropriate answer for each statement. 
ADR reporting is a professional obligation for pharmacists. 
Agree Q Disagree E] No opinion F] 
One ADR report makes no difference to the Yellow card scheme. 
Agree Q Disagree Q No opinion E] 
All serious ADRs are identified by the time a drug is marketed. 
Agree Q Disagree Q No opinion 
Q 
Yellow cards are too complicated to fill in 
Agree 11 Disagree [] No opinion 
It is adequately clear to me what I should and should not report to the CSM. 
Agree Q Disagree Q No opinion 
Q 
8. Have you ever contacted a pharmaceutical manufacturer with regard to a 
suspected ADR? Please lick. 
Yes Q No F] 
if 'Yes', did the company send you forms or documents to be completed with regard 
to the suspected ADR? Please tick. 
Yes No 
If 'Yes' did this request for follow up deter you from contacting them for information 
again? Please tick. 
Yes QNo Q 
9. in your opinion should ADR reporting via the CSM/ MCA Yellow Card scheme be 
compulsory or voluntary? 
Compulsory Q Voluntary Q No opinion Q 
10. Since April 1997, have you had patient contact as part of your job? Please tick 
Yes D No D 
If 'No' go to `Section 3' 
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Section 2: Reporting adverse drug reactions 
11. Which of the following factors would encourage you to report an ADR? Please 
tick the appropriate answer for each statement. 
The reaction is of a serious nature 
The reaction is unusual 
The reaction is to a new product 
Certainty that the reaction is a true ADR 
The reaction is a well recognised for a particular agent 
Yes Q NO F] 
Yes Q No Q 
Yes Q No Q 
Yes r] No LI 
Yes LI No LI 
12. Have you at any time since April 1997 not reported an ADR knowing that a 
doctor would be reporting the reaction themselves? Please tick. 
Yes F] No [] Situation has never arisen 
13. Have you at any time since April 1997 prepared or completed a Yellow Card for 
a doctor to sign? Please tick 
Yes 
F1 
No 
Q 
Situation has never arisen 
Q 
14. Have you ever used information obtained from the CSM, i. e. numbers or details 
of previous reports, to assist you in the evaluation of a potential adverse drug 
reaction? 
Yes LI No 
15. Do you have access to CSM information in your department either in microfiche 
or CD ROM format ? 
Yes Q No Q Don't know Q 
16. Are you aware that the patients consultant receives a copy of Yellow Card 
reports you send to the CSM? 
Yes Q No Q 
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17. Which of the following factors might discourage you from reporting an ADR? 
You may tick more than 1 answer. 
Concern that a doctor gets a copy of my Yellow Card report 
Lack of confidence in discussing a potential ADR with the prescriber Q 
Apprehension about sending in an inappropriate report 
Lack of time to fill in a report 
Q 
Concern that a report would generate follow up from the CSM Q 
resulting in extra work 
The absence of a fee for reporting ADRs Q 
Lack of time to actively look for ADRs while in clinical practice 
Level of clinical knowledge makes it difficult to decide whether 
or not an ADR has occurred. 
Don't feel the need to report well recognised reactions 
pharmacist yellow card report forms not available when needed 
S. For the following examples, please indicate whether you would report an ADR 
via the Yellow Card scheme. Assume that each symptom is likely to have been 
caused by the suspect drug. Please tick the appropriate answer for each 
statement 
Jaundice with frusemide Yes [] No [] Don't Know 
Headache with venlafaxine Yes [J No [] Don't Know 
Cold extremities with ß blockers Yes El No [] Don't Know El 
Thrombocytopenia with heparin Yes El No El Don't Know El 
Nausea with montelukast Yes [] No [] Don't Know El 
Gastrointestinal bleed with didofenac Yes El No El Don't Know El 
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19. Have you received specific training about ADRs? Please tick 
Yes [] No 9 
If 'Yes', what is the nature of the training you received? Please tick 
Departmental meeting 
Local RPSGB branch meeting 
CSM study day / study evening 
Odw 
Yes [] No 
Yes LI No 
Yes LI No 
Yes LI No 
20. How could reporting of ADRs by hospital pharmacists be improved or made 
easier? 
21. Where would you obtain information concerning ADRs or ADR reporting? 
Section 3: For the purposes of demographical and statistical analysis, please 
complete the following section about yourself. 
22. Job titre 
23. Age 
24. Are you retired? 
25. Please state the number of years you have been 
qualified 
26. How many of these have been spent in hospital 
practice? 
O 
Yes Q No Q 
II 
II 
27. Is the area in which you practice part of a CSM regional monitoring centre (i. e. 
CSM Mersey, Wales, Midlands or Northern)? 
Yes [] No [] Don't know 
Thank you for completing this questionnaire, please feel free to add any further 
comments or observations below or on the reverse side of this page. 
P. -' 
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0151-231-2066 
Dear Colleague, 
Re: Hospital Pharmacists and their new role in ADR reporting 
As a PhD research project, we are investigating the role of hospital 
pharmacists in adverse drug reaction monitoring, particularly with regard to 
the Yellow Card scheme. We should therefore be grateful if you could 
complete the enclosed questionnaire. 
Although the questionnaire may appear lengthy, virtually all questions are 
'tick box' and it is anticipated that it will take approximately five minutes to 
complete. The completed questionnaire may be returned anonymously via the 
'FREEPOST addressed envelope provided. As this is a key component of 
our research, it would be greatly appreciated if you would return the 
questionnaire within the next two weeks. 
Thanking you in anticipation of your response. 
Chris Green. BSc (Hons), Pgd. Dip. Prof. D. Mottram. B. Pharm, 
Clin. Pharm. M. R. Pharm. S. PhD, F. R. Pharm. S 
rl", 
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0151-231-2066 
Dear Colleague, 
Re: Hospital Pharmacists and their new role in ADR reporting. 
We recently sent you a copy of the enclosed questionnaire concerning 
hospital pharmacists' involvement in adverse drug reaction monitoring. 
Unfortunately, the initial distribution of this questionnaire resulted in lower 
return rate than we had hoped for. In order to gain a meaningful response 
rate, it is necessary to distribute the questionnaire a second time. If you 
have already completed and returned a copy of this questionnaire, please 
ignore this letter and we apologise for the inconvenience caused. 
Although the questionnaire may appear lengthy, virtually all questions are 
'tick box' and it is anticipated that it will take approximately five minutes to 
complete. The completed questionnaire may be returned anonymously via the 
'FREEPOST addressed envelope provided. As this is a key component of 
our research, it would be greatly appreciated if you would return the 
questionnaire within the next few weeks. 
Thanking you in anticipation of your response, 
Yours sincerely, 
Chris Green. BSc (Hons), Pgd. Dip. Prof. D. Mottram. B. Pharm, 
Clin. Pharm. M. R. Pharm. S. PhD, F. R. Pharm. S 
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Appendix 5: 
Data collection forms and 
assessment criteria used in the 
local ADR reporting scheme 
(Chapter 9 and Chapter 11) 
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Causality assessment 
From: Venulet J. Ten Ham M. Methods for monitoring and documenting 
adverse drug reactions. Int. J. Clin. Pharmacol. Ther. 1996; 34 (3): 112-129. 
Certain. A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administration and which cannot be 
explained by concurrent disease or other drugs or chemicals. The response 
to withdrawal of the drug (dechallenge) should be clinically plausible. The 
event must be definitive pharmacologically or phenomenologically, using a 
satisfactory rechallenge procedure if necessary. 
probable I likely. A clinical event, including laboratory test abnormality, with 
a reasonable time sequence to administration of the drug, unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and which 
follows a clinically reasonable response on withdrawal (dechallenge). 
Rechallenge information is not required to fulfil this definition. 
possible. A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug but which could also 
be explained by concurrent disease or other drugs or chemicals. Information 
on drug withdrawal may be lacking or unclear. 
Unlikely. A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a causal 
relationship improbable and in which other drugs, chemicals or disease 
provide plausible explanation. 
Conditional I unclassified A clinical event including laboratory test 
abnormality, reported as an adverse drug reaction about which more data is 
essential for a proper assessment or the additional data are under 
examination 
Unassessable I unclassified A report suggesting an adverse drug reaction 
which cannot be judged because information is insufficient or contradictory 
and which cannot be supplemented or verified. 
Severity assessment 
Following CSM guidelines, 'Serious' reactions include those that are fatal, life 
threatening, disabling, incapacitating or which result in or prolong 
hospitalisation. The remainder are classified as 'Non serious'. N. B. All 
reactions should be reported for black triangle drugs'. 
PAGE/PAGES 
EXCLUDED 
UNDER 
INSTRUCTION 
FROM 
UNIVERSITY 
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ADR Investigation Form 
patient's name / unit number 
or Adressograph: 
Age yrs Weight kg 
Rsievant medical history 
Reason for admission 
........................................................................ 
........................................................................ 
........................................................................ 
Wand / Clinic 
................... 
Consultant ............................................ 
Male / Female Pregnant Y/N 
Date // 
........................................................... 
........................................................... 
........................................................... 
Other diagnoses Chronic I Acute Dates / Duration 
C/A 
DRUG THERAPY - see attached sheet 
OTC / Herbal / Other ...................................................................................................... 
ALLERGIES 
(prigs or otherwise) Y/N/ NK 
Details ................................................................. 
Lab data sheet attached? Y/N 
................................................................. 
Renal function Normal / Impaired / Unknown 
Hepatic function Normal / Impaired / Unknown 
AdvarlS event details 
Dale of onset Time after suspect drug ........................ 
Duration of adverse event ..................... Time after admission............................ 
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Description ............................................................................................................................. 
................................................................................................................................................ 
................................................................................................................................................ 
................................................................................................................................................ 
................................................................................ 
Severity (Circle): Fatal / Serious / Moderate / Mild / Unclassifiable 
TypeAorB A/B 
Was hospital admission due to ADR? 
Suspect drug withdrawn 
pose reduced 
dose ................. 
Was drug therapy altered? 
Was corrective treatment prescribed? 
Y/N 
Y/N/Statdose 
Y/N/ NA If 'Yes' state new 
Y/N/NA 
Y/N/NA 
If 'Yes' give details: Drug ..................................................... 
Dose 
..................................................... 
Indication 
.............................................. 
Duration 
................................................ 
Did symptoms resolve? Y/N 
Was hospital stay prolonged? Y/N/ NA / OPD 
Comment ....................................................................................................... 
Full recovery / Almost resolved / No change / Worse / Fatal 
NON DRUG CAUSES: - Ask opinion of experienced doctor. 
Could the patients medical condition have caused the event? 
Almost definitely / Probably / Possibly / Unlikely I Unknown 
yellow Cana Report appropriate? Y/N 
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ADR invests ation form - bents rucis 
Drug Dosage Dose Route Freq. Start Stop Indication 
form (Y / N) date date 
Appendix 6: 
Questionnaire used in postal 
questionnaire survey of 
general practitioners 
(Chapter 10) 
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Adverse Drug Reactions experienced by hospital in-patients. An evaluation of 
the provision of information to general practitioners and their patients. 
part 1. Current provision of information 
1.1) How often do you see patients who have experienced an adverse drug 
reaction while a hospital in-patient? 
Never / Rarely / Occasionally / Frequently 
If `Never' please got to question 1.6, otherwise please continue 
1.2) How often has a patient told you that they experienced an ADR whilst in 
hospital but there is no record of this in their discharge documentation. Please 
circle. 
Never / Rarely / Occasionally / Frequently 
If 'Never please got to question 1.6, otherwise please continue 
1.3) How often can these patients name the exact drug suspected of causing the 
ADR? 
Never / Rarely / Occasionally / Frequently 
1.4) How often can these patients describe the exact nature of the reaction? 
Never / Rarely / Occasionally / Frequently 
1.5) How confident are you in the information patients give you? 
Very confident / Confident / Uncertain / Very uncertain 
1.6) Where ADRs are reported in the discharge documentation, how frequently is 
the information available sufficient to make an informed opinion concerning a 
patients ADR? 
Never / Rarely / Occasionally / Frequently 
1.7) How frequently is the combined information available from the patient and the 
tischarge documentation sufficient to make an informed opinion concerning a 
patients ADR? 
Never / Rarely / Occasionally / Frequently 
1.8) How could hospitals improve the communication of ADR data to general 
piers? Please comment. 
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Part 2: ADR notification form. 
Attached, is a sample of a standard form we intend to send to general practitioners 
who's patients have experienced an ADR at the RL&BUHT. 
2.1) What additional information would you like to receive? Please state. 
2.2) What information included in the form is unnecessary? Please state 
2.3) Should patients receive a copy of this notification form? 
Please give reasons for your answer. 
Yes / No 
2.4) It is proposed to supply patients with a 'credit card' sized ADR warning card 
naming the drug(s) suspected of causing an ADR. Do you consider this to be a 
useful idea? 
Yes / No 
Please comment if you wish. 
2.5) If introduced, should this card include a description of the ADR experienced by 
the patient? 
Yes / No 
Please comment if you wish. 
2.6) How would you prefer to receive information about ADRs, please tick one only. 
As part of the discharge documentation Q 
As a separate notification form D 
Other, please state ................................................................................. 
Thank you for completing this questionnaire. Please feel free to add any further 
comments below or overleaf. 
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Sample ADR Notification Form 
A GP 
The Surgery 
A Road 
A Town 
Dear Doctor, 
I am writing to inform you of a suspected adverse drug reaction 
experienced by one of your patients. Details of the patient concerned 
and the nature of the suspected reaction are listed below. 
Patient Name: A Patient 
Date of Birth: DOB 
Patient address: A road, A town 
Unit Number: 12345678S 
Consultant: A Doctor 
Suspect Drug: A drug 
Details of ADR: Details of reaction including 
details of abnormal laboratory 
data. 
Additional Information: This section will be used for 
further information when needed. 
A 'Yellow Card' report of this reaction was / was not sent to the CSM. 
Additional information is available from the pharmacy department at the Royal 
Liverpool Hospital. For further or related information, please telephone 706- 
2096. Please quote the ADR number when calling. 
Yours sincerely, 
AN Other. 
258 
Pharmacy Department 
Ext 2135 
Dear Doctor, 
Re: Adverse Drug Reactions - announcement of a new ADR notification 
scheme. 
At the Royal Liverpool and Broadgreen University Hospitals, we are aiming to 
improve our documentation and communication of data relating to adverse 
drug reactions. 
Enclosed is a form that we propose to use to notify general practitioners of 
ADRs experienced by their patients. As the form is intended to provide you 
with information, it is vital that we receive your comments concerning its 
content. 
We would therefore be grateful if you could review the sample notification 
form enclosed, complete the short questionnaire and return it to us at the 
RL&BUHT using the envelope provided. The majority of questions are'circle' 
or 'tick box' in design and the questionnaire is designed to be completed in a 
few minutes. 
Yours sincerely, 
Chris Green Solomon Almond 
ADR research pharmacist. Senior Registrar, 
Clinical Pharmacology. 
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Pharmacy Department 
Ext. 2135 
Dear Doctor, 
Re: Adverse Drug Reactions - announcement of a new ADR notification 
scheme. 
We recently sent you a copy of the enclosed questionnaire concerning the 
communication of data concerning adverse drug reactions. Unfortunately, the 
initial distribution of this questionnaire resulted in lower return rate than we 
had hoped for. In order to gain a meaningful response rate, it is necessary to 
distribute the questionnaire a second time. If you have already completed 
and returned a copy of this questionnaire, please ignore this letter and we 
apologise for the inconvenience caused. 
At the Royal Liverpool and Broadgreen University Hospitals, we are aiming to 
improve our documentation and communication of data relating to adverse 
drug reactions. Enclosed is a form that we propose to use to notify general 
practitioners of ADRs experienced by their patients. As the form is intended 
to provide you with information, it is vital that we receive your comments 
concerning its content. 
We would therefore be grateful if you could review the sample notification 
form enclosed, complete the short questionnaire and return it to us at the 
RL&BUHT using the envelope provided. The majority of questions are 'circle' 
or 'tick box' in design and the questionnaire is designed to be completed in a 
few minutes. 
Yours sincerely, 
Chris Green Solomon Almond 
ADR research pharmacist. Senior Registrar, 
Clinical Pharmacology. 
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Appendix 7: 
CSM / MCA Yellow Card 
3rd party copyright material excluded from digitised thesis. 
Please refer to the original text to see this material. 
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Appendix 8: 
Publications associated with this 
thesis. 
3rd party copyright material excluded from digitised thesis. 
Please refer to the original text to see this material. 
